Document:

Commercial Manufacturing Agreement

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 Exhibit 10.75 
 COMMERCIAL MANUFACTURING AGREEMENT

 InterMune, Inc., Pirfenidone Capsules 
 This Commercial Manufacturing Agreement (“Agreement”) is made as of this 10th day of September, 2009 (“Effective Date”), by and between InterMune, Inc., a Delaware
corporation, with a place of business at 3280 Bayshore Blvd., Brisbane, CA 94005 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company with a place of business at 14 Schoolhouse Road, Somerset, New
Jersey 08873 (“Catalent”). 
 RECITALS 
 A.      Client is a pharmaceutical company that develops, markets and sells pharmaceutical
products, including the Product (as defined in this Agreement); 
 B.      Catalent provides contract pharmaceutical development, manufacturing, packaging and analytical services to the pharmaceutical industry; 
 C.      Client desires to engage Catalent to provide certain services to Client in connection
with the processing of Client’s Product, and Catalent desires to provide such services, all pursuant to the terms and conditions set forth in this Agreement. 
 THEREFORE, in consideration of the mutual covenants, terms and conditions set forth below, the parties agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 The following terms have the following meanings in this Agreement: 
 1.1    “Acknowledgement” has the meaning set forth in Section 4.2. 
 1.2    “Affiliate(s)” means, with respect to Client or any third party, any corporation, firm,
partnership or other entity that controls, is controlled by or is under common control with such entity; and with respect to Catalent, Catalent Pharma Solutions, Inc. (“CPS, Inc.”) and any corporation, firm, partnership or other
entity controlled by CPS, Inc. For the purposes of this definition, “control” shall mean the ownership of greater than 50% of the voting share capital of an entity or any other comparable equity or ownership interest. 
 1.3    “Agreement” has the meaning set forth in the introductory paragraph, and includes all its
Attachments and other appendices (all of which are incorporated herein by reference) and any written amendments to any of the foregoing executed by the parties herein and made as provided herein or therein. 
 1.4    “API” means the compound pirfenidone whose chemical composition is [ * ], as
further described in the Specifications. 
 1.5    “Applicable Laws” means all laws,
ordinances, rules and regulations of the Territory applicable to the Processing or any aspect thereof and the obligations of Catalent or Client, as the context requires, under this Agreement, as amended from time to time, including without

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
limitation (A) all applicable federal, state and local laws and regulations of the United States, (B) the U.S. Federal Food, Drug and Cosmetic Act and (C) cGMP. 
 1.6    “Background Catalent IP” has the meaning set forth in Article 11. 
 1.7    “Background Client IP” has the meaning set forth in Article 11. 
 1.8    “Catalent Defective Processing” has the meaning set forth in Section 5.1. 
 1.9    “Catalent” has the meaning set forth in the introductory paragraph, or any successor or
permitted assign. Catalent shall have the right to cause any of its Affiliates to perform any of its obligations hereunder with Client’s prior written approval not to be unreasonably withheld or delayed, and Client shall accept such performance
as if it were performance by Catalent; provided, however that Catalent shall remain ultimately responsible for performance under this Agreement. 
 1.10    “Catalent Indemnitees” has the meaning set forth in Section 13.2. 
 1.11    “Catalent IP” has the meaning set forth in Article 11. 
 1.12    “cGMP” means current Good Manufacturing Practices promulgated by the Regulatory Authorities, including within the meaning of 21 C.F.R. Parts 210 and 211, as
amended. 
 1.13    “Client” has the meaning set forth in the introductory paragraph, or
any successor or permitted assign. 
 1.14    “Client Indemnitees” has the meaning set
forth in Section 13.1. 
 1.15    “Client IP” has the meaning set forth in Article 11.

 1.16    “Client-supplied Materials” means any materials to be supplied by or on behalf
of Client to Catalent for Processing, as provided in Attachment B, including API. 
 1.17    “Commencement Date” means, with respect to a Product and subject to Regulatory Authority approval of Catalent as a manufacturer of the Product, the date projected by Client as Client’s
expected date of Launch and to be set forth on Attachment C through an amendment to this Agreement by the parties when Client is able to provide such expected date of Launch. 
 1.18    “Commercial Requirements” means any and all Product intended for commercial sale or use, including but not limited to trade or physician
samples. 
 1.19    “Confidential Information” has the meaning set forth in
Section 10.2. 
 1.20    “Contract Year” means each consecutive 12 month period
beginning on the Commencement Date or anniversary thereof, as applicable. 
 1.21    “Defective
Product” has the meaning set forth in Section 5.1. 
 1.22    “Effective
Date” has the meaning set forth in the introductory paragraph. 
  

 2 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	1.23	 “Facility” means Catalent’s facility located in Winchester, Kentucky or such other facility as agreed upon by the parties in
writing. 

  

	1.24	 “Firm Commitment” has the meaning set forth in Section 4.1. 

  

	1.25	 “Invention” has the meaning set forth in Article 11. 

  

	1.26	 “Launch” shall mean the first sale for end use or consumption of such Product (provided that such Product is one which has received
Regulatory Approval from the applicable Regulatory Authority(ies) in the country) in a country within the Territory, excluding, however, any sale or other distribution for compassionate use, named patient use or for use in a clinical trial, for test
marketing or for compassionate or similar use in a country. 

  

	1.27	 “Losses” has the meaning set forth in Section 13.1. 

  

	1.28	 “Process” or “Processing” means the compounding, filling or pressing, producing and bulk packaging (but not
secondary or retail packaging) of the API and any other Client-supplied Materials as applicable and Raw Materials into Product, in accordance with the Specifications and under the terms of this Agreement and “Processed” has the
meaning correlative to the foregoing. 

  

	1.29	 “Processing Date” means the day on which Product is scheduled to be Processed by Catalent, as identified in an acceptance
Acknowledgement in accordance with Section 4.2. 

  

	1.30	 “Product” means the fully compounded bulk pharmaceutical product containing the API that has been Processed in accordance with the
Specifications. 

  

	1.31	 “Product Lot” means a defined quantity of Product that has been or is being Processed in accordance with the Specifications.

  

	1.32	 “Product Maintenance Services” has the meaning set forth in Section 2.4. 

  

	1.33	 “Purchase Order” has the meaning set forth in Section 4.2. 

  

	1.34	 “Quality Agreement” means the form of quality agreement attached hereto as Attachment D which governs the quality-related
activities between the parties with respect to the Processing and Product under this Agreement. 

  

	1.35	 “Raw Materials” means all raw materials, supplies, components and packaging necessary to manufacture and ship Product in accordance
with the Specifications, as provided in Attachment B, but not including Client-supplied Materials. 

  

	1.36	 “Recall” has the meaning set forth in Section 9.2. 

  

	1.37	 “Regulatory Approval” means any approvals, permits, product and/or establishment licenses, registrations or authorizations,
including but not limited to approvals pursuant to U.S. Investigational New Drug applications, New Drug Applications, Abbreviated New Drug Applications and European Medicines Agency (EMEA) Marketing Authorisation

  

 3 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	 	 
Application, as applicable, of any Regulatory Authorities that are necessary or advisable in connection with the development, manufacture, testing, use, storage, exportation, importation,
transport, promotion, marketing, distribution or sale of Product in the Territory. 

  

	1.38	 “Regulatory Authority” means the international, federal, state or local governmental or regulatory bodies, agencies, departments,
bureaus, courts or other entities in the Territory (including but not limited to the United States Food and Drug Administration and the European Medicines Agency (EMEA)) responsible for (A) the regulation (including pricing) of any aspect of
pharmaceutical or medicinal products intended for human use or (B) health, safety or environmental matters generally. 

  

	1.39	 “Rolling Forecast” has the meaning set forth in Section 4.1. 

  

	1.40	 “Specifications” means the procedures, requirements, standards, quality control testing and other data and the scope of services as
set forth in Attachment B, along with any valid amendments or modifications thereto, in accordance with Article 8. 

  

	1.41	 “Supplier” has the meaning set forth in Section 3.2(B). 

  

	1.42	 “Term” has the meaning set forth in Section 16.1. 

  

	1.43	 “Territory” means the [ * ] existing during the term of this Agreement, as well as [ * ], and any
other country that the parties agree in writing to add to this definition of Territory in an amendment to this Agreement. 

  

	1.44	 “Unit Pricing” has the meaning set forth in Section 7.1(B). 

  

	1.45	 “Validation Services” has the meaning set forth in Section 2.1. 

 ARTICLE 2 
 VALIDATION, PROCESSING & RELATED SERVICES 
 2.1    Validation Services.
Prior to the execution of this Agreement by the parties, the parties entered into that certain Quotation entitled “Process Validation of Pirfenidone Manufacture Capsulation ([ * ]) dated July 28, 2009, a copy of which is
attached hereto as Attachment A (the “Validation Services Quotation”), whereby Catalent shall perform for Client the qualification and Process validation services set forth therein (the “Validation
Services”). The parties acknowledge and agree that pursuant to the terms of the Validation Services Quotation, upon execution of this Agreement, Catalent shall manufacture the fully compounded bulk pharmaceutical product containing API in
accordance with the terms and conditions set forth in the Validation Services Quotation. The parties hereby agree that upon completion of the manufacture of the [ * ] batches of such product referred to as “Campaign I” in
the Validation Services Quotation by Catalent, release of such batches by Catalent, final release of such batches by Client, and completion of all the other services all as set forth in the Validation Services Quotation, such batches shall be
referred to herein as “Commercial Validation Batches” and the products within such batches shall be deemed “Products” for purposes of this Agreement and shall be available for Catalent’s fulfillment of Client’s
Purchase Orders under Article 4 of this Agreement. For purposes of clarity, all the activities set forth in the Validation Services

  

 4 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
Quotation shall be governed by the existing terms and conditions thereunder and this Agreement shall have no legal effect thereon; provided, however that when the products within the Commercial
Validation Batches become Products for purposes of this Agreement, this Agreement shall then govern. 
 2.2    Supply and Purchase of Product; Exclusivity. Catalent shall Process Product in accordance with the Specifications, the Applicable Laws and the terms and conditions of this Agreement. Client and its
Affiliates shall purchase from Catalent, and Catalent will be the supplier to Client and its Affiliates for, Client’s and its Affiliates’ requirements of Product in the Territory as detailed in the applicable Purchase Order submitted by
Client for the Firm Commitment and for which Catalent has issued an acceptance Acknowledgement, all in accordance with Article 4 of this Agreement. For the first three (3) Contract Years of this Agreement, Client and its Affiliates shall
exclusively purchase from Catalent 100% of its Commercial Requirements for the Product in the Territory and Catalent shall exclusively Process and supply Products to Client and its Affiliates. For the two (2) Contract Years following
thereafter, Client and its Affiliates shall exclusively purchase from Catalent and Catalent shall exclusively Process and supply to Client and its Affiliates at minimum 50% of Client’s Commercial Requirements for the Product in the United
States and the parties agree that the purchase and supply arrangement for the Product for Client’s Commercial Requirements in all the other geographical areas within the Territory shall be non-exclusive. For each Contract Year thereafter, the
purchase and supply arrangement for the Product for commercialization in all areas within the Territory shall be non-exclusive. Notwithstanding anything to the contrary contained herein, nothing contained in this Agreement shall be deemed to limit
Client’s right at any time to qualify a second source supplier for the Product at Client’s sole cost. In the event at any time that Catalent is unable to meet Client’s commercial requirements for the Product (per the Firm Commitment)
on a timely basis under this Agreement, in addition to any other remedies available to Client under this Agreement, Client shall have the right (but not the obligation) to purchase the Product from such second source supplier in order to mitigate
the interruption in Product supply for any quantity of Product which Catalent is unable to supply and only for the period of that shortfall in supply. In addition, in the event Client, in accordance with the requirements specified in
Section 4.2(A), requests quantities of Product in excess of the quantities specified in the Firm Commitment and Catalent is unable to accommodate Client’s request after using commercially reasonable efforts under Section 4.2(C),
Client shall have the right (but not the obligation) to purchase such excess quantities of Product from its second source supplier up to the net difference between the quantity of excess Product that Catalent can accommodate and
[ * ]% of the quantities specified in the Firm Commitment. For example, where the Firm Commitment is for [ * ] ([ * ]) lots and Client requests an increase to [ * ]
([ * ]) lots (a [ * ]% increase) in accordance with the request requirements specified in Section 4.2(A), if Catalent, after using commercially reasonable efforts to accommodate this request, can only
accommodate [ * ] ([ * ]) lots (a [ * ]% increase), Client cannot use this Section 2.2 as a means to purchase the additional quantities from its second source supplier. 
 2.3.    Commercial Validation Batches. With respect to the Products from the Commercial Validation Batches (as
defined in Section 2.1 above), where reasonably possible, Catalent shall use such Products to fulfill Client’s Purchase Orders submitted under this Agreement; provided however that notwithstanding anything to the contrary contained in this
Agreement, such Products from the Commercial Validation Batches shall be deemed fully paid for by Client under

  

 5 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
the Validation Services Quotation and no further payment shall be due and owing by Client for the supply of such Products by Catalent to Client under this Agreement. 
 2.4    Product Maintenance Services. Client will receive the following product maintenance services (the
“Product Maintenance Services”): one dedicated project manager at Winchester to coordinate and expedite all shipments in lieu of Client; [ * ] (as further described in the Quality Terms); regulatory audits (as
further described in the Quality Terms); one annual Product review (within the meaning of 21 CFR § 211.180); Product document and sample storage relating to cGMP requirements (including without limitation storage of reference materials for
assays); access to document library over and above the Quality Terms, including additional copies of Product Lot paperwork or other Product Lot documentation; assistance in preparing Regulatory Approvals; annual Raw Materials vendor
re-qualification; maintenance, updates and storage of master batch records and audit reports; bulk stability ([ * ] months, warehouse conditions); and replacement product-dedicated fluid bed filter bags and HPLC columns, as
applicable (including but not limited to ensuring the inventory of an adequate stock of replacement parts for instruments and equipment required in order to perform the Processing). For avoidance of doubt, the following services and items are not
included in Product Maintenance Services: technology transfer; analytical work; stability, other than the bulk stability described above; and any process changes specifically requested by Client. 
 2.5    Other Related Services. Catalent shall provide such Product-related services, other than Validation
Services, Processing or Product Maintenance Services, as agreed to in writing by the parties from time to time. Such writing shall include the scope and fees for any such services and specify whether the terms and conditions of this Agreement shall
govern and apply to such services. 
 2.6    Ad Hoc Orders of Clinical Supply. With respect to
clinical supply of product containing the API, the parties acknowledge that prior to the Effective Date, Client has been purchasing from Catalent and Catalent has been supplying to Client on an ad hoc basis via individual quotations and purchase
orders certain quantities of such product for clinical purposes. The parties hereby agree that Client shall continue to purchase such clinical supply and Catalent will continue to supply to Client such clinical materials through the same mechanism
of ad hoc quotations provided by Catalent (with previously negotiated terms and conditions attached or referenced therein) and written purchase orders that may be submitted from time to time by Client to Catalent for such clinical purposes. The
supply of and pricing for such materials shall be consistent with the supply and pricing practices Catalent has imposed upon Client in the past with respect to such materials and shall be at all times reasonable. 
 ARTICLE 3 
 MATERIALS 
 3.1    API. 
 A.      At Client’s sole cost and risk subject to the terms and conditions of this
Agreement (including but not limited to Catalent’s liability for claims for lost, damaged or destroyed API or other Client-Supplied Materials set forth herein), Client shall supply to Catalent for Processing, API, applicable reference standards
and any other Client-supplied Materials, in quantities sufficient to meet Client’s requirements for Product, as set forth in Article 4. Client

  

 6 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
shall deliver such items, together with associated certificates of analysis, to the Facility no later than [ * ] days before, but not earlier than [ * ] days
before, the Processing Date upon which such items will be used by Catalent. Client shall be responsible at its expense for [ * ]. Catalent shall use such items solely and exclusively for Processing. Prior to delivery of any such
items, Client shall provide to Catalent a copy of all associated material safety data sheets, certificates of analyses, safe handling instructions and health and environmental information, and shall promptly provide any updates or revisions thereto.
After each Processing campaign, Catalent shall inform Client what quantity of Client-supplied Materials remains in Catalent’s possession for use in the next Processing campaign. 
 B.      Within [ * ] days of receipt of API or any other Client-supplied
Materials by Catalent, Catalent shall inspect such items to verify their identity. Unless otherwise expressly required by the Specifications, Catalent shall have no obligation to test such items to confirm that they meet the associated
specifications or certificate of analysis or otherwise; but in the event that Catalent detects a nonconformity with Specifications, Catalent shall give Client prompt oral and written notice of such nonconformity. Catalent shall not be liable for any
defects in API or any other Client-supplied Materials, or in Product as a result of defective API or any other Client-supplied Materials unless such defect is caused by Catalent or Catalent failed to properly perform the foregoing obligations.
Catalent shall follow Client’s reasonable written instructions in respect of return or disposal of defective API or any other Client-supplied Materials, at Client’s sole cost and risk. 
 C.      Client shall retain title to API and any other Client-supplied Materials at all times
and shall bear the risk of loss thereof subject to the terms and conditions of this Agreement. 
 3.2      Raw Materials. 
 A.      Catalent shall be responsible for procuring, inspecting and releasing adequate Raw Materials as necessary to meet the Firm Commitment, unless otherwise agreed to by the parties in writing. Unless a
particular Raw Material can be replaced with the same raw material from another supplier, Catalent shall not be liable for any delay in delivery of Product if (i) Catalent is unable to obtain, in a timely manner, a particular Raw Material
necessary for Processing and; (ii) Catalent placed orders for such Raw Materials promptly following receipt of Client’s Firm Commitment; and (iii) with respect to obtaining such Raw Materials necessary for Processing, Catalent’s
planning therefore was commercially reasonable and in accordance with industry standards based on Client’s Rolling Forecast and Firm Commitment. In the event that any Raw Material becomes subject to purchase lead time beyond the Firm Commitment
time frame through no fault of either party, Catalent will notify Client in writing, [ * ], the parties will negotiate in good faith an appropriate amendment to this Agreement. 
 B.      In certain instances, Client may require a specific supplier, manufacturer or vendor
(“Supplier”) to be used for Raw Material. In such an event, (i) such Supplier will be identified in the Specifications, (ii) Client shall be responsible for the timeliness, quantity and quality of supply of Raw Materials
from such Supplier so long as any delay in the delivery of Product to Client does not arise from Catalent’s failure to performs its obligations set forth in Section 3.2.A. above, (iii) Catalent shall not be liable for any defects in
Raw Materials from such Supplier, or in Product as a result of such defective Raw Materials, unless such defect is caused by Catalent or Catalent failed to properly perform any testing required by the Specifications, and

  

 7 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
(iv) the Raw Materials from such Supplier shall be deemed, for purposes of liability hereunder, Client-supplied Materials unless otherwise expressly specified in this Agreement. If the cost of
the Raw Material from any such Supplier is greater than Catalent’s costs for the same raw material of equal quantity and quality from other suppliers, [ * ]. Client will be responsible for [ * ]. 
 3.3    Reimbursement for Materials. In the event of (A) a Specification change for any reason,
(B) obsolescence of any Raw Material or (C) further to Section 16.3(C), termination or expiration of this Agreement, [ * ] shall bear the cost of any unused Raw Materials (including packaging), so long as
[ * ]. 
 ARTICLE 4 
 PURCHASE ORDERS & FORECASTS 
 4.1    Forecast. On or before the [ * ] ([ * ]) day of each calendar month, at minimum beginning approximately [ * ] ([ * ]) months prior to the
Commencement Date, and continuing for [ * ] ([ * ]) months following Launch, Client shall furnish to Catalent on a [ * ] basis a written [ * ] ([ * ]) month rolling
forecast of the quantities of Product that Client intends to order from Catalent (“Rolling Forecast”); provided however that beginning on the [ * ] following [ * ] ([ * ]) months
post-Launch, Client shall furnish the Rolling Forecasts on a [ * ] basis. The Rolling Forecast (subject to Client’s right to adjust the quantities of Product forecasted upward or downward by [ * ]
([ * ]) Product lots with respect to the last [ * ] ([ * ]) months of the Rolling Forecast) shall constitute a binding order for the quantities of Product specified therein (“Firm
Commitment”). Prior to the time when Client is obligated to deliver the first official Rolling Forecast pursuant to this Section 4.1, Client may deliver to Catalent from time to time and solely for informational purposes non-binding
preliminary [ * ] ([ * ]) month forecasts for the Product (“Preliminary Forecast”). Upon receipt of a Preliminary Forecast, Catalent shall promptly notify Client whether Catalent is able to meet
Client’s requirements for Products forecasted in such Preliminary Forecast. For any Preliminary Forecast which Catalent has indicated that it is able to meet Client’s Product requirements forecasted therein, Client shall have the right to
designate such Preliminary Forecast as the official initial Rolling Forecast for purposes of this Agreement. 
 4.2    Purchase Orders. 
 A.      From time
to time as provided in this Section 4.2(A), Client shall submit to Catalent a binding, non-cancelable purchase order for Product specifying the number of Product Lots to be Processed, the Product Lot size (to the extent the Specifications
permit Product Lots of different sizes) and the requested delivery date for each Product Lot (“Purchase Order”); provided, that no Purchase Order may be for less than [ * ] ([ * ]) Product
Lots. Concurrently with the submission of each Rolling Forecast, Client shall submit a Purchase Order for the Firm Commitment. Purchase Orders for quantities of Product in excess of the Firm Commitment shall be submitted by Client at least
[ * ] days in advance of the delivery date requested in the Purchase Order. 
 B.      Within [ * ] days following receipt of a Purchase Order, Catalent shall issue a written acknowledgement specifying whether it accepts or rejects such Purchase Order
(“Acknowledgement”); provided, however that Catalent shall accept such Purchase Order so

  

 8 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
long as such Purchase Order issued is consistent with the Firm Commitment and given in accordance with this Agreement. Each acceptance Acknowledgement shall either confirm the delivery date set
forth in the Purchase Order or set forth a reasonable alternative delivery date close in proximity (i.e., within no more than [ * ] ([ * ]) days from the delivery date set forth in the Purchase Order issued by
Client), and shall include the Processing Date. Catalent may reject Purchase Orders in excess of the Firm Commitment or otherwise not given in accordance with this Agreement. 
 C.      In the event Client requests in writing quantities of Product in excess of the quantities specified in the Firm Commitment, notwithstanding
Section 4.2(B), Catalent shall use commercially reasonable efforts to supply Client with quantities of Product which are up to [ * ]% in excess of the quantities specified in the Firm Commitment, subject to Catalent’s
other supply commitments and manufacturing, packaging and equipment capacity; provided, that Catalent’s failure to supply Client with quantities in excess of the quantities specified in the Firm Commitment after using commercially
reasonable efforts shall not constitute a breach of this Agreement by Catalent. In the event Catalent is able to accommodate requests from Client for excess quantities of Product, Catalent shall notify Client and Client shall issue a Purchase Order
(or amend an existing Purchase Order) for such excess quantities and Catalent shall accept such Purchase Order and supply to Client such excess quantities of Product. 
 D.      In the event of a conflict between the terms of any Purchase Order or Acknowledgement and this Agreement, the terms of this Agreement shall
control. 
 4.3    Catalent’s Cancellation of Purchase Orders. Notwithstanding Section 4.4,
if Client refuses or fails to timely supply conforming API or any other Client-supplied Materials in accordance with Section 3.1, Catalent reserves the right to cancel all, or any part of, a Purchase Order upon written notice to Client, and
Catalent shall have no further obligations or liability with respect to such Purchase Order. Any such cancellation of Purchase Orders shall not constitute a breach of this Agreement by Catalent. 
 4.4    Client’s Modification or Cancellation of Purchase Orders. 
 A.      Client may modify the delivery date or quantity of Product in a Purchase Order only by
submitting a written change order to Catalent at least [ * ] days in advance of the earliest Processing date covered by such change order. Such change order shall be effective and binding against Catalent only upon the written
approval of Catalent, not be unreasonably withheld or delayed, and notwithstanding the foregoing, Client shall remain responsible for the Firm Commitment. 
 B.      If Client fails to place Purchase Orders sufficient to satisfy the Firm Commitment, Client shall, within [ * ] days of receipt of invoice, pay to
Catalent the Unit Pricing for all Units that would have been Processed if Client has placed Purchase Orders sufficient to satisfy the Firm Commitment. 
 4.5    Unplanned Delay or Elimination of Processing. Subject to the terms and conditions of this Agreement (including without limitation Sections 4.3 and 18.12), Catalent shall
meet the Purchase Orders it has accepted. Catalent shall provide Client with as much advance notice as

  

 9 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
possible (and will provide at least [ * ] days’ advance notice where possible) if Catalent determines that any Processing will be delayed or eliminated for any reason.

 4.6    Observation of Processing. In addition to Client’s audit rights pursuant to the
Quality Agreement, and upon at least [ * ] ([ * ]) days prior notice, subject to approval of the visit by Catalent, whose approval will not be unreasonably withheld, Client may send up to [ * ]
([ * ]) representatives to the Facility to observe Processing. Such observance of Processing shall be limited to that number of days as is reasonably necessary for Client to monitor the efficiency and effectiveness of the Process
(e.g., in terms of meeting Specifications, complying with timelines and optimizing Product yield) and to determine whether modifications or improvements to the Process may be warranted. Client and Catalent shall cooperate with one another in good
faith to ensure that such Process observation by Client representatives shall not interfere with Catalent’s day to day operations. Such representatives shall abide by all Catalent safety rules and other applicable employee policies and
procedures, and Client shall be responsible for such compliance. Client shall indemnify and hold harmless Catalent for any action, omission or other activity of such representatives while on Catalent’s premises except for those actions,
omission or other activity of such representative mandated by Catalent personnel or its safety rules and employee policies and procedures. Catalent reserves the right to require such representatives to enter into separate confidentiality agreements
directly with Catalent in such persons’ individual capacities on terms substantially similar to those set forth in Article 10. Should the number of calendar man-days per Contract Year exceed [ * ] ([ * ]) days,
additional fees, as indicated on Attachment C, may be assessed. 
 4.7    Certified Annual Statement.
[ * ] shall provide to [ * ] on [ * ] basis a certified statement (i.e., a statement signed by an authorized personnel of [ * ]) that sets forth [ * ]. Such
statement shall include: [ * ] and such other information [ * ] as may be reasonably requested by [ * ] and [ * ]. 
 4.8    Meeting of Project Managers. Client and Catalent shall each appoint one or more representatives who will act as project managers (“Project
Managers”) and who will each have appropriate project management, technical and quality assurance credentials, experience and knowledge and who will maintain ongoing familiarity with the Product Processing, order and supply activities under
this Agreement. The Project Managers will hold regular meetings or telephone conferences to be scheduled at mutually convenient times in order to oversee and facilitate the Product Processing, order and supply activities under this Agreement. Either
party may request a meeting or telephone conference of the Project Managers at any time and the other party will cooperate in good faith in scheduling such a meeting and telephone conference and attending such meeting or teleconference. Each party
shall be responsible for its own cost and expense in having its Project Manager(s) attend any such meeting or telephone conference. 
 ARTICLE 5 
 DEFECTIVE PRODUCT 
 5.1    Discrepant Results. As more specifically addressed in the Quality Agreement, in the event of a disagreement between the parties regarding whether a
Product is non-conforming due to a failure to meet to Specifications or cGMP (“Defective Product”) and/or whether the cause of the nonconformity is attributable to Catalent (“Catalent Defective Processing”), which
disagreement cannot be resolved by the parties, the parties shall cause a mutually agreeable

  

 10 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
independent third party to review records, test data and to perform comparative tests and/or analyses on samples of the alleged Defective Product and its components, including API and other
Client-supplied Materials. The independent party’s results as to whether or not Product is in fact Defective Product and the cause of any nonconformity shall be final and binding. Unless otherwise agreed to by the parties in writing, the costs
associated with such testing and review shall be borne by [ * ], and by [ * ]. For avoidance of doubt, where the cause of nonconformity cannot be determined or assigned, [ * ]; provided, however,
that, notwithstanding anything to the contrary contained in this Agreement, where nonconformity cannot be determined or assigned, [ * ] and [ * ]. 
 5.2    Defective Processing. In the event of Catalent Defective Processing of any Product Lot, Catalent shall promptly reimburse Client for
[ * ], subject to [ * ]. Subject to [ * ], Catalent will, at Client’s option, [ * ]. 
 5.3    Supply of Material for Defective Product. In the event Catalent replaces Defective Product pursuant to Section 5.2, Client shall supply, at its cost
([ * ]), Catalent with sufficient quantities of API and other Client-supplied Materials in order for Catalent to make such replacement. 
 ARTICLE 6 
 DELIVERY 
 6.1    Delivery. Catalent shall tender Product for delivery Ex Works (Incoterms 2000) the Facility promptly
following Catalent’s release of Product. Catalent shall segregate and store all Product until tender of delivery. [ * ]. 
 6.2    Failure to Take Delivery. If Client fails to take delivery of any Product on any scheduled delivery date, Catalent shall store such Product as Client’s agent, and
Client shall be invoiced on the first day of each month following such scheduled delivery for reasonable administration and storage costs. For each such Product Lot of stored Product, Client agrees that: (A) Client has made a fixed commitment
to purchase such Product, (B) title and risk of loss for such Product passes to Client, (C) such Product shall be on a bill and hold basis for legitimate business purposes, (D) if no delivery date is determined at the time of billing,
Catalent shall have the right to ship such Product to Client within [ * ] months after billing, and (E) Client will be responsible for any decrease in market value of such Product that relates to factors and circumstances
outside of Catalent’s control. Within [ * ] days following a written request from Catalent, Client shall provide Catalent with a letter confirming items (A) through (E) of this Section for each Product Lot of stored
Product. 
 ARTICLE 7 
 PAYMENTS 
 7.1    Fees. In consideration for
Catalent performing services hereunder: 
 (A)      With respect to the Validation
Services, Client shall pay to Catalent the fees for Validation Services in accordance with the Validation Services Quotation attached hereto as Attachment A. 
  

 11 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 (B)      Client shall pay Catalent the unit pricing for Product set forth on Attachment
C (“Unit Pricing”). Such fees shall be paid within [ * ] days following invoice, which invoice shall be submitted to Client by Catalent upon tender of delivery of Product as provided in Section 6.1. For
purposes of clarity, Client shall pay Catalent for any Product that was a part of the Commercial Validation Batches defined in Section 2.1 hereof in accordance with the terms and conditions set forth in the Validation Services Quotation and
accordingly, such Product shall be deemed fully paid for by Client and the unit pricing shall not be applicable to such Product for purposes of this Agreement. 
 (C)      Client shall pay Catalent the [ * ] fees for Product Maintenance Services set forth on Attachment C, if any. Such fees
shall be paid within [ * ] days following invoice, which invoice shall be submitted to Client by Catalent upon the Effective Date and upon each anniversary of the Effective Date during the Term. 
 (D)      Other Fees. Client shall pay Catalent for all other fees and expenses of
Catalent owing in accordance with the terms of this Agreement, including pursuant to Sections 2.5, 4.1, 6.2 and 16.3. Such fees and expenses shall be paid within [ * ] days following invoice, which invoice shall be submitted to
Client by Catalent as and when appropriate. 
 7.2    Unit Pricing Increase. Beginning on
[ * ], and continuing on [ * ], Catalent may increase the Unit Pricing for the Product by an amount [ * ]; provided, however, that (i) Client shall receive not less than [ * ]
days’ prior written notice of such Unit Pricing increase; (ii) such Unit Pricing increase shall occur no more frequently than [ * ]; and (iii) in the event that the Unit Pricing Increase is such that it causes
Catalent to increase the Unit Pricing by more than [ * ] percent ([ * ]%) of the then existing Unit Pricing, the parties agree to renegotiate in good faith appropriate commercial terms contained in this Agreement in
order to help alleviate the burden to Customer due to such Unit Pricing increase (including, but not limited to allowing Client to adjust its Rolling Forecast and Firm Commitment by up to [ * ]%). 
 7.3    Payment Terms. Client shall make payment in U.S. dollars, and otherwise as directed in the applicable
invoice; provided, however that in the event Client disputes any invoice in good faith, Client shall promptly notify Catalent in writing and the parties shall in good faith work together to resolve such dispute within [ * ] days of
such written notification by Client and any obligation upon Client to pay any such invoice in dispute shall be suspended until the earlier of the expiration of the aforementioned [ * ] day period and resolution of the parties of the
dispute. In the event payment is not received by Catalent on or before the [ * ] day after the date of the invoice (except in the case of a disputed invoice), then Catalent may, in addition to any other remedies available at equity
or in law, at its option, elect to do any one or more of the following: (A) charge interest on the outstanding sum from the due date (both before and after any judgment) at [ * ]% per month until paid in full (or, if less, the
maximum amount permitted by Applicable Laws); (B) suspend any further performance hereunder until such invoice is paid in full; and/or (C) terminate this Agreement pursuant to Section 16.2(B). 
 7.4    Taxes. All taxes, duties and other amounts assessed (excluding tax based on net income and franchise
taxes) on services, components, API or Product prior to or upon provision or sale to Catalent or Client, as the case may be, and on any other Client-supplied Materials, are the responsibility of [ * ], and [ * ]
shall reimburse [ * ] for all such taxes, duties or other expenses paid by [ * ] or such sums will [ * ], where applicable]. 
  

 12 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 7.5    Client and Third Party Expenses. Except as may be expressly covered by Product Maintenance Service fees set forth in Section 7.1.C above,
Client shall be responsible for [ * ]% of its own and all third-party expenses associated with the development, Regulatory Approvals and commercialization of Product, including regulatory filings and post-approval marketing studies.

 ARTICLE 8 
 CHANGES TO SPECIFICATIONS 
 All Specifications and any changes thereto
agreed to by the parties from time to time shall be in writing, dated and signed by the parties. Any change to the Process shall be deemed a Specification change. No change in the Specifications shall be implemented by Catalent, whether requested by
Client or requested or required by any Regulatory Authority, until the parties have agreed in writing to such change, the implementation date of such change, and any increase or decrease in costs, expenses or fees associated with such change
(including any change to Unit Pricing). Catalent shall respond promptly to any request made by Client for a change in the Specifications, and both parties shall use commercially reasonable, good faith efforts to agree to the terms of such change in
a timely manner. As soon as possible after a request is made for any change in Specifications, Catalent shall notify Client of the costs associated with such change and shall provide such supporting documentation as Client may reasonably require.
[ * ]. If there is a conflict between the terms of this Agreement and the terms of the Specifications, this Agreement shall control. Catalent reserves the right to postpone effecting changes to the Specifications until such time as
the parties agree to and execute the required written amendment. In the event the parties are unable to agree upon the terms and conditions of such written amendment, in addition to the termination rights set forth in Article 16, Client shall have
the right to terminate this Agreement with [ * ] months written notice to Catalent. 
 ARTICLE 9

 REGULATORY MATTERS; RECALL 
 9.1    Regulatory Compliance. Client shall be solely responsible for obtaining all Regulatory Approvals, including any applications and amendments in connection therewith.
Catalent will be responsible to maintain all permits and licenses required by any Regulatory Authority with respect to the Facility generally. During the Term, Catalent will assist Client with all regulatory matters relating to Processing, at
Client’s request and at Client’s expense. Each party intends and commits to cooperate to satisfy all Applicable Laws relating to Processing. 
 9.2    Recall. In the event Catalent believes a recall, field alert, Product withdrawal or field correction (“Recall”) may be necessary with respect to any
Product provided under this Agreement, Catalent shall immediately notify Client in writing. Catalent will not act to initiate a Recall without the express prior written approval of Client, unless otherwise required by Applicable Laws. In the event
Client believes a Recall may be necessary with respect to any Product provided under this Agreement, Client shall immediately notify Catalent in writing and Catalent shall provide all necessary cooperation and assistance to Client. The cost of any
Recall shall be borne by [ * ] and [ * ] shall [ * ] for expenses incurred with any Recall, in each case unless such Recall is [ * ]. For purposes hereof, subject also to
[ * ], such cost shall be limited to [ * ], in accordance with [ * ]. 
  

 13 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 9.7    Quality Agreement. Contemporaneously or simultaneously with the execution of this Agreement, the parties shall execute the Quality Agreement. The
Quality Agreement shall in no way determine liability or financial responsibility of the parties for the responsibilities set forth therein. In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement with
respect to quality-related activities, including compliance with cGMP, the provisions of the Quality Agreement shall govern. In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement with respect to any
commercial matters, including allocation of risk, liability and financial responsibility, the provisions of this Agreement shall govern. The form of Quality Agreement may be amended from time to time by the parties only through a written amendment
of this Agreement executed by both parties hereto. 
 ARTICLE 10 
 CONFIDENTIALITY AND NON-USE 
 10.1    Mutual Obligation. Catalent and Client each agrees that it will not use the other party’s Confidential Information except in connection with the performance of its obligations hereunder and will not
disclose the other party’s Confidential Information to any third party without the prior written consent of the other party, except as required by law, regulation or court or administrative order; provided, that prior to making any such
legally required disclosure, the party making such disclosure shall give the other party as much prior notice of the requirement for and contents of such disclosure as is practicable under the circumstances in order for the other party to seek the
appropriate protective orders or other remedies to resist or limit disclosure requirements or legal process. Notwithstanding the foregoing, each party may disclose the other party’s Confidential Information to any of its Affiliates that
(A) need to know such Confidential Information for the sole purpose of performing under this Agreement, (B) are advised of the contents of this Article and (C) agree to be bound by the terms of this Article. 
 10.2    Definition. As used in this Agreement, the term “Confidential Information” includes all
such information furnished by Catalent or Client, or any of their respective representatives or Affiliates, to the other party or its representatives or Affiliates, furnished on or after the Effective Date hereof and furnished in any form, including
written, verbal, visual, electronic or in any other media or manner. Confidential Information includes all proprietary technologies, know-how, trade secrets, discoveries, inventions and any other intellectual property (whether or not patented),
analyses, compilations, business or technical information and other materials prepared by either party, or any of their respective representatives or Affiliates, containing or based in whole or in part on any such information furnished by the other
party or its representatives or Affiliates. Confidential Information also includes the existence of this Agreement and its terms, subject to Section 10.4 hereof. 
 10.3    Exclusions. Notwithstanding Section 10.2, Confidential Information does not include information that (A) is or becomes generally available to the public or
within the industry to which such information relates other than as a result of a breach of this Agreement, (B) is already known by the receiving party at the time of disclosure as sufficiently evidenced by the receiving party’s written
records, (C) becomes available to the receiving party on a non-confidential basis from a source that is entitled to disclose it on a non-confidential basis without breach of any obligation owed to the other party or (D) was or is
independently developed by or for the receiving party without reference to the Confidential Information of the other party as sufficiently evidenced by the receiving party’s written records. 
  

 14 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 10.4    Publicity. Neither party will make any press release or other public disclosure regarding this Agreement or the transactions contemplated hereby
without the other party’s express prior written consent, except as required under Applicable Laws, by any governmental agency or by the rules of any stock exchange on which the securities of the disclosing party are listed, in which case the
party required to make the press release or public disclosure shall use commercially reasonable efforts to consult with the other party as to the form, nature and extent of the press release or public disclosure prior to issuing the press release or
making the public disclosure. In addition, Client may disclose to its legal and financial advisors and any of its partners or collaborators (or any potential partners or collaborators with which Client is actively engaging in negotiations) for the
development and commercialization of the Product the existence of, and terms and conditions contained in, this Agreement provided that each such parties are advised of the contents of this Article and agree to be bound by terms of this Article. In
the event any potential partner or collaborator of Client desire to perform a site audit of Catalent, such potential partner or collaborator shall first negotiate and execute a confidentiality agreement directly with Catalent, or if more
appropriate, the parties shall first negotiate and execute a three-way confidentiality agreement with such potential partner or collaborator. 
 10.5    No Implied License. Except as expressly set forth in this Agreement, the receiving party will obtain no right of any kind or license under any Confidential Information
of the disclosing party, including any patent application or patent, by reason of this Agreement. All Confidential Information will remain the sole property of the party disclosing such information or data, subject to Article 11. 
 10.6    Return of Confidential Information. Upon expiration or termination of this Agreement, the party receiving
Confidential Information will cease its use and, upon request, within [ * ] days either return or destroy (and certify as to such destruction) all Confidential Information of the other party, including any copies thereof, except for
a single copy thereof which may be retained for the sole purpose of determining the scope of the obligations incurred under this Agreement. 
 10.7    Survival. The obligations of this Article will terminate [ * ] years from the expiration or termination of this Agreement, except with respect to trade
secrets, for which the obligations of this Article will continue for so long as such information remains a trade secret under applicable law. 
 10.8    Injunctive Relief. Each party acknowledges and agrees that the other party may be irreparably injured by a breach of this Article 10 by such party and that monetary
remedies may be inadequate to protect the other party against any actual or threatened breach of this Article 10 of such party. Accordingly, each party agrees that the other party shall be entitled to seek an injunction or injunctions (without the
proof of actual damages) to prevent breaches or threatened breaches of this Article 10 and/or to compel specific performance of this Article 10, and that such party shall not oppose the granting of such relief. Such remedies shall not be deemed to
be the exclusive remedy for actual or threatened breaches of this Article 10 but shall be in addition to all other remedies available at law or in equity. 
  

 15 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 ARTICLE 11 
 INTELLECTUAL PROPERTY 
 For purposes hereof, “Background Client IP” means all intellectual property and embodiments thereof owned by or licensed to Client as of
the date hereof or developed, conceived, or reduced to practice by Client other than in connection with this Agreement. “Background Catalent IP” means all intellectual property and embodiments thereof owned by or licensed to
Catalent as of the date hereof or developed, conceived, or reduced to practice by Catalent other than in connection with this Agreement. Client and Catalent acknowledge and agree that as of the Effective Date, [ * ] will be used or
is necessary to be used by Catalent in connection with Catalent’s performance under this Agreement given the Process and the Specifications as they exist as of the Effective Date. As used herein, “IP” means any and all
inventions, improvements, information and know-how, including without limitation those related to processes, compositions of matter and methods of use, developed, conceived or reduced to practice by or on behalf of either party individually or
jointly, arising out of the performance of this Agreement, whether protectable by patent or as a trade secret, and all intellectual property rights therein and thereto. Determination of whether an invention was developed, conceived or reduced to
practice by one party or jointly by the parties shall be made in accordance with the principles of inventorship under the United States patent laws. 
 [ * ] which is related to Background Client IP or Client Confidential Information [ * ] (“Client IP”). Catalent shall have a license to Background Client IP and Client Confidential
Information to the extent necessary to perform its obligations under this Agreement. Catalent agrees to assign, and shall automatically be deemed to have assigned, Catalent’s entire right, title and interest in and to all Client IP to Client.
Upon request by Client, and without additional consideration, Catalent agrees to promptly execute documents, testify and take such other acts at Client’s expense as Client may deem necessary or desirable to procure, maintain, perfect, and
enforce the full benefits, enjoyment, rights, title and interest of the Client IP on a worldwide basis, and to render all necessary or reasonably requested assistance in making application for and obtaining original, divisional, renewal, or reissued
utility and design patents, copyrights, mask works, trademarks, trade secrets, and all other technology and intellectual property rights throughout the world related to any of the Client IP, in Client’s name and for its benefit. Catalent shall
promptly provide Client with a copy of any formal invention disclosure document that relates to the IP. Client IP shall be deemed to be Confidential Information of Client under this Agreement. 
 Catalent shall own all IP developed, conceived or reduced to practice by Catalent or its Affiliates in the performance of this Agreement which is not Client
IP and which is related to Background Catalent IP, Catalent Confidential Information, or [ * ] without the disclosure of any Confidential Information of Client (“Catalent IP”); provided, however, that under no
circumstances shall Catalent, without Client’s prior written consent, incorporate or use Catalent IP or Background Catalent IP in the performance of this Agreement hereunder and that in the event such Catalent IP or Background Catalent IP is
used or incorporated without Client’s prior written consent such that Client would require a license under such Catalent IP or Background Catalent IP to manufacture on its own or through a third party the API and/or Product for Client’s
use or sale, Catalent shall be deemed to have hereby granted to Client a royalty-free, fully paid-up, non-exclusive, perpetual, irrevocable, sublicenseable license to exploit such Catalent IP or such Background Catalent IP, as applicable, to
manufacture API and/or Product or any improvement

  

 16 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
thereto. [ * ] hereby grants, and automatically will be deemed to have granted, to [ * ] a [ * ] to [ * ]. To the extent Client
acquires any right, title or interest in and to any Catalent IP by virtue of this Agreement or by operation of law (with the exception of the licenses granted by Catalent to Client hereunder), Client agrees to assign, and shall automatically be
deemed to have assigned, such right, title and interest in and to such Catalent IP to Catalent. Upon request by Catalent, and without additional consideration, Client agrees to promptly execute documents, testify and take such other acts at
Catalent’s expense as Catalent may deem necessary or desirable to procure, maintain, perfect, and enforce the full benefits, enjoyment, rights, title and interest of the Catalent IP on a worldwide basis, and to render all necessary or
reasonably requested assistance in making application for and obtaining original, divisional, renewal, or reissued utility and design patents, copyrights, mask works, trademarks, trade secrets, and all other technology and intellectual property
rights throughout the world related to any of the Catalent IP, in Catalent’s name and for its benefit. Catalent IP shall be deemed to be Confidential Information of Catalent under this Agreement. 
 [ * ] 
 ARTICLE
12 
 REPRESENTATIONS AND WARRANTIES 
 12.1    Catalent. Catalent represents, warrants and undertakes to Client that 
 A.      at the time of delivery by Catalent as provided in Section 6.1, Product shall have been Processed in accordance with Applicable Laws and in conformance with the
Specifications and shall not be adulterated, misbranded or mislabeled within the meaning of Applicable Laws; provided, that Catalent shall not be liable for defects primarily attributable to API or other Client-supplied Materials (including
artwork, packaging and labeling); and 
 B.      to the best of Catalent’s
knowledge, the work to be performed by Catalent under this Agreement will not violate or infringe upon any trademark, tradename, copyright, patent, trade secret, or other intellectual property or other right held by any person or entity. 

 

	12.2    	 Client. Client represents, warrants and undertakes to Catalent that: 

 A.      the API and all other Client-supplied Materials shall have been produced in accordance
with Applicable Laws, shall comply with all applicable specifications, including the Specifications, shall not be adulterated, misbranded or mislabeled within the meaning of Applicable Laws, and shall have been provided in accordance with the terms
and conditions of this Agreement; 
 B.      no specific safe handling
instructions, health and environmental information or material safety data sheets are applicable to Product, API or any other Client-supplied Materials, except as provided to Catalent in writing by Client in sufficient time for review and training
by Catalent; 
 C.      all Product delivered to Client by Catalent will be held,
used and disposed of by or on behalf of the Client in accordance with all Applicable Laws and Client will otherwise

  

 17 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
comply with all laws, rules, regulations and guidelines applicable to Client’s performance under this Agreement and its use of Product provided by Catalent under this Agreement; 

D.      Client will not release any Product Lot of Product if the required certificates of
analysis indicate that Product does not comply with the Specifications; 
 E.      Client shall not market or sell, or license any other party to market or sell, the Product without first making every reasonable effort to ensure that Product is safe and effective for its intended
purpose or any other purpose for which such Product might reasonably be utilized; 
 F.      to the best of Client’s knowledge, Client has all necessary authority to use and to permit Catalent to use pursuant to this Agreement all intellectual property related to Product, API, and all
other Client-supplied Materials (including artwork), including any copyrights, trademarks, trade secrets, patents, inventions and developments; 
 G.      the content of all artwork provided to Catalent shall comply with all Applicable Laws; and 
 H.      to the best of Client’s knowledge, the work to be performed by Catalent under this Agreement will not violate or infringe upon any
trademark, tradename, copyright, patent, trade secret, or other intellectual property or other right held by any person or entity. 
 12.3    Limitations. THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS ARTICLE ARE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES MADE BY EACH PARTY TO THE OTHER PARTY, AND NEITHER PARTY MAKES ANY OTHER
REPRESENTATIONS, WARRANTIES OR GUARANTEES OF ANY KIND WHATSOEVER, INCLUDING ANY IMPLIED WARRANTIES OF NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE. 
 ARTICLE 13 
 INDEMNIFICATION 
 13.1    Indemnification by Catalent. Catalent shall indemnify and hold harmless Client, its Affiliates, and their
respective directors, officers, employees and agents (“Client Indemnitees”) from and against any and all suits, claims, losses, demands, liabilities, damages, costs and expenses (including reasonable attorneys’ fees and
reasonable investigative costs) in connection with any suit, demand or action by any third party (“Losses”) arising out of or resulting from (A) any breach of its representations, warranties or obligations set forth in this
Agreement; (B) any actual or alleged infringement or violation of any third party patent, trade secret, copyright, trademark or other proprietary rights by intellectual property or other information by any Catalent IP or Background Catalent IP
used by Catalent hereunder in its performance of this Agreement; or (C) any negligence, recklessness or willful misconduct by Catalent; in each case except to the extent that any of the foregoing arises out of or results from any Client
Indemnitee’s negligence, recklessness, willful misconduct or breach of this Agreement. 
 13.2    Indemnification by Client. Client shall indemnify and hold harmless Catalent, its Affiliates, and their respective directors, officers, employees and agents (“Catalent Indemnitees”) from
and against any and all Losses arising out of or resulting from (A) any

  

 18 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
breach of its representations, warranties or obligations set forth in this Agreement, (B) any manufacture, packaging, sale, promotion, distribution or use of or exposure to Product, API or
any other Client-supplied Materials, including product liability or strict liability, (C) Client’s exercise of control over the Processing, to the extent that Client’s instructions or directions violate Applicable Laws, (D) the
conduct of any clinical trials utilizing Product or API, (E) any actual or alleged infringement or violation of any third party patent, trade secret, copyright, trademark or other proprietary rights by intellectual property or other information
provided by Client, including Client-supplied Materials, or (F) any negligence, recklessness or willful misconduct by Client; in each case except to the extent that any of the foregoing arises out of or results from any Catalent
Indemnitee’s negligence, recklessness, willful misconduct or breach of this Agreement. 
 13.3    Indemnification Procedures. All indemnification obligations in this Agreement are conditioned upon the party seeking indemnification (A) promptly notifying the indemnifying party of any claim or
liability of which the party seeking indemnification becomes aware (including a copy of any related complaint, summons, notice or other instrument); provided, that failure to provide such notice within a reasonable period of time shall not
relieve the indemnifying party of any of its obligations hereunder except to the extent the indemnifying party is prejudiced by such failure, (B) allowing the indemnifying party, if the indemnifying party so requests, to conduct and control the
defense of any such claim or liability and any related settlement negotiations (at the indemnifying party’s expense), (C) cooperating with the indemnifying party in the defense of any such claim or liability and any related settlement
negotiations (at the indemnifying party’s expense) and (D) not compromising or settling any claim or liability without prior written consent of the indemnifying party; which consent shall not be unreasonably withheld or delayed.

 ARTICLE 14 
 LIMITATIONS OF LIABILITY 
 14.1    WITH RESPECT TO EACH
BATCH OF CLIENT-SUPPLIED MATERIALS REQUIRED TO PRODUCE A PRODUCT LOT WHICH IS SUPPLIED BY CLIENT HEREUNDER, CATALENT’S LIABILITY UNDER THIS AGREEMENT FOR ANY AND ALL CLAIMS FOR THE LOSS, DAMAGE OR DESTRUCTION OF SUCH BATCH, IN ITS ENTIRETY, OF
API AND/OR OTHER CLIENT-SUPPLIED MATERIALS, WHETHER OR NOT SUCH API OR CLIENT-SUPPLIED MATERIALS ARE INCORPORATED INTO PRODUCT, SHALL NOT EXCEED THE LESSER OF (A) $[ * ] OR (B) [ * ]. 
 14.2    SOLELY WITH RESPECT TO [ * ] AND SUBJECT TO [ * ], THE OBLIGATION OF CATALENT
TO REPLACE CATALENT DEFECTIVE PROCESSING WITH PROCESSING IN ACCORDANCE WITH THE SPECIFICATIONS OR CREDIT PAYMENTS MADE BY CLIENT FOR DEFECTIVE PRODUCT ATTRIBUTABLE TO CATALENT DEFECTIVE PROCESSING SHALL BE CLIENT’S SOLE AND EXCLUSIVE REMEDY
UNDER THIS AGREEMENT FOR DEFECTIVE PRODUCT AND IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, PROVIDED HOWEVER THAT THIS SECTION 14.2 SHALL NOT APPLY TO [ * ]. 
 14.3    EXCEPT WITH RESPECT TO [ * ] FOR [ * ], CATALENT’S TOTAL LIABILITY UNDER THIS AGREEMENT SHALL IN NO EVENT EXCEED
[ * ] ([ * ]) TIMES THE

  

 19 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
TOTAL FEES PAID BY CLIENT TO CATALENT UNDER THIS AGREEMENT FOR THE PRODUCT LOT OR SERVICES GIVING RISE TO THE CLAIM; PROVIDED, HOWEVER SUCH LIMITATION OF LIABILITY SHALL NOT APPLY TO
[ * ]. 
 14.4    WITH RESPECT TO A PARTY’S BREACH OF ARTICLE 10 HEREOF, SUCH
PARTY’S TOTAL LIABILITY FOR SUCH BREACH SHALL IN NO EVENT EXCEED [ * ] DOLLARS (US$[ * ]). 
 14.5    EXCEPT WITH RESPECT TO [ * ], NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR LOSS OF REVENUES OR PROFITS, DAMAGES TO
REPUTATION, OR LOSS OF DATA ARISING OUT OF PERFORMANCE UNDER THIS AGREEMENT, WHETHER IN CONTRACT OR IN TORT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES (PROVIDED HOWEVER, FOR PURPOSES OF CLARITY THAT [ * ]
SHALL NOT BE CHARACTERIZED AS CONSEQUENTIAL TO CLIENT OR CATALENT [ * ]). 
 ARTICLE 15 

INSURANCE 
 15.1    Catalent Insurance. Catalent shall, at its own cost and expense, obtain and maintain in full force and effect the following insurance during the Term: (A) Commercial General Liability Insurance with a
per-occurrence limit of not less than an amount equivalent to $[ * ]; (B) Products and Completed Operations Liability Insurance with a per-occurrence limit of not less than an amount equivalent to $[ * ];
(C) Workers Compensation and Employers Liability Insurance, with statutory limits for Workers Compensation and Employers Liability limits of not less than an amount equivalent to $[ * ] per accident; and (D) Professional
Services Errors & Omissions Liability Insurance with per-claim and aggregate limits of not less than an amount equivalent to $[ * ]. The parties hereby acknowledge and agree that Catalent may self-insure all or any portion
of the required insurance. Catalent shall maintain levels of insurance or self insurance sufficient to meet its obligations under this Agreement. In the event that any of the required policies of insurance are written on a claims made basis, then
such policies shall be maintained during the entire Term and for a period of not less than [ * ] years following the expiration or termination of this Agreement. Catalent shall obtain a waiver from any insurance carrier with whom
Catalent carries Workers’ Compensation insurance releasing its subrogation rights against Client. Catalent shall furnish to Client a certificate of insurance or other evidence of the required insurance and additional insured status as soon as
practicable after the Effective Date and within [ * ] days after renewal of such policies. Each insurance policy which is required under this Agreement, other than self-insurance, shall be obtained from an insurance carrier with an
A.M. Best rating of at least A- VII. 
 15.2    Client Insurance. Client shall, at its own cost and
expense, obtain and maintain in full force and effect the following insurance during the Term: (A) Commercial General Liability Insurance with a per occurrence limit of not less than an amount equivalent to $[ * ];
(B) Products and Completed Operations Liability Insurance (including coverage for Products used in clinical trials) with a per occurrence limit of not less than an amount equivalent to $[ * ]; (C) Workers Compensation and
Employers Liability Insurance with statutory limits for Workers Compensation and Employers Liability limits of not less than an amount equivalent to $[ * ] per

  

 20 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
accident; and (D) All Risk Property Insurance, including transit coverage, in an amount equal to [ * ]. The parties hereby acknowledge and agree that Client may self-insure
all or any portion of the above-required insurance. Client shall maintain levels of insurance or self insurance sufficient to meet its obligations under this Agreement. In the event that any of the required policies of insurance are written on a
claims made basis, then such policies shall be maintained during the entire Term and for a period of not less than [ * ] years following the expiration or termination of this Agreement. Client shall obtain a waiver from any
insurance carrier with whom Client carries Property Insurance releasing its subrogation rights against Catalent. Client shall not seek reimbursement for any property claim or portion thereof that is not fully recovered from Client’s Property
Insurance policy. Client shall obtain a waiver from any insurance carrier with whom Client carries Workers’ Compensation insurance releasing its subrogation rights against Catalent. Client shall furnish certificates of insurance evidencing the
required insurance policies and additional insured status to Catalent as soon as practicable after the Effective Date and within [ * ] days after renewal of such policies. Each insurance policy that is required under this Agreement
shall be obtained from an insurance carrier with an A.M. Best rating of at least A- VII. 
 ARTICLE 16 
 TERM AND TERMINATION 
 16.1    Term. This Agreement shall commence on the Effective Date and shall continue until the end of the fifth Contract Year, unless earlier terminated in accordance with Section 16.2 (as may be extended in
accordance with this Section, the “Term”). The Term shall automatically be extended for successive 2-year periods unless and until one party gives the other party at least 12 months’ prior written notice of its desire to
terminate as of the end of the then-current Term. 
  

	16.2    Termination.	 This Agreement may be terminated immediately without further action: 

 A.        by either party if the other party files a petition in bankruptcy, or
enters into an agreement with its creditors, or applies for or consents to the appointment of a receiver, administrative receiver, trustee or administrator, or makes an assignment for the benefit of creditors, or suffers or permits the entry of any
order adjudicating it to be bankrupt or insolvent and such order is not discharged within [ * ] days, or takes any equivalent or similar action in consequence of debt in any jurisdiction; or 
 B.        by either party if the other party materially breaches any of the
provisions of this Agreement and such breach is not cured within [ * ] days after the giving of written notice requiring the breach to be remedied; provided, that in the case of a failure of Client to make payments in
accordance with the terms of this Agreement, Catalent may terminate this Agreement if such payment breach is not cured within [ * ] days of receipt of notice of non-payment from Catalent. 
 16.3    Effect of Termination. Expiration or termination of this Agreement shall be without prejudice to any
rights or obligations that accrued to the benefit of either party prior to such expiration or termination. In the event of a termination of this Agreement: 
 A.        Catalent shall promptly return to Client, at Client’s expense and at Client’s direction, any remaining inventory of
Product, API or other Client-supplied Materials; provided,

  

 21 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
that Catalent shall have no obligation to so return such items until all undisputed outstanding invoices sent by Catalent to Client have been paid in full; 
 B.        Client shall pay Catalent all undisputed invoiced amounts outstanding
hereunder, plus, upon receipt of invoice therefor, for any (i) Product that has been shipped pursuant to Purchase Orders but not yet invoiced, (ii) Product Processed pursuant to Purchase Orders that has been completed but not yet shipped,
and (iii) in the event that this Agreement is terminated for any reason other than by Client pursuant to Section 16.2(A) or (B), or by Catalent pursuant to Section 16.2(C), all Product in process of being Processed pursuant to
Purchase Orders (or, alternatively, Client may instruct Catalent to complete such work in process, and the resulting completed Product shall be governed by clause (ii)); provided, in the event of any disputed invoice amounts, the parties shall
promptly and in good faith cooperate with one another to resolve such dispute; and 
 C.        in the event that this Agreement is terminated for any reason other than by Client pursuant to Section 16.2(A), Client shall pay Catalent for [ * ]. 
 16.4    Survival. The rights and obligations of the parties shall continue under Articles 11 (Intellectual
Property), 13 (Indemnification), 14 (Limitations of Liability), 17 (Notice), 18 (Miscellaneous); under Articles 10 (Confidentiality and Non-Use) and 15 (Insurance), in each case to the extent expressly stated therein; and under Sections 7.4 (Payment
Terms), 7.5 (Taxes), 7.6 (Client and Third Party Expenses), 9.2 (Recall), 12.3 (Limitations on Warranties), 16.3 (Effect of Termination) and 16.4 (Survival), in each case in accordance with their respective terms if applicable, notwithstanding
expiration or termination of this Agreement. For purposes of clarity, those terms and provisions set forth in the Quality Agreement which expressly survives termination or expiration of the Quality Agreement shall also survive termination or
expiration of this Agreement. 
 ARTICLE 17 
 NOTICE 
 All notices and other communications hereunder shall be in writing
and shall be deemed given: (A) when delivered personally; (B) when delivered by facsimile transmission (receipt verified); (C) when received or refused, if mailed by registered or certified mail (return receipt requested), postage
prepaid; or (D) when delivered if sent by express courier service, to the parties at the following addresses (or at such other address for a party as shall be specified by like notice; provided, that notices of a change of address shall
be effective only upon receipt thereof): 
  

			
	To Client:	  	InterMune, Inc.
		  	3280 Bayshore Blvd.
		  	Brisbane, CA 94005
		  	USA
		  	Attn: General Counsel
		  	Facsimile: +1 (415) 508-0006

  

 22 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

			
	To Catalent:	  	Catalent Pharma Solutions
		  	1100 Enterprise Drive
		  	Winchester, KY 40391
		  	USA
		  	Attn: VP, General Manager
		  	Facsimile: +1 (859) 745 6636
		
	With a copy to:	  	Catalent Pharma Solutions, LLC
		  	14 Schoolhouse Road
		  	Somerset, NJ 08873
		  	USA
		  	Attn: General Counsel (Legal Department)
		  	Facsimile: +1 (732) 537-6491

 ARTICLE 18

 MISCELLANEOUS 
 18.1    Entire Agreement; Amendments. This Agreement, together with the Quality Agreement, that certain Mutual Confidential Disclosure Agreement dated May 5, 2003 between
Client and Catalent (successor in interest to Cardinal Health PTS, Inc.) to the extent it relates to confidential information disclosed thereunder and the Validation Services Quotation as defined in Section 2.1 hereof, constitutes the entire
understanding between the parties, and supersedes any contracts, agreements or understandings (oral or written) of the parties, with respect to the subject matter hereof. No term of this Agreement, including but not limited to, the Quality
Agreement, may be amended except upon written agreement of both parties, unless otherwise expressly provided in this Agreement. 
 18.2    Captions; Certain Conventions. The captions in this Agreement are for convenience only and are not to be interpreted or construed as a substantive part of this Agreement. Unless otherwise expressly
provided herein or the context of this Agreement otherwise requires, (A) words of any gender include each other gender, (B) words such as “herein”, “hereof”, and “hereunder” refer to this Agreement as a whole
and not merely to the particular provision in which such words appear, (C) words using the singular shall include the plural, and vice versa, (D) the words “include(s)” and “including” shall be deemed to be followed by
the phrase “but not limited to”, “without limitation” or words of similar import, (E) the word “or” shall be deemed to include the word “and” (e.g., “and/or”) and (F) references to
“Article,” “Section,” “subsection,” “clause” or other subdivision, or to an Attachment or other appendix, without reference to a document are to the specified provision or Attachment of this Agreement. This
Agreement shall be construed as if it were drafted jointly by the parties. 
 18.3    Further
Assurances. The parties agree to execute, acknowledge and deliver such further instruments and to take all such other incidental acts as may be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement.

 18.4    No Waiver. Failure by either party to insist upon strict compliance with any term of this
Agreement in any one or more instances will not be deemed to be a waiver of its rights to insist upon such strict compliance with respect to any subsequent failure. 
  

 23 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 18.5    Severability. If any term of this Agreement is declared invalid or unenforceable by a court or other body of competent jurisdiction, the remaining
terms of this Agreement will continue in full force and effect. 
 18.6    Independent Contractors.
The relationship of the parties is that of independent contractors, and neither party will incur any debts or make any commitments for the other party except to the extent expressly provided in this Agreement. Nothing in this Agreement is intended
to create or will be construed as creating between the parties the relationship of joint ventures, co-partners, employer/employee or principal and agent. Neither party shall have any responsibility for the hiring, termination or compensation of the
other party’s employees or contractors or for any employee benefits of any such employee or contractor. 
 18.7    Successors and Assigns. This Agreement and any rights arising hereunder may not be assigned by either party without the prior written consent of the other party, which consent may not be unreasonably or
arbitrarily withheld. Notwithstanding anything to the contrary contained herein, this Agreement may be assigned by a party without the consent of the other party to an Affiliate or an acquiring person or entity upon the acquisition, merger,
consolidation of the assigning party, or of the assets or substantially all the assets by such person or entity, relating to the assigning party’s performance hereunder. Any permitted assignee shall assume all obligations of its assignor under
this Agreement. This Agreement will be binding upon and inure to the benefit of the parties, their successors and permitted assigns. 
 18.8    No Third Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any person or entity other than the parties named herein and their respective successors and permitted assigns.

 18.9    Governing Law. This Agreement shall be governed by and construed under the laws of the
State of New York, USA excluding its conflicts of law provisions. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement. 
 18.10    Alternative Dispute Resolution. If any dispute arises between the parties in connection with this Agreement, such dispute shall be presented to
the respective presidents or senior executives of Catalent and Client for their consideration and resolution. If such parties cannot reach a resolution of the dispute, then such dispute may be resolved by binding alternative dispute resolution in
accordance with the then existing commercial arbitration rules of CPR Institute for Dispute Resolution, 366 Madison Avenue, New York, NY 10017. 
 18.11    Prevailing Party. In any dispute resolution proceeding between the parties in connection with this Agreement, the prevailing party will be entitled to recover its
reasonable attorney’s fees and costs in such proceeding from the other party. 
 18.12    Force
Majeure. Except as to payments required under this Agreement, neither party shall be liable in damages for, nor shall this Agreement be terminable or cancelable by reason of, any delay or default in such party’s performance hereunder if
such default or delay is caused by events beyond such party’s reasonable control, including acts of God, law or regulation or other action or failure to act of any government or agency thereof, war or insurrection, civil commotion, destruction
of production facilities or materials by earthquake, fire, flood or weather, labor disturbances, epidemic or failure of suppliers, public utilities or common carriers;

  

 24 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
provided, that the party seeking relief under this Section shall immediately notify the other party of such cause(s) beyond such party’s reasonable control. The party that may invoke
this Section shall use commercially reasonable efforts to reinstate its ongoing obligations to the other party as soon as practicable. If the cause(s) shall continue unabated for [ * ] days, then both parties shall meet to discuss
and negotiate in good faith what modifications to this Agreement should result from such cause(s). 
 18.13    Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument. Any photocopy,
facsimile or electronic reproduction of the executed Agreement shall constitute an original. 
 [Signature page follows] 

  

 25 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 IN WITNESS WHEREOF, the parties have caused their respective duly authorized representatives to execute this Agreement effective as of
the Effective Date. 
  

									
	Catalent Pharma Solutions, LLC	 		 	InterMune, Inc.
					
	By:	 	   /s/ Ian Muir
	 		 	By:	 	   /s/ Daniel G. Welch

					
	Name:	 	   Ian Muir
	 		 	Name:	 	   Daniel G. Welch

					
	Its:	 	   VP/GM, Catalent
	 		 	Its:	 	   Chairman, CEO & President

  

 Signature Page to Commercial Manufacturing Agreement 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 ATTACHMENT A 
 VALIDATION SERVICES QUOTATION

 See attached. 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 Quotation 
 Process Validation of Pirfenidone 

 Manufacture Capsulation 
 [ * ] 
 Confidential for: 
 Shelly Barbanica 
 Associate Director Manufacturing Operations 
 Intermune, Inc. 
 3280 Bayshore Blvd. 
 Brisbane, CA 94005 
 Phone: ###### 
 E-mail: ###### 
 Catalent Contact: 
 Torin M. Dewey, Ph.D. 
 Phone: ###### 
 E-mail: ###### 
 Prepared By: 
 James Norton 
 Phone: ###### 
 E-mail: ###### 
 28 July 2009 
  

			
	

	  	 Modified Release Technologies
 1100 Enterprise Drive
 Winchester, KY 40391

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 2 of 15

  

	Section 1.	Executive Summary 

 Catalent Pharma Solutions, LLC located in Winchester, Kentucky (“Catalent”) proposes to carry out the following activities for Intermune, Inc. (“Intermune”), pursuant to the terms and conditions included herein.

 Intermune would like to validate the process that has been developed and scaled-up for the [ * ] mg
Pirfenidone capsule. 
 This program has been developed in good faith based on assumptions regarding development outcomes and
Client objectives. Therefore, risks inherent to development are borne by the work plan in order to expedite submission of this estimate and strategy. If the product does not meet the performance specifications during formulation and process
development or the dosage form fails a stability challenge, Client approved scope change would be required for further development by Catalent. 
 This quote has been presented based on assumptions regarding the ability for appropriate safe handling of the API and subsequent blends and solutions of the API and notification of current customers of
the introduction of this class of API to the manufacturing facility. 
  

	Section 2.	Project Activities, Support, and Supplies 

  

	2.1	Project Continuation Fee 

 Catalent will carry out the following project continuation activities: 
  

	 	1.	Identify project team members. 

  

	 	2.	Establish project timeline. 

  

	 	3.	Provide project management and communication plans for the following: 

  

	 	a.	Excipient ordering as noted in Section 2.4. 

  

	 	b.	Identify and receive necessary reference standards, API lots, and excipients for the manufacturing. 

  

	 	c.	Propose and document specifications, batch records, and protocols – as applicable – in support of the project. 

  

					
	2.1	 	Project Continuation Fee	  	$ [ * ]

  

	2.2	Manufacturing 

 Catalent will
carry out the following manufacturing activities in support of the project: 
  

	 	1.	Prepare batch records and protocols necessary. 

  

	 	2.	Clean the process equipment. 

  

	 	3.	Manufacture the product as outlined in Table 1. 

  

	 	4.	Prepare necessary development report(s) as outlined in Table 1. 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 3 of 15

  

 Table 1. Process Map 
  

									
	Lot status	 	Granulation
Number	 	 Blend
 Number
	 	 Encapsulation
 #
	 	 Theoretical
 Number of
 Capsules

	 Campaign I (cGMP
Process Validation)
  
	 	  	 	  	 	  	 	  
	 Process Validation batches
  
	 	 1, 2, and 3 ([ * ] kg)
  
	 	 1, 2, and 3
 ([ * ] kg)
  
	 	 1, 2, and 3
 ([ * ] kg)
  
	 	 [ * ] each batch
 ([ * ] batches)
  

  

	
	[ * ]
	[ * ]

	[ * ]

	[ * ]

	[ * ]

  

					
	 	 	Validation Protocol with implementation and report	  	 $ [ * ]

	 	 	Manufacturing Campaign I ([ * ] full scale batches)	  	 $ [ * ]

	2.2	 	Manufacturing Costs Sub-Total	  	 $ [ * ]

  

	2.3	Analytical Support 

 Catalent
will carry out the following analytical activities in support of the project: 
 cGMP full release-testing of
[ * ] ([ * ]) batches of API cGMP testing of excipient raw materials according to NF/EP per Catlent raw material specification RM-09-269. 
 cGMP Process Validation batches: 
  

	 	1.	Protocol In-process testing: 

  

	 	a.	Granulation (per batch): moisture (9) – after drying only, particle size distribution, and density. 

  

	 	b.	Blend: particle size distribution, and density, blend uniformity (assumes ten sampling points, sampled in triplicate, [ * ] samples run initially, an
additional [ * ] if a failure occurs). 

  

	 	2.	Protocol encapsulation testing (per batch): [ * ] content uniformity samples (additional [ * ] if a failure occurs),
[ * ] dissolution tests (beginning/middle/end). 

  

	 	3.	Release testing (composite per batch): appearance, assay / related substances, content uniformity, and dissolution. 

  

					
	2.3	 	cGMP Release of Excipient Raw Materials (NF/EP assumes
[ * ])*	  	$        [ * ]
	2.3	 	cGMP Release of API – full release (assumes [ * ])	  	$        [ * ]
	2.3	 	Analytical Support for Campaign I (Product Release) ($[ * ] per batch)	  	$        [ * ]
	2.3	 	Analytical Support for Campaign I (Process Validation Protocol)	  	$        [ * ]
	2.3	 	Campaign I - Cleaning Verification	  	$        [ * ]
	2.3	 	Costs Sub-Total	  	$        [ * ]

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 4 of 15

  

 * All raw material release testing assumes [ * ] per batch with additional
samples as required for EP testing. 
  

	2.4	Raw Materials, Equipment, and Supplies 

 Catalent will carry out the following raw materials procurement, equipment procurement, and testing activities as listed in Table 2. 
 Table 2. cGMP Materials Procurement 
  

					
	Item	  	Quantity	  	Estimated Cost $
	[ * ]	  	 	  	Supplied by Client
	[ * ]	  	[ * ] kg drums  	  	 [ * ]

	[ * ]	  	[ * ] kg drums  	  	 [ * ]

	[ * ]	  	[ * ] kg drums  	  	 [ * ]

	[ * ]	  	[ * ] kg drum  	  	 [ * ]

	[ * ]	  	 [ * ] boxes of
[ * ]  
 capsules  
	  	 [ * ]

	[ * ]	  	NA  	  	 [ * ]

	Estimated Freight	  	 	  	 [ * ]

	Raw Material Subtotal	  	 	  	 [ * ]

	[ * ]	  	 	  	 [ * ]

	SUB-TOTAL Table 3	  	 	  	 [ * ]

  

	Section 3.	Preliminary Timeline 

 Catalent has provided an estimated timeline (Table 3 below) for the proposed activities outlined above. All timelines are estimates based on Catalent’s experience and do not reflect other circumstances beyond Catalent’s control.

 Table 3. Estimated Timeline 
  

					
	Section Reference	  	Activity	  	Duration
	2.4	  	Order and receive excipients	  	[ * ] weeks
	2.3	  	Test raw materials	  	[ * ] weeks
	2.2	  	Manufacturing	  	[ * ] weeks
	2.3	  	Analytical Evaluation	  	[ * ] weeks

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 5 of 15

  

	Section 4.	Cost Proposal 

  

	4.1	Total Estimated Project Cost 

  

					
	Section Reference	  	Activity	  	Estimated Cost ($)
	2.1	  	Project Initiation	  	   [ * ]

	2.2	  	Manufacturing	  	   [ * ]

	2.3	  	Analytical Support	  	   [ * ]

	2.4	  	Raw Materials / Equipment Procurement	  	   [ * ]

	Total Estimated Project Cost	  	 $[ * ]

 The summary of costs detailed above does not include any extra reformulation activities, any post submission activities and/or any activities required for
commercial batch manufacture, unless otherwise specified. Additionally, it does not include any post approval tasks such as annual stability testing or storage. If requested by the Client, these costs will be quoted separately. 
  

	4.2	Project Continuation Fees 

 The
Client shall pay a non-refundable payment for the Project Continuation Fee $ [ * ]+ [ * ] and [ * ] $ [ * ] for a total of $ [ * ] upon signed delivery of the
proposal to Catalent. 
  

	4.3	Revisions to Pricing 

 Catalent
reserves the right to revise the quoted costs for any project as a result of initial scope change, revisions in protocols, modifications of test methods, final review of test methods, undocumented requirements, retesting or any unforeseen difficulty
in executing the project. In addition, the quoted costs are subject to [ * ] review to account for changes in inflation. The additional work will be performed based on written agreement from the Client and will be documented on a
Catalent Quotation Amendment Record (“QAR”). 
  

	Section 5.	Project Management 

  

	5.1	Communication 

 In order to
establish a collaborative relationship between the Client and Catalent, both parties will appoint a Project Manager to serve as a point of contact to oversee the progress on this project. Upon initiation of the project, Catalent and the Client will
establish a communication plan that may include conference calls, visits and timelines. Client communication is encouraged. 
  

	5.2	Catalent Project Management Responsibilities 

  

	 	1.	Excipient ordering for batches as described. 

  

	 	2.	Equipment ordering for batches as described. 

  

	 	3.	Identify and receive necessary reference standards, API lots, and excipients for the manufacturing. 

  

	 	4.	Propose and document specifications, batch records, and protocols - as applicable - in support of the project. 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 6 of 15

  

	 	5.	Catalent will provide sampling of raw materials, project in process materials, and project finished materials for the Client during the QC sampling of the raw materials
and during the direct processing and release of the product batches for this project.1 

  

	5.3	Client Project Management Responsibilities 

 Client agrees to provide the following supporting activities: 
  

	 	1.	The Client will sign the quote and provide a P.O. to cover the project. 

  

	 	2.	The Client will provide a technical contact that will be available for technical discussions and to make decisions that are needed for this project.

  

	 	3.	The Client will provide batch records, development reports, materials, and product specifications as required for initiation and continuation of this project, as
applicable. 

  

	 	4.	The Client will provide the cleaning verification analytical methodology for transfer to Catalent. Note: This has been completed. 

  

	 	5.	The Client will provide the API for this project. 

  

	 	6.	If the product does not meet the performance specifications during formulation, process development, or process validation, or the dosage form fails a stability
challenge, then a Client-approved scope change will be required for further development by Catalent. All required investigational work (such as OOS investigations, trouble shooting, etc.) will be conducted according to the terms of the Quality
Agreement. 

  

	 	7.	The Client will provide all specifications necessary to perform this project. 

  

	 	8.	Unused raw materials, finished products and waste, including organic solvents, will be returned or destroyed, if not used within [ * ] months of the
conclusion of the validation batches manufacturing campaign, [ * ]. (These materials will be destroyed via incineration @ $ [ * ] per kg for solid and $ [ * ] per kg for liquid waste).

  

	 	9.	Client must review with Catalent material inventory and advise Catalent on a [ * ] basis of the material status and planned date of usage. After
[ * ] days of no project activity, Catalent reserves the right to return, dispose, or maintain any of material inventories of the Client’s. Client may incur pallet storage fees of $[ * ] per pallet per month
plus additional handling charges based on inventory evaluation between Client and Catalent, as applicable. 

  

	5.4	Project Initiation and Scheduling 

 The following must be submitted prior to any project work to guarantee scheduled time in the manufacturing facility. 
  

	 	1.	The Client must provide a signed purchase order and the signed quote by fax, email, or mail a minimum of [ * ] ([ * ]) weeks prior to
any work to allow adequate time for project initiation. 

  
 1
 If additional samples not directly associated with the QC sampling of the raw materials for this project or the processing and release associated with this project are required, Catalent
will charge a sampling fee of $ [ * ] per sample to cover the handling and additional inventory accounting costs associated with the sampling. Shipping associated with these samples will be rebilled to the Client. 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 7 of 15

  

	 	2.	If raw material purchases are included in this purchase order, then the P.O. and signed quote must be received prior to the order of any raw materials (see requirements
for raw materials below). 

  

	 	3.	The Client must provide batch record details [ * ] ([ * ]) weeks prior to any batch manufacture. Batch record completion and approval
(by Catalent and the Client) must be completed [ * ] ([ * ]) business days prior to the scheduled batch manufacture. 

  

	 	4.	The Client must provide raw materials a minimum of [ * ] ([ * ]) weeks prior to batch manufacture for feasibility or demonstration
work and ([ * ]) weeks prior to batch manufacture for cGMP work. If full compendial testing is required, delivery must be a minimum of [ * ] ([ * ]) weeks prior to batch manufacture.

  

	Section 6.	Invoicing, Payment, and Shipment Terms 

  

	6.1	Invoicing Terms 

 Catalent will
issue invoices monthly for work completed in that month. 
 Payment Terms-Refer to Section 7.9 
 Remit all payments to: 
  

					
	Wire to:	  	Overnight mail to:	  	Regular mail to:
	 Wachovia
Bank 
 Address: ######
 City/State:
######
 ABA #: ######
 Swift Code:
######
 Account #: ######
 Bene:
Catalent Pharma Solutions, LLC
 Ref: Credit to Catalent Winchester
	  	 Attn:    Cheryl Flack Catalent
 1100 Enterprise Drive
 Winchester, KY
40391
	  	 Catalent Pharma Solutions, LLC
 1581 Solutions Center
 Chicago, IL
60677-1005

  

	6.2	Shipment 

 Refer to
Section 7.9 
  

	Section 7.	Additional Project Terms 

  

	7.1	Safety 

  

	7.1.1	Catalent’s Safety Responsibilities 

 Catalent will assess all vendor and Client Material Safety Data Sheets (“MSDS”) and all handling data for the samples and materials associated with this project. If categorized as a Category four (4) or five (5) (out of
a scale of five), the samples, materials and work will require special handling precautions and will be subject to a Hazardous Material Fee for all handling and testing directly associated with the samples and materials. As applicable, this
Hazardous Materials Handling Surcharge has been included in the project costs. 
  

	7.1.2	Client’s Safety Responsibilities 

 The Client will provide the MSDS and all sample and material handling data for the samples and materials associated with this project. If any sample or material has any

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 8 of 15

  

 
special handling considerations, the Client will notify Catalent prior to the initiation of the project. 
  

	7.2	Equipment Failure 

 Catalent is
not in any manner responsible for material, scheduling or financial losses due to equipment failure (beyond the direct cost of materials contained within the respective product container). In the event of equipment failure, every effort will be made
to repair the equipment and reschedule the Client in the timeliest manner. 
  

	7.3	Non-Validated Work 

 Refer to
Section 7.9 
  

	7.4	Samples 

 As applicable, the
Client will provide all samples and materials necessary to perform this project. The samples and materials should arrive at Catalent with all proper documentation. If samples and materials are not available, the Client will request that Catalent
purchase all necessary samples and materials needed to perform this project. If return shipment is requested, the Client will notify Catalent prior to the disposition of samples/materials. 
  

	7.5	Termination 

 Either party may
terminate the project or any portion thereof at any time by providing [ * ] ([ * ]) days written notice. Upon receipt of any such notice of termination, Catalent shall promptly wind down the affected portion of the
project work or study and avoid (or minimize, where not cancellable) any further related expenses. 
  

	7.6	Cancellation 

 Refer to
Section 7.9 
  

	7.7	General Shipping 

 All supplies
that are shipped to Catalent in Winchester, Kentucky must be clearly marked with the Client company name and addressed “Attention: Process Technology”. 
 All materials shipped to Catalent in Winchester, Kentucky freight collect or COD will incur an additional handling surcharge of $ [ * ] or [ * ]% of the respective bill
(whichever is greater). 
 All materials shipped to Catalent in Winchester, Kentucky that require US customs clearance must be
assigned a customs broker arranged for by the Client. 
  

	7.8	Analytical Rush Services 

 Rush
services are available at Client’s request. If rush services are agreed between Client and Catalent, additional costs will be invoiced based on the schedule below. 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 9 of 15

  

			
	% Turn Around Time (TAT) Reduction
	 	% Rush Charge
	25	 	[ * ]
	50	 	[ * ]
	75	 	[ * ]
	>75	 	[ * ]

  

	7.9	Terms and Conditions 

 The
parties agree that this quotation and all work performed hereunder is subject to the Catalent and Intermune Terms and Conditions (Attachment 1) and the Quality Agreement dated 05 April 2006 between the parties unless a commercial supply
agreement executed by parties specifically states that some or all of the terms and conditions of the supply agreement supersedes the T’s & C’s attached hereto and in the Quality Agreement. The parties agree that process
validation batch manufacturing will not commence unless the parties have executed a supply agreement. 
  

	Section 8.	Revision History 

  

			
	Revision Number	  	Comments
	[ * ]	  	Initial Proposal
	[ * ] 	  	 [ * ] lots of API, full
release testing
 Revised several terms
 Referred to the Supply Agreement and Existing T&Cs between the parties

	[ * ]	  	Noted “as applicable” in Section 5.3; clarified Section
7.9

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 10 of 15

  

	Section 9.	Project Approval and Authorization 

 Client agrees to the terms and conditions set forth in this Quotation 
 Invoicing
for the Project should be sent to: 
  

					
	Name:	 	 	  	
			
	Department:	 	 Accounts Payable
	  	
			
	Telephone No.:	 	 ######
	  	
			
	Address:	 	 3280 Bayshore Blvd.
	  	
		
	 Brisbane, CA 94005
	  	

					
			
	Purchase Order Number	 	TBD	  	

  

					
	 Intermune, Inc.
	 		  	 Catalent Pharma Solutions, LLC

			
	 /s/ Lawrence Kahn
	 		  	 /s/ Michael J. Valazza

	Signature	 		  	Signature
			
	 Lawrence Kahn
	 		  	 Michael J. Valazza, R.Ph.

	Printed Name	 		  	Printed Name
			
	 VP, Corporate Development
	 		  	Vice President, Global Business Development
	Title	 		  	 Modified Release Technologies

		 		  	Title
			
	 07/28/09
	 		  	 28 July 2009

	Date	 		  	Date

 Mail, email, or fax this completed Project
Approval and Authorization page to: 
 Cheryl Flack 
 Catalent Pharma Solutions 
 1100 Enterprise Drive 

Winchester, KY 40391 
 (859) 745-6636 (fax) 
 ###### 
 If this signed document is not returned within 5 days, any tentative manufacturing dates noted in this proposal or otherwise communicated may be assigned to another Client. 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 11 of 15

  

 
Attachment 1: 
 Catalent Pharma Solutions, LLC and InterMune Standard Terms and Conditions, 
 March 11, 2005

  

 1.        Catalent Obligations. Catalent
Pharma Solutions, LLC (“Catalent”) represents and warrants that it will perform the work defined in this quotation (the “Project”) in accordance with written specifications agreed to by the parties (“Specifications”),
applicable master batch records, protocols, standard operating procedures, all applicable laws, rules and regulations, including without limitation cGMP (as defined below)), and other written instructions agreed to by the parties (the “Project
Instructions”). As used herein “cGMP” means current Good Manufacturing Practices pursuant to (a) the U.S. Federal Food, Drug and Cosmetics Act as amended (21 USC 301 et seq.), (b) relevant U.S. regulations found in Title 21
of the U.S. Code of Federal Regulations (including but not limited to Parts 11, 210, 211, 600 and 611), (c) EEC Directive 91/356/EEC of 13 June 1991, (d) the Canadian Food and Drugs Act, Part C (drugs) and Good Manufacturing Practice
Guidelines and (e) the EC Guide to Good Manufacturing Practice for Medicinal Drug Products, including respective guidance documents and any comparable laws, rules or regulations of any agreed upon foreign jurisdiction, as each may be amended
from time to time. cGMP also includes adherence to any applicable Product license requirements, relevant current International Conference on Harmonization (ICH) guidance documents, and other relevant guidance documents. 
 2.        Customer Obligations. Unless otherwise agreed to by the parties in writing,
Customer is solely responsible to (i) provide what Customer reasonably believes to be complete and accurate scientific data regarding the Project and Customer’s requirements for the Project, including without limitation test methods and
development, formulation, fill and finish of the Product if applicable, (ii) provide Catalent with what Customer reasonably believes to be complete and accurate information necessary to develop the scope of work, and estimated or fixed costs
for the projects, (iii) review and approve all Project Instructions, (iv) if applicable, review and approve all in-process and finished product test results to ensure conformity of such results with the product Specifications, regardless
of which party is responsible for finished product release, and (v) if applicable, prepare all submissions to regulatory authorities. 
 3.        Non-Validated Work. Notwithstanding the terms of Section 1 of these Terms and Conditions, if product is to be manufactured, Customer
shall [ * ]. 
 4.        Use of Customer Materials. Catalent
will use all materials provided by Customer to Catalent to perform the Project, including without limitation active pharmaceutical ingredient, and Product (collectively, “Materials”) solely for the performance of the Project, and will not
transfer such materials to any third party other than an affiliate of Catalent actually performing the Project, in each case except with Customer prior written consent. Upon completion or earlier termination of the Project, Catalent will promptly
return or destroy any unused

 
portion of such materials. In the latter case, upon Customer’s request, Catalent will provide Customer with a certificate of destruction. Catalent shall comply with all applicable laws,
rules, regulations and guidelines in the use, storage, handling and transportation of the Materials. Customer shall retain all right, title and interest in and to all Materials at all times. 
 5.        Audits/Records. Customer may conduct [ * ] QA facility audit per [ * ]. Additional audits
will be invoiced separately at the current rate for such services. [ * ]. Catalent shall keep documentation and records in accordance with the requirements of cGMP. Catalent shall provide fully executed copies of all documents
approved by Customer promptly following signature of such documents by each party’s authorized representative. Catalent will provide Customer with copies of all records relating to its performance of the Project in accordance with the terms of
this Quotation, including but not limited to information relating to batch records, specifications, methods, method validations, equipment and the facility, for review and inclusion as necessary in Customer’s regulatory submissions, and will
supply raw data upon Customer’s request. Catalent will store all records in accordance with applicable law, including without limitation cGMP. Prior to Catalent’s destruction of any of the records or documentation relating to the Project,
Catalent shall notify Customer in writing specifically identifying the records or documentation that it wishes to destroy. Customer shall have [ * ] ([ * ]) days from its receipt of such notice to notify Catalent
that it desires to receive such records or documentation. In such event, such records or documentation shall be delivered to Customer or its designee [ * ]. If Customer does not notify Catalent that it desires to receive such
records or documentation within such [ * ]-day period, then Catalent shall be free to destroy such records or documentation. 
 6.        Pricing and Purchase Orders. Customer shall pay for the Project as provided in the attached quotation and these Terms and Conditions (collectively,
“Quotation”). Customer must provide a signed purchase order (the “Purchase Order”) and signed quotation to initiate the Project. This Quotation supercedes any terms and conditions contained in a purchase order or other
documentation exchanged by the parties. Customer’s Purchase Order should reference the Quotation Number and date of such Quotation. 
 7.        Price Changes. Catalent may revise the prices provided in this Quotation if (i) any information relating to the Project provided by Customer
is inaccurate or incomplete, 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 12 of 15

  

 
(ii) Customer materially revises Catalent’s manufacturing responsibilities, the Specifications, the Project Instructions, procedures,
assumptions, development processes, test methods or analytical requirements after Customer’s original submission of its request for a quote, or (iii) circumstances not reasonably foreseeable by Catalent affect the work required to complete
the Project. Catalent will notify Customer immediately if the costs to complete the Project will exceed the prices stated in this Quotation. Customer will have no liability for any costs in excess of those specified in this Quotation, unless agreed
to in writing in advance by an authorized officer of Customer and subject to the terms of this Section and the terms and conditions of this Quotation. Catalent will not be obligated to proceed without Customer’s approval of such additional
costs. 
 8.        Invoicing and Payment. Customer shall pay each invoice within
[ * ] days of receipt. Catalent will charge a late payment fee of [ * ]% per month, or the maximum amount permitted by law if less than [ * ]% per month, for any payment not received within
[ * ] days from receipt of invoice. Failure to bill for interest due shall not be a waiver of Catalent’s right to charge interest. Customer will pay any sales, use, gross receipts, compensating or other taxes, licenses, or fees
(excluding tax based on net income and franchise taxes) required to be paid by Catalent to any state or tax jurisdiction as a result of any action necessary to fulfill the terms of this Quotation. 
 Catalent will issue invoices based on achievement of the milestones identified in Section 4.1. If a draft report is issued Intermune
will have [ * ] ([ * ]) business days to return comments to Catalent. If no comments are received, Catalent will finalize the report and issue the final invoice. If comments are received after issuance of final report InterMune
will be billed at the current standard hourly rate for the time required to complete changes and reissue the report. 
 9.        REFUNDS, CANCELLATIONS AND POSTPONEMENT. Customer may cancel or postpone the Project or any portion thereof upon written notice. IF CUSTOMER CANCELS OR POSTPONES ANY PORTION OF THE
PROJECT WORK, CUSTOMER SHALL PAY AN ACCOMMODATION FEE AS FOLLOWS: (i) for batch manufacture, Customer shall pay a fee In accordance with the following schedule: 
  

			
	 Section 10 Notification
 prior to Date of
 Compounding
	  	Section 11 Fee (% of Total
Batch Cost)
	[ * ] days	  	[ * ]%
	[ * ] days	  	[ * ]%
	[ * ] days	  	[ * ]%
	[ * ] days	  	[ * ]%
	[ * ] days	  	[ * ]%

 and (ii) for any portion of the Project which is not batch manufacture, Customer shall pay [ * ]. Catalent will
deliver to Customer all materials paid for by Customer under this Section. Termination of this Agreement shall not relieve either party of

 
any liability or obligation which accrued hereunder prior to the effective date of such termination, nor preclude either party from pursuing all rights and remedies it may have hereunder or at
law or in equity with respect to any breach of this Agreement, nor prejudice either party’s right to obtain performance of any obligation. Sections 4, 5, 9, 13, 14, 15, 16, 18, 19, 20 and 25 through 34, inclusive, of these terms and conditions
will survive any termination hereof. 
 10.        Hazardous Materials. Customer
warrants to Catalent that no specific safe handling instructions are applicable to any substance or material provided by Customer to Catalent, except as disclosed to Catalent in writing by the Customer in sufficient time for review and training by
Catalent prior to delivery. 
 11.        Shipment. All product, raw materials
and components shipped by Catalent are shipped F.O.B. Catalent’s facilities, not including crating. 
 12.        Limitations of Liability. 
 A.        NOTWITHSTANDING ANY OTHER PROVISION IN THIS QUOTATION (INCLUDING, WITHOUT LIMITATION, SECTION 12.D.), CATALENT’S TOTAL LIABILITY UNDER THIS QUOTATION SHALL NOT EXCEED THE TOTAL AMOUNT
PAID BY CUSTOMER TO CATALENT FOR THE PROJECT, PROVIDED, HOWEVER, THAT SUCH LIMITATION SHALL NOT APPLY TO OR IN ANY MANNER LIMIT, CATALENT’S OR ITS AFFILIATES’ LIABILITY FOR CLAIMS ARISING FROM CATALENT’S OR ITS AFFILIATES’ GROSS
NEGLIGENCE OR WILLFUL MISCONDUCT. 
 B.        NOTWITHSTANDING THE
FOREGOING, CATALENT’S TOTAL LIABILITY FOR ANY LOSS OF ANY MATERIALS PROVIDED BY CUSTOMER SHALL NOT EXCEED $[ * ] PER OCCURRENCE. 
 C.        NOTWITHSTANDING ANY OTHER PROVISION IN THIS QUOTATION, CUSTOMER’S TOTAL LIABILITY FOR BREACH OF THIS QUOTATION SHALL NOT EXCEED THE TOTAL AMOUNT OWED
BY CUSTOMER TO CATALENT FOR THE PROJECT IN ACCORDANCE WITH SECTION 7, PROVIDED, HOWEVER, THAT SUCH LIMITATION SHALL NOT APPLY TO OR IN ANY MANNER LIMIT CUSTOMER’S OBLIGATION TO INDEMNIFY CATALENT FOR THIRD PARTY CLAIMS UNDER SECTION 16.

 D.        IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER
PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), WHETHER OR NOT FORESEEABLE, ARISING FROM OR RELATING TO THIS QUOTATION OR THE SUBJECT MATTER HEREOF,
PROVIDED, HOWEVER, THAT THE LIMITATION IN THIS SECTION 12.D. SHALL NOT APPLY (I) TO THE EXTENT THAT ANY INDEMNIFICATION 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 13 of 15

  

 
OBLIGATIONS SET FORTH IN SECTION 16 ARE DEEMED TO BE CONSEQUENTIAL DAMAGES, (II) TO ANY DAMAGES RESULTING SOLELY FROM A PARTY’S USE OR
DISCLOSURE OF THE OTHER PARTY’S CONFIDENTIAL INFORMATION IN BREACH OF SECTION 13 OR THE CDA, OR (III) TO ANY DAMAGES RESULTING FROM A PARTY’S BREACH OF ITS OBLIGATIONS RELATING TO INTELLECTUAL PROPERTY UNDER SECTION 14. 
 13.        Confidentiality. The parties will remain subject to the Mutual Confidentiality
Agreement entered into between the parties effective May 5, 2003 (the “CDA”). All information exchanged by the parties in connection with the Project will be deemed “Information” under the CDA. 
 14.        Intellectual Property. As used herein, “IP” means any and all
inventions, improvements, information and know-how, including without limitation those related to processes, compositions of matter and methods of use, made by or on behalf of either party individually or jointly, arising out of the performance of
the Project, whether protectable by patent or as a trade secret, and all intellectual property rights therein and thereto. Customer shall be the sole and exclusive owner of all IP developed by Catalent or its affiliates or [ * ]
which can be used solely in connection with the Product (“InterMune IP”). Catalent shall own all IP developed by Catalent or its affiliates in the performance of the Project which can be used apart from the Product without the disclosure
of any InterMune Information (as defined in the CDA) (“Cardinal IP”). [ * ]. Catalent hereby grants, and automatically will be deemed to have granted, to Customer a royalty-free, fully paid-up, non-exclusive, perpetual,
irrevocable, sublicenseable license to exploit the Cardinal IP solely in connection with the manufacture, use or sale of the Product or any improvement thereto. Catalent agrees to assign, and shall automatically be deemed to have assigned,
Catalent’s entire right, title and interest in and to all InterMune IP to Customer. Upon request by Customer, and without additional consideration, Catalent agrees to promptly execute documents, testify and take such other acts at
Customer’s expense as Customer may deem necessary or desirable to procure, maintain, perfect, and enforce the full benefits, enjoyment, rights, title and interest of the InterMune IP on a Worldwide basis, and to render all necessary or
reasonably requested assistance in making application for and obtaining original, divisional, renewal, or reissued utility and design patents, copyrights, mask works, trademarks, trade secrets, and all other technology and intellectual property
rights throughout the world related to any of the InterMune IP, in Customer’s name and for its benefit. Catalent shall promptly provide Customer with a copy of any formal invention disclosure document that relates to the IP. InterMune IP shall
be deemed to be InterMune Information under the CDA. 
 15.        Deliverables.
Cardinal will use reasonable efforts to deliver all deliverables hereunder in accordance with the timelines set forth herein. Catalent represents and warrants that all deliverables, including without limitation Product, delivered

 
to Customer hereunder will be delivered free and clear of any lien, claim or encumbrance. 
 16.        Indemnification. Customer will indemnify and hold harmless Catalent, its affiliates and their officers, directors, agents and employees against
any third party claim to the extent arising directly or indirectly from (a) any negligence or intentional wrongdoing by Customer in connection with the manufacture, promotion, marketing, distribution or sale of the Product, (b) use or exposure to
the Product or any material provided to Catalent by Customer, or (c) Catalent’s or its affiliates’ use of any intellectual property provided by Customer to Catalent, except in each case to the extent such claim is the result of
Catalent’s or its affiliates’ negligence, willful misconduct or breach of the terms of this Quotation. 
 Catalent
will indemnify and hold harmless Customer, its affiliates and their officers, directors, agents and employees for any third party claim to the extent arising directly or indirectly from (a) any negligence, intentional wrongdoing or breach of
this Quotation by Catalent or its affiliates, (b) use of any Cardinal IP, or (c) Cardinal’s or its affiliates’ misappropriation of any third party’s intellectual property, except in each case to the extent such claim is the
result of Customer’s negligence, willful misconduct or breach of the terms of this Quotation. 
 17.        Force Majeure. Neither party will be liable for any failure to perform or for delay in performance resulting from any cause beyond its reasonable control or due to compliance with
any regulations, orders, or act of any federal, provincial, state or municipal government, or any department or agency thereof, civil or military authority, acts of God, acts or omissions of the other party, fires, floods, or weather; strikes or
lockouts, factory shutdowns, embargoes, wars, hostilities or riots, delays or shortages in transportation; provided, however, that if Catalent cannot complete an order within [ * ] ([ * ]) days due to any such
cause, Customer may terminate this Quotation without liability to Catalent, and [ * ]. 
 18.        Use and Disposal. Customer represents and warrants to Catalent that all product delivered to Customer by Catalent will be held, used and/or disposed of by the Customer in accordance
with all applicable laws, rules and regulations. Customer will pay for any materials, components or equipment ordered by Catalent pursuant to this Quotation specifically for Customer, and, to the extent that such materials and components are not
consumed in Catalent’s performance of the Project, Catalent will promptly deliver all such materials and components to Customer at the completion or earlier termination of the Project. Customer will retain title to all equipment paid for by
Customer under this Quotation, and Catalent will 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 14 of 15

  

 
promptly deliver all such equipment to Customer at the completion or earlier termination of the Project. 
 19.        Unlabeled Product. If Catalent is to provide Customer with product which is not
labeled, Customer represents and warrants that it will comply with all applicable regulations, including without limitation 21 CFR § 201.150. 
 20.        Independent Contractor. The arrangement between Catalent and Customer is one of service provider and Customer. No joint venture, partnership or
agency is to be created or deemed as between Catalent and the Customer. Neither party will use the other party’s name without such party’s prior written consent. 
 21.        Publicity. Neither party will make any press release or other public disclosure regarding this Agreement or the transactions
contemplated hereby without the other party’s express prior written consent, except as required under applicable law or by any governmental agency, in which case the party required to make the press release or public disclosure shall use
commercially reasonable efforts to obtain the approval of the other party as to the form, nature and extent of the press release or public disclosure prior to issuing the press release or making the public disclosure. 
 22.        Authority. Customer grants Catalent full authority to use any Customer materials
or substances necessary to perform the Project in accordance with the terms hereof. Customer and Catalent each represent and warrant that such party has taken all necessary action on its part to authorize the execution and delivery of this Quotation
and this Quotation has been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with its terms. 
 23.        Representations and Warranties. Each party hereby represents and warrants that
(a) this Quotation does not conflict with its duties and obligations under any other agreement to which it is a party; (b) it is free to disclose any information and materials that it furnishes to the other party in connection with the
Project; (c) it has not been “debarred” by the United States Food and Drug Administration or any foreign equivalent, nor have debarment proceedings been commenced against it. Each party will promptly inform the other party in writing
should any conflict or possible conflict of duties and obligations arise, or of any debarment, or the commencement of any debarment or like proceedings against it during the term of this Quotation. 
 24.        Disclaimer of Warranties. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES
SPECIFICALLY AND EXPRESSLY SET FORTH HEREIN, THERE ARE NO OTHER WARRANTIES, REPRESENTATIONS OR GUARANTEES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, MADE BY EITHER PARTY REGARDING THIS AGREEMENT, INCLUDING WITHOUT LIMITATION ANY EXPRESS OR
IMPLIED WARRANTIES

 
OF MERCHANTABILITY, NONINFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE. 
 25.        This Quotation is personal to Catalent and may not be assigned, transferred or any obligation hereunder subcontracted, in each case without Customer’s prior written permission.

 26.        This Quotation will be governed and construed in accordance with the laws
of the State of California, USA as applied to transactions taking place wholly within California between California residents. For any legal action arising from or related to this Quotation, the parties hereby: (i) consent and submit solely to
jurisdiction and venue of the state and federal courts located in the county where the defending party is located, (ii) agree that such courts will be the sole courts utilized and (iii) hereby waive any jurisdictional or venue objections
to such courts, including without limitation, forum non conveniens. 
 27.        If any dispute arises between the parties with respect to the matters covered by this Quotation which leads to a proceeding to resolve such dispute, the prevailing party in such proceeding
will be entitled to receive its reasonable attorneys’ fees, expert witness fees and out-of-pocket costs incurred in connection with such proceeding, in addition to any other relief it may be awarded. 
 28.        Each party hereby acknowledges that the promises or agreements contained in this
Agreement relating to confidentiality or intellectual property are necessary and reasonable in order to protect the parties and their respective businesses, and each party expressly agrees that monetary damages would be inadequate to compensate the
other party for the breach thereof, and that any such violation or threatened violation will cause irreparable injury to the other party. Accordingly, in addition to any other remedies that may be available, in law, in equity or otherwise, each
party will be entitled to obtain injunctive relief against the breach or threatened breach by of such obligations by the other party, without the necessity of proving actual damages. 
 29.        In case any one or more of the provisions contained in this Quotation will, for any reason, be held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Quotation, and this Quotation will be construed as if such invalid, illegal or unenforceable provision had never been
contained herein. If moreover, any one or more of the provisions contained in this Quotation will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing
it, so as to be enforceable to the extent compatible with the applicable law as it will then appear. 
 30.        Ambiguities, if any, in this Quotation will not be construed against any party, irrespective of which party may be deemed to have authored the ambiguous provision. 
 31.        Catalent agrees not to export, directly or indirectly, any U.S. source technical data
acquired from Customer or any products utilizing such data to countries outside the United 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
	[ * ]	 	Confidential	 	Page 15 of 15

  

 States, which export may be in violation of the United States export laws or regulations.

 32.        Unless specifically and expressly provided otherwise, the remedies
provided under this Quotation are cumulative, and are not exclusive of other remedies available to a party in law or equity. 
 33.        Each party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and
intent of this Quotation. 
 34.        No waiver of any breach of this Quotation will
be a waiver of any preceding or succeeding breach. No waiver of any right under this Quotation will be construed as a waiver of any other right. No notice will be required to enforce strict adherence to all terms of this Quotation. 
 35.        Entire Agreement. This Quotation constitutes the entire agreement by the parties
related to the Project, the Product and the materials and services to be provided hereunder. Any previous written acknowledgement, statement or prior understanding between the parties related to the Project, other than the CDA, is superceded by this
Quotation. This Quotation may not be modified except in a writing executed by an authorized representative of each party. 
  

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 ATTACHMENT B 
 SPECIFICATIONS 

I. Client-Supplied Materials 
 [ * ] 
 II. Raw Materials 
  

	 	1)	[ * ] 

  

	 	2)	[ * ] 

  

	 	3)	[ * ] 

  

	 	4)	[ * ] 

  

	 	5)	[ * ] 

 III. Product
Specifications 
 [ * ] 

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 ATTACHMENT C 
 UNIT PRICING AND FEES 

 Client’s projected date of Launch: To be included via an amendment to the Agreement by the parties pursuant to Section 1.17 of
the Agreement. 
  

					
	UNIT PRICING*
	Product	 	Dosage Form / Unit Strength	 	Initial Unit Price
	Pirfenidone	 	Capsules	 	$[ * ] per thousand
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 * One unit is
[ * ] ([ * ]) capsules. Prices do not include cost of API, tooling or other Product-specific capital items (other than those items specified in Section 2.4), artwork, shipping, insurance or duty. Prices also do
not include any testing, retesting or testing supplies other than as expressly set forth in the Specifications. Prices are based on certain assumptions as to manufacturing processes, storage conditions, etc., including those set forth in that
Validation Services Quotation (as defined in Section 2.1 of the Agreement). Accordingly, prices are subject to adjustment in the event any such assumptions are subject to revision in connection with the validation of the Product under the
Validation Services Quotation; provided, however that any price adjustment shall be strictly proportional to changes arising from the specific changes in assumptions and be adequately supported. 
  

					
	ADDITIONAL FEES
	Type of Fee	 	Amount	 	Payable
	Product Maintenance Fee	 	$[ * ]	 	[ * ] Per Section 7.1(C)
	Additional Audits (beyond QAA Allowance)	 	Per Quality Agreement	 	Net [ * ] Days following invoice
	Additional Copies (beyond QAA Allowance) of
Documents	 	Per Quality Agreement	 	Net [ * ] Days following invoice
	Excess Site Visits, greater than [ * ] but
not more than [ * ] calendar man-days	 	$[ * ]	 	Net [ * ] Days following invoice
	Additional Excess Site Visits, greater than
[ * ] calendar man-days	 	$[ * ]	 	Net [ * ] Days following invoice

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 ATTACHMENT D 
 QUALITY AGREEMENT

 See attached. 

 [ * ] = Certain information on this document has been redacted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
 QUALITY AGREEMENT 

 BY AND BETWEEN 
 InterMune, Inc. 
 3280 Bayshore Blvd. 
 Brisbane, CA 94005 
 (hereafter called “INTERMUNE”) 
 Approved by: 
 InterMune, Inc. 
  

							
	By:	 	   /s/ Sandy Mohan
	  		 	Date: 9/11/09
	Sandy Mohan	  		 	
	Vice President, Quality Assurance	  		 	
	
	AND
			
	 Catalent Pharma Solutions, LLC
 1100 Enterprise Drive
 Winchester, KY 40391 USA
 (hereafter called “CATALENT”)
  
 Approved
by:
 CATALENT Pharma Solutions, LLC
	  		 	
				
	By:	 	   /s/ Jeremy Nash
	  		 	Date: 9/15/09
	 Jeremy Nash
 Director, Quality Systems

	  		 	

  
  

			
	InterMune/Catalent - KY Quality Agreement	  	Confidential
		  	Page i

  

  

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	1.	QUALITY AGREEMENT 

  

	 	1.1	Purpose 

 This QUALITY AGREEMENT shall serve
to define the quality requirements and obligations placed upon CATALENT and INTERMUNE with respect to the manufacturing, testing, storage, packaging, labeling, certification and delivery of PRODUCT. 

	 	

	 	1.2	Scope 

 This QUALITY AGREEMENT applies to the
development and manufacture of clinical and commercial supplies of Pirfenidone PRODUCT (defined in the Agreement as the “PRODUCT”). 
 This QUALITY AGREEMENT covers any PRODUCT intended for supply to any TERRITORY that applies the same PRODUCT SPECIFICATIONS and release requirements as contained in approved filings in the European Union and/or the United States of America.
If PRODUCT is intended for supply to a TERRITORY that does not apply the same PRODUCT SPECIFICATIONS and release requirements as the European Union or the United States of America, the PARTIES shall agree on terms consistent with the regulatory
requirements specific to that TERRITORY. 
 PRODUCT will be manufactured at CATALENT, Winchester, while packaging will be performed at
Catalent, Philadelphia. Stability testing will be performed at Catalent, Somerset. This AGREEMENT is between INTERMUNE and CATALENT, Winchester. 
  

	 	1.3	Relationship to Supply Agreement 

 This
QUALITY AGREEMENT shall supplement the SUPPLY AGREEMENT between CATALENT and INTERMUNE. 
 In the event of a conflict between any of the
provisions of the Supply Agreement and the Quality Agreement with respect to quality-related activities, including compliance with CGMP, the provisions of the Quality Agreement shall govern. In the event of a conflict between any of the provisions
of the Supply Agreement and the Quality Agreement with respect to any commercial matters, including allocation of risk, liability and financial responsibility, the provisions of the Supply Agreement shall govern 
  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 1 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	 	1.4	Definitions 

  

					
		 	1.4.1	  	“API” shall mean the compound pirfenidone whose chemical composition is [ * ], as further described in the SPECIFICATIONS.
			
		 	1.4.2	  	“APPLICABLE LAWS” means all laws, ordinances, rules and regulations within the Territory applicable to the PROCESSING of PRODUCT and the obligations of CATALENT or INTERMUNE, as the
context requires, including, without limitation, (i) all applicable federal, state and local laws and regulations of each Territory; (ii) the U.S. Federal Food, Drug and Cosmetic Act, and (iii) the “GMPs.” APPLICABLE LAWS
shall also include all laws, ordinances, rules and regulations applicable in TERRITORIES added to this QUALITY AGREEMENT after the Effective Date of this Agreement, solely to the extent Customer or its designee has provided written copies of such
laws to CATALENT prior to CATALENT PROCESSING PRODUCT under this QUALITY AGREEMENT. Copies of all laws shall be in the English language.
			
		 	1.4.3	  	“BATCH RECORD” shall mean the written documentation of the manufacture of a lot of PRODUCT.
			
		 	1.4.4	  	“CATALENT” shall mean the company known as Catalent Pharma Solutions, LLC, located at 1100 Enterprise Drive, Winchester, Kentucky, 40391.
			
		 	1.4.5	  	“CERTIFICATE OF ANALYSIS (COA)” is a listing of all results for tests conducted on samples of the lot of PRODUCT compared to the SPECIFICATIONS defined by INTERMUNE and listed in
regulatory applications, and applicable compendia.
			
		 	1.4.6	  	“CERTIFICATE OF COMPLIANCE (COC)” is a statement that the lot of PRODUCT was manufactured, packaged and tested in accordance with CGMPs, identifies the master batch record
documents, and lists any incident reports, investigations and corrective and/or preventative actions (CAPA) identified associated with the lot of PRODUCT.
			
		 	1.4.7	  	“CLINICAL PRODUCT” shall mean drug that is used as a test material in a human clinical trial.
			
		 	1.4.8  	  	“CMC” shall mean the Chemistry, Manufacturing and Controls section of the IND or NDA.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 2 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
		 	1.4.9  	  	“COMMERCIAL PRODUCT” shall mean a drug that has been approved for sale.
			
		 	1.4.10	  	“COMPONENTS” shall mean the EXCIPIENTS and packaging and labeling materials necessary to manufacture the PRODUCT in accordance with the PRODUCT SPECIFICATIONS. API is not included
as part of the PRODUCT COMPONENTS.
			
		 	1.4.11	  	“CRITICAL DEVIATION” shall mean a departure from an approved instruction or established standard that will affect the safety, identity, strength, purity and/or quality of a PRODUCT.

			
		 	1.4.12	  	“DATE OF MANUFACTURE” shall mean the date that the Active Pharmaceutical Ingredient is added to other components during the PROCESS.
			
		 	1.4.13	  	“EXCIPIENTS” shall mean the PRODUCT COMPONENTS, other than packaging and labeling components, required to manufacture the Bulk PRODUCT in accordance with the PRODUCT SPECIFICATIONS.

			
		 	1.4.14	  	“FACILITY” means CATALENT’s facility located in Winchester, Kentucky or such other facility as agreed upon by the parties in writing.
			
		 	1.4.15	  	“FINAL RELEASE” shall mean the release of PRODUCT by INTERMUNE after such PRODUCT has been released by CATALENT.
			
		 	1.4.16	  	“FDA” shall mean the United States Food and Drug Administration.
			
		 	1.4.17	  	“GMPs” or “CGMPs” shall mean the current Good Manufacturing Practices for Finished Pharmaceuticals promulgated by the FDA, as amended from time to time. GMPs shall also
include good manufacturing practice regulations promulgated by a REGULATORY AUTHORITY in a Territory added to this Agreement after the Effective Date of this QUALITY AGREEMENT.
			
		 	1.4.18	  	“IND” shall mean Investigational New Drug (Application).
			
		 	1.4.19	  	“INTERMUNE” shall mean InterMune, Inc. located at 3280 Bayshore Boulevard, Brisbane, California, 94005.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 3 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
		 	1.4.20	  	“MAJOR DEVIATION” shall mean a departure from an approved instruction or established standard that may effect the safety, identity, strength, purity and/or quality of a PRODUCT.

			
		 	1.4.21	  	“MARKETING AUTHORIZATION APPLICATION” shall mean an application for marketing authorization which has not yet been approved by the FDA or other REGULATORY AUTHORITY, including
without limitation, FDA New Drug Application, FDA Abbreviated New Drug Application, and other similar marketing applications promulgated by Regulatory Authorities.
			
		 	1.4.22	  	“MARKETING AUTHORIZATIONS” shall mean any approved application for marketing authorization, including without limitation, FDA New Drug Application, FDA Abbreviated New Drug
Application, and other similar MARKETING AUTHORIZATIONS promulgated by Regulatory Authorities.
			
		 	1.4.23	  	“MASTER BATCH RECORDS” shall mean the approved instructions for the manufacture of a lot of DRUG PRODUCT.
			
		 	1.4.24	  	“MANUFACTURER’S RELEASE” means CATALENT QAs formal approval indicating suitability of the PRODUCT for release by INTERMUNE QA.
			
		 	1.4.25	  	“MINOR DEVIATION” shall mean a departure from an approved instruction or established standard that does not effect the safety, identity, strength, purity and/or quality of a DRUG
PRODUCT.
			
		 	1.4.26	  	“NDA” shall mean New Drug Application.
			
		 	1.4.27	  	“OUT OF SPECIFICATION (OOS)” means a result that does not meet the approved SPECIFICATIONS.
			
		 	1.4.28	  	“PAI” shall mean any pre-approval inspection by REGULATORY AUTHORITIES.
			
		 	1.4.29	  	“PARTIES” shall mean CATALENT and INTERMUNE.
			
		 	1.4.30	  	“PRODUCT SPECIFICATIONS” shall mean the SPECIFICATIONS for the PRODUCT as agreed upon by the PARTIES, as such SPECIFICATIONS may be amended from time to time by mutual written
agreement of the PARTIES, including, without limitation such amendments as may be required to obtain PRODUCT Approval.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 4 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
		 	1.4.31	  	“PROCESS” or “PROCESSING” means the compounding, filling or pressing, producing and bulk packaging (but not secondary or retail packaging) of the API and any other
Client-supplied Materials as applicable and Raw Materials into Product, in accordance with the Specifications and under the terms of this Agreement and “Processed” has the meaning correlative to the foregoing.
			
		 	1.4.32	  	“PRODUCT” shall mean the fully compounded bulk pharmaceutical product containing the API that has been Processed in accordance with the SPECIFICATIONS. “
			
		 	1.4.33	  	“QUALITY AGREEMENT” shall mean a written legal agreement that defines mutually agreed expectations for compliance to GMPS and other applicable regulations by all
PARTIES.
			
		 	1.4.34	  	“REGULATORY AUTHORITY” shall mean the international, federal, state or local governmental or regulatory bodies, agencies, departments, bureaus, courts or other entities in the
Territory (including but not limited to the United States Food and Drug Administration and the European Medicines Agency (EMEA)) responsible for (A) the regulation (including pricing) of any aspect of pharmaceutical or medicinal products
intended for human use or (B) health, safety or environmental matters generally. “.
			
		 	1.4.35	  	“RETESTING” shall mean the additional analysis of a test sample as part of an OOS investigation, which may include re-sampling, if the original sample is depleted or it’s
handling is in question.
			
		 	1.4.36	  	“SISPQ” shall mean safety, identity, strength, purity and quality.
			
		 	1.4.37	  	“SPECIFICATIONS” means the procedures, requirements, standards, quality control testing and other data and the scope of services as set forth in Attachment B, along with any
valid amendments or modifications thereto, in accordance with Article 8 of the Supply Agreement.
			
		 	1.4.38	  	“STANDARD OPERATING PROCEDURES” (SOPs) shall mean the written practices in effect at CATALENT which have been approved by CATALENTs Quality Assurance department and which are
applicable to the PROCESS.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 5 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
		 	1.4.39	  	“SUPPLY AGREEMENT” shall mean a written legal agreement that defines mutually agreed expectations for the manufacture, storage and shipping of DRUG PRODUCT as well as financial
compensation for services rendered and agreed upon by all PARTIES.
			
		 	1.4.40	  	“TERRITORIES” means the [ * ] existing during the term of this Agreement, as well as [ * ], and any other country that the parties agree in writing to add to this
definition of Territory in an amendment to this Agreement.
			
		 	1.4.41	  	“TEST METHOD” shall mean a procedure for the analysis of PRODUCT, COMPONENTS, or API.
			
		 	1.4.42	  	“VALIDATION MASTER PLAN” shall mean a high level written strategy for the overall setup, installation, operation and/or performance of various parameters critical to the lifecycle
of the PRODUCT, COMPONENT, TEST METHOD or PROCESS.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 6 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	2.	QUALITY CONTACTS 

 INTERMUNE

 InterMune, Inc. 
 3280
Bayshore Blvd. 
 Brisbane, CA 94005 
 David Schmidt, 
 Senior Director, Quality Assurance 
 Phone: ###### 
 Fax: ###### 

E-mail: ###### 
 CATALENT

 CATALENT Pharma Solutions, LLC 
 1100 Enterprise Dr. 
 Winchester, KY 40391 
 Jeremy Nash 
 Title: Director, Quality Systems 
 Phone: ###### 
 Fax: ###### 

E-mail: ###### 
  

	3.	TERM AND TERMINATION OF AGREEMENT 

 This
QUALITY AGREEMENT shall become effective and binding upon approval by both CATALENT and INTERMUNE. This QUALITY AGREEMENT will expire or terminate automatically upon the expiration or termination of the SUPPLY AGREEMENT. Notwithstanding the
expiration or termination of this QUALITY AGREEMENT, the rights and obligations of Retain Samples, PRODUCT Complaints and Recalls, Records Retention and Regulatory Compliance of this QUALITY AGREEMENT shall survive. 
  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 7 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	4.	GENERAL STATEMENT 

  

	 	4.1	Both CATALENT and INTERMUNE shall operate in compliance with CGMP requirements and all APPLICABLE LAWS, regulations, and local laws concerning manufacture, quality assurance and
quality control of the PRODUCT. 

  

	 	4.2	The detailed steps with regard to the Services to be fulfilled by CATALENT are listed in the SUPPLY AGREEMENT. The tasks and responsibilities to be carried out by the PARTIES
under this QUALITY AGREEMENT are listed in detail herein. 

  

	5.	MANUFACTURING AND CGMP COMPLIANCE 

  

	 	5.1	Premises 

  

					
		 	5.1.1	  	CATALENT will perform required operations for manufacturing activities at its Winchester, Kentucky FACILITY.
			
		 	5.1.2	  	CATALENT shall be responsible for maintaining CGMP compliance of all operations, including manufacturing, testing, storage, packaging, labeling, certification and delivery of
PRODUCT.
			
		 	5.1.3	  	CATALENT will maintain controlled access to the premises according to established CATALENT systems and procedures.

  

	 	5.2	Active Pharmaceutical Ingredient (API) 

  

					
			
		 	5.2.1	  	INTERMUNE is responsible for providing CATALENT with API that meets SPECIFICATIONS and a CERTIFICATE OF ANALYSIS from the API vendor.
			
		 	5.2.2	  	INTERMUNE is responsible for qualifying the API manufacturer to ensure full compliance with GMPs and APPLICABLE LAWS and will provide CATALENT with a statement of qualification for each API
manufacturer.
			
		 	5.2.3	  	CATALENT and INTERMUNE are responsible for creating and approving SPECIFICATIONS for API.
			
		 	5.2.4	  	CATALENT is responsible for sampling, testing, and releasing each lot of API according to internal SOPs and approved SPECIFICATIONS.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 8 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
		 	5.2.5	  	CATALENT will store the API at the facilities in accordance with the API SPECIFICATIONS until manufacture of the PRODUCT.

  

	 	5.3	Components 

  

					
		 	5.3.1	  	CATALENT is responsible for ensuring that all COMPONENTS procured by CATALENT for use in the PRODUCT are in full compliance with SPECIFICATIONS. CATALENT will only use COMPONENTS released by
its Quality Department in accordance with CATALENT SOPs.
			
		 	5.3.2	  	CATALENT is responsible for auditing and qualifying vendors of COMPONENTS used in PRODUCT according to approved internal procedures.
			
		 	5.3.3	  	CATALENT is responsible for creating SPECIFICATIONS for COMPONENTS. CATALENT and INTERMUNE are responsible for approving such SPECIFICATIONS.
			
		 	5.3.4	  	CATALENT is responsible for ensuring that all COMPONENTS are stored properly, appropriately sampled and tested according to CATALENT SOPs upon receipt, used correctly, and traceable to the
relevant CERTIFICATE OF ANALYSIS.
			
		 	5.3.5	  	INTERMUNE is responsible for ensuring that COMPONENTS provided by INTERMUNE (if any) for use in the PRODUCT are in full compliance with the registered SPECIFICATIONS and are accompanied by a
CERTIFICATE OF ANALYSIS

  

	 	5.4	Production 

  

					
			
		 	5.4.1	  	CATALENT is responsible for creating PRODUCT-specific master documents (e.g. MASTER BATCH RECORDS, SPECIFICATIONS and analytical procedures) according to its established formats and approved
procedures. CATALENT and INTERMUNE are is responsible for approving PRODUCT-specific master documents.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 9 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
		 	5.4.2	  	CATALENT is responsible for maintaining any SOPs required to manufacture, test, store, disposition for release PRODUCT, and destroy materials, in accordance with applicable CGMP regulations.

			
		 	5.4.3	  	CATALENT is responsible for maintenance, qualifications and validation of the FACILITY, equipment, instruments, computer systems and PROCESSES associated with the PRODUCT, including cleaning
validation and PRODUCT changeover procedures.
			
		 	5.4.4	  	CATALENT will manufacture the PRODUCT in a suitably controlled environment and such facilities will be regularly monitored for parameters critical to the PROCESS to demonstrate compliance
with (i) applicable CGMP guidelines and (ii) any conditions registered in the NDA or IND application.
			
		 	5.4.5	  	CATALENT is responsible for performing manufacturing operations (including in-PROCESS testing) in accordance with the approved Master Batch records and SPECIFICATIONS. CATALENT will not
rework PRODUCT batches.
			
		 	5.4.6	  	CATALENT is responsible for labeling bulk PRODUCT in accordance with the SPECIFICATIONS.
			
		 	5.4.7	  	CATALENT is responsible for packaging PRODUCT in accordance with the SPECIFICATIONS and for shipping PRODUCT upon FINAL RELEASE to final packaging and labeling site.
			
		 	5.4.8	  	INTERMUNE will have the option to be present in the plant during all PRODUCT-related activities in accordance with the required notice period of the Supply Agreement.
			
		 	5.4.9	  	CATALENT and INTERMUNE are jointly responsible for performing PRODUCT specific investigations.
			
		 	5.4.10	  	CATALENT will store the bulk PRODUCT in accordance with the SPECIFICATIONS pending release of the PRODUCT to the packaging FACILITY.
			
		 	5.4.11	  	CATALENT is responsible for periodic trending of manufacturing data, as agreed upon by both PARTIES.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 10 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	 	5.5	Lot Codes and Expiration Date 

  

					
		 	5.5.1	  	CATALENT will assign and apply lot codes and expiration dates on the bulk PRODUCT on a lot-by-lot basis per STANDARD OPERATING PROCEDURES.
			
		 	5.5.2	  	INTERMUNE is responsible for providing the approved PRODUCT Expiration Date.

  

	 	5.6	Storage and Shipment 

  

					
		 	5.6.1	  	CATALENT will store the bulk PRODUCT under conditions specified by PRODUCT label requirements as supplied by INTERMUNE. CATALENT will ensure that during storage before shipping of the
PRODUCT, appropriate controls are in place to insure that there is no interference, theft, contamination, or mixture with any other products or materials. INTERMUNE will provide details of any labeling requirements, container sealing and integrity,
and storage and shipping conditions for the PRODUCT.
			
		 	5.6.2	  	The PRODUCT will be labeled and packaged according to instructions provided to CATALENT in writing by INTERMUNE and complying with CGMP.
			
		 	5.6.3	  	CATALENT will maintain proper segregation of the PRODUCT according to established CATALENT systems and procedures. Different types of products will not be mixed on a single
pallet.
			
		 	5.6.4	  	Only PRODUCT that has completed FINAL RELEASE will be shipped by CATALENT to INTERMUNE-designated locations approved by INTERMUNE. CATALENT can ship commercial PRODUCT that is under
quarantine to other Catalent sites mentioned in the Scope of this document. Shipment of Clinical Trial Materials (“CTM”) that are under quarantine requires prior written consent from INTERMUNE Quality Assurance.

  

	6.	QUALITY UNIT 

  

	 	6.1	Product Testing 

  

					
		 	6.1.1	  	CATALENT shall conduct release testing on every batch of PRODUCT and issue a COA.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 11 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
			
		 	6.1.2	  	Each in-process test performed by CATALENT shall have defined acceptance criteria (i.e. action limit) and each PRODUCT release test shall have a SPECIFICATION assigned. Changes to the TEST
METHODS, acceptance criteria, or SPECIFICATIONS shall be handled under Change Control.
			
		 	6.1.3	  	INTERMUNE may perform testing to confirm CATALENT test results, [ * ]. Dispute resolution for conflicting test data shall be handled in accordance with this Quality
Agreement.
			
		 	6.1.4	  	CATALENT will provide INTERMUNE with a list of all contract test laboratories and services provided in support of PRODUCT.
			
		 	6.1.5	  	CATALENT shall ensure the compliance with CGMPs of any testing laboratories that may be contracted by CATALENT to perform its testing of the PRODUCT or materials used in the manufacture of
the PRODUCT.
			
		 	6.1.6	  	CATALENT shall conduct OOS investigations in accordance with its approved procedures and inform INTERMUNE within [ * ] ([ * ]) working days by e-mail or facsimile of any OOS
investigation requiring RETESTING of a batch or any confirmed OOS.
			
		 	6.1.7	  	INTERMUNE and CATALENT are jointly responsible for approving investigation reports for all OOSs.
			
		 	6.1.8	  	CATALENT shall provide a OOS investigation report to INTERMUNE with the release documentation for the PRODUCT.

  

	 	6.2	Deviations 

  

					
		 	6.2.1	  	CATALENT shall fully investigate, evaluate, and document any CRITICAL DEVIATION, MAJOR DEVIATION or MINOR DEVIATION occuring during the course of manufacturing, testing, packaging, labeling,
storage, and shipping of the PRODUCT in accordance with approved procedures
			
		 	6.2.2	  	CATALENT shall notify INTERMUNE, in writing, of any CRITICAL DEVIATION or MAJOR DEVIATION related to the PRODUCT, including any previously shipped DRUG PRODUCT batches. For MAJOR DEVIATIONS
this notification will occur within [ * ] ([ * ]) working days after being notified of the deviation. For CRITICAL

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 12 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
			
		 		  	DEVIATIONS, this notification should occur as soon as reasonably practicable.
			
		 	6.2.3	  	INTERMUNE and CATALENT are jointly responsible for approving investigation results for CRITICAL DEVIATIONS and MAJOR DEVIATIONS.
			
		 	6.2.4	  	CATALENT shall provide a list of all DEVIATIONS to INTERMUNE with the release documentation for the PRODUCT.

  

	 	6.3	Lot Disposition 

  

					
		 	6.3.1	  	CATALENT QA is responsible for the MANUFACTURER’S RELEASE of PRODUCT. INTERMUNE QA is responsible for the FINAL RELEASE of PRODUCT.
			
		 	6.3.2	  	CATALENT QA reviews and approves BATCH RECORDS according to its approved internal procedures.
			
		 	6.3.3	  	The executed batch record must be reviewed by both CATALENT and INTERMUNE for a period of time (“Initial Period”) that is mutually agreed upon. Initial Period is the period of time
related to the manufacturing of the Process Validation lots and ([ * ]) PRODUCT batches after the Process Validation campaign. After CATALENT review and approval of the manufacturing batch record and analytical test results, CATALENT will
send copies of the following documentation to INTERMUNE QA for its review:

							
				
		 		    	•	  	Copies of executed BATCH RECORDS and analytical data
				
		 		    	•	  	Copies of MINOR AND MAJOR DEVIATION reports and investigations associated with the batch.
				
		 		    	•	  	Certificate of Analysis (COA)
				
		 		    	•	  	Certificate of Compliance (COC)

					
			
		 		  	After the completion of the Initial Period, CATALENT will send

							
				
		 		    	•	  	Certificate of Analysis;
				
		 		    	•	  	Certificate of Compliance;
				
		 		    	•	  	A list of all batch deviations;

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 13 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

							
		 		    	•	  	Copies of all deviation and OOS/OOT investigations and sheet (“Reconciliation Sheet”) which reports miscellaneous batch information. The specific batch information to be included on
the Reconciliation Sheet will be developed and mutually agreed to by both parties. Examples of the type of information for the Reconciliation Sheet include, Kg of Product per batch, a list of investigations for deviations or OOS per batch,
in-process yields, etc.

  

					
		 	6.3.4	  	CATALENT QA shall release PRODUCT batches to INTERMUNE within [ * ] days from the last unit operation.
			
		 	6.3.5	  	For the FINAL RELEASE, INTERMUNE QA shall review all deviations and investigations as part of its review and release process.
			
		 	6.3.6	  	INTERMUNE will review the PRODUCT batch records and all associated documentation and provide comments to CATALENT within [ * ] ([ * ]) calendar days of receiving the
documentation. CATALENT agrees to respond to the comments and any deficiencies or discrepancies within [ * ] ([ * ]) business days.
			
		 	6.3.7	  	CATALENT will provide additional requested information (e.g., investigation reports, summary of SOPs) to INTERMUNE in order for INTERMUNE to complete the disposition of the
PRODUCT.
			
		 	6.3.8	  	INTERMUNE shall notify CATALENT of its disposition of the PRODUCT in writing. PRODUCT cannot be shipped until CATALENT receives the INTERMUNE FINAL RELEASE.
			
		 	6.3.9	  	Conforming and Non-conforming Product

  

							
		 		  	6.3.9.1	  	After the approval by CATALENT of the batch production records, INTERMUNE shall review the Certificate of Analysis and other documentation provided by CATALENT to determine whether the
Product conforms to the Product Specifications (including the master batch record) and was produced in compliance with CGMPs (including compliance with CATALENT’s current SOPs).

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 14 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

							
		 		  	6.3.9.2	  	If INTERMUNE believes that any batch of Product is non-conforming, it shall notify CATALENT by phone within the required time period (with prompt confirmation of such notice in writing by fax
or overnight courier), including such detailed explanation as INTERMUNE can then offer for such non-conformity based on the information then available to INTERMUNE. Upon receipt of such oral notice from INTERMUNE, CATALENT will investigate such
alleged non-conformity diligently within [ * ] ([ * ]) days.
				
		 		  	6.3.9.3	  	If CATALENT agrees that the Product is non-conforming, CATALENT will deliver to INTERMUNE a corrective action plan within such [ * ] ([ * ]) business day period or such
additional time as is reasonable required, as mutually agreed upon by the Parties if such investigation requires data from sources other than CATALENT or INTERMUNE.
				
		 		  	6.3.9.4	  	If CATALENT does not agree that the Product is non-conforming, CATALENT will so notify INTERMUNE by telephone within [ * ] ([ * ]) days (with prompt confirmation of such notice
in writing by fax or overnight courier), including such detailed explanation as CATALENT can then offer based on the information then available to CATALENT.
				
		 		  	6.3.9.5	  	If the Parties dispute whether the Product is conforming or non-conforming or whether the non-conformance was caused by CATALENT or INTERMUNE, samples of the Product will be submitted to a
mutually acceptable Third Party testing laboratory for resolution, whose determination of conformity or non-conformity and the party responsible therefore shall be binding on the Parties. [ * ].
				
		 		  	6.3.9.6	  	Product cannot be deemed non-conforming based solely on attributes listed as information only or a specification of “record.”

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 15 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	 	6.4	Reserve Samples 

  

					
		 	6.4.1	  	CATALENT will store and inspect retain samples of PRODUCT, API, and EXCIPIENTS according to CATALENT SOPs. The amount of sample retained will be at least twice the quantity required to carry
out all of the tests required to determine if the material meets its SPECIFICATIONS.
			
		 	6.4.2	  	CATALENT will retain samples of the PRODUCT for at least [ * ] ([ * ]) year beyond the expiry period and will retain samples of API for at least [ * ] year after
expiration date of the last lot of PRODUCT that the API was used in.
			
		 	6.4.3	  	For clinical trial materials that do not have an expiration date, reserve samples shall be maintained for a period not less than [ * ] ([ * ]) years from the conclusion of the
trial in which the lots were used. Prior to the destruction of any such sample, CATALENT shall give written notice thereof to INTERMUNE, and INTERMUNE shall have the right to request, receive and retain such samples.
			
		 	6.4.4	  	For other components or EXCIPIENTS used in the manufacture or packaging of the PRODUCT, sufficient samples shall be retained, per CATALENT internal procedures.

  

	 	6.5	Records Retention 

  

					
		 	6.5.1	  	CATALENT will retain, at a minimum, lot production records for the PRODUCT and COMPONENTS for a period of [ * ] ([ * ]) years from the date of disposition by InterMune, or such
longer period of time as may be required by applicable regulatory requirements. CATALENT will retain validation records and associated documentation according to CATALENT’s SOPs.
			
		 	6.5.2	  	CATALENT will notify INTERMUNE prior to destruction of PRODUCT related records.

  

	 	6.6	Product Complaints 

  

					
		 	6.6.1	  	INTERMUNE is responsible for receiving and initially investigating any PRODUCT complaints, whether they are quality or patient-related. INTERMUNE will notify CATALENT of any problems thought
to be due to manufacturing or shipping of the PRODUCT.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 16 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
		 	6.6.2	  	When requested by INTERMUNE, CATALENT will promptly perform investigations for these problems. Investigation reports should be completed within [ * ] ([ * ]) calendar days
following the date of receipt of the complaint by CATALENT.
			
		 	6.6.3	  	INTERMUNE is responsible for reporting any complaint to the appropriate REGULATORY AUTHORITY including adverse drug events reports.
			
		 	6.6.4	  	Any complaint received by CATALENT will be forwarded to INTERMUNE within [ * ] ([ * ]) business day.

  

	 	6.7	Product Recalls 

  

					
		 	6.7.1	  	INTERMUNE, with data and assistance provided by CATALENT, is responsible for filing field alerts and initiating PRODUCT recalls when necessary. INTERMUNE will provide CATALENT with a copy of
any regulatory correspondence related to field alerts or recalls.
			
		 	6.7.2	  	In the event that CATALENT has reason to believe that any PRODUCT should be recalled or withdrawn from distribution, CATALENT shall promptly inform INTERMUNE in writing.
			
		 	6.7.3	  	INTERMUNE shall notify the FDA, and any applicable foreign regulatory agencies of any PRODUCT recall, and shall be responsible for coordinating all necessary activities regarding the action
taken.
			
		 	6.7.4	  	CATALENT and INTERMUNE agree to cooperate fully regarding any proposed recall, PRODUCT withdrawal, or field correction; and the PARTIES agree to keep each other advised, and to exchange
copies of such documentation as may be required, to assure regulatory compliance.

  

	7.	VALIDATION 

  

	 	7.1	CATALENT shall ensure that all PROCESS, equipment, utilities, facilities, computer, cleaning and method validations are compliant to manufacture, test, package, and label PRODUCT
according to its approved procedures and shall ensure that PROCESS, equipment, computer systems, cleaning procedures and analytical methods remain in a validated state. 

  

	 	7.2	CATALENT will generate a VALIDATION MASTER PLAN. 

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 17 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	 	7.3	PROCESS, cleaning, and TEST METHOD validation protocols and reports related to the PRODUCT will be reviewed and approved by INTERMUNE. A copy of each approved PRODUCT, PROCESS,
and TEST METHOD validation protocol and report shall be forwarded to INTERMUNE. 

  

	8.	CHANGE MANAGEMENT 

  

	 	8.1	Change Control Request Initiated by CATALENT  

  

					
		 	8.1.1	  	CATALENT will follow change control procedures for all changes that may or may not affect the safety, identity, strength, purity, or quality (SISPQ) of the PRODUCT.
			
		 	8.1.2	  	CATALENT will not make changes that may affect the safety, identity, strength, purity or quality (SISPQ) of the PRODUCT relating to the CGMP manufacture of PRODUCT without obtaining prior
written approval of INTERMUNE. The changes may include the following but are not limited to, changes in PRODUCT SPECIFICATIONS, TEST METHOD, equipment, COMPONENTS, API or PROCESS, SOPs and/or batch records relating to the CGMP manufacturing of
PRODUCT.
			
		 	8.1.3	  	CATALENT shall provide INTERMUNE with the most current version of the MASTER BATCH RECORDS and SPECIFICATIONS for PRODUCT, COMPONENTS and TEST METHODS. Any authorized changes will be
implemented consistent with CATALENT SOPs. Any changes which are determined by CATALENT not to affect the safety, identity, strength, purity or quality (SISPQ) of the PRODUCT will be documented and forwarded to INTERMUNE.

  

	 	8.2	Change Control Request Initiated by INTERMUNE 

  

					
		 	8.2.1	  	Changes requested by INTERMUNE that are to be implemented at CATALENT will be approved in writing by both INTERMUNE and CATALENT according to appropriate SOPs. Once the change has been
implemented, CATALENT must forward a copy of the completed change implementation documents to INTERMUNE.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 18 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	9.	REGULATORY COMPLIANCE 

  

	 	9.1	Regulatory Inspections 

  

					
		 	9.1.1	  	INTERMUNE and its licensees shall inform CATALENT (and vice versa) with as much advance notice as possible, but at least within [ * ] ([ * ]) business day of notification, of
any regulatory activities of which they become aware that could reasonably be expected to prompt an Inspection at CATALENT involving the PRODUCT (e.g. pre-approval or for cause Inspections).
			
		 	9.1.2	  	CATALENT will inform INTERMUNE within [ * ] ([ * ]) business day of any regulatory inspections that may involve the PRODUCT and permit representative(s) from INTERMUNE Quality
to be present. If they choose not to be present, then INTERMUNE shall receive daily updates of the inspection. Updates will be scheduled at times that are convenient to CATALENT.
			
		 	9.1.3	  	CATALENT will secure INTERMUNE’s agreement prior to making any commitment to a regulatory agency regarding PRODUCT.
			
		 	9.1.4	  	CATALENT will inform INTERMUNE within [ * ] ([ * ]) business day, in writing, of any regulatory issue that impact the ability to manufacture the PRODUCT.
			
		 	9.1.5	  	For regulatory observations that specifically involve the PRODUCT, CATALENT shall hold discussions with INTERMUNE sufficiently in advance of any CMC commitment to a regulatory agency.
INTERMUNE shall prepare and/or comment on CATALENT proposed responses within time commitments needed to address regulatory concerns. INTERMUNE and CATALENT have joint final approval for the PRODUCT responses to be submitted.
			
		 	9.1.6	  	For regulatory observations that involve any quality, production, material, laboratory, facilities, equipment or packaging system-related CGMP issues, which are not specific to the PRODUCT,
CATALENT has final approval for the responses to be submitted.
			
		 	9.1.7	  	CATALENT shall provide INTERMUNE, upon request, with copies of completed regulatory Inspection reports and responses. In each case said reports shall be purged only of trade secret or other
confidential or proprietary information of CATALENT that is unrelated to its obligations under this QUALITY AGREEMENT or is unrelated to PRODUCT, prior to filing the response.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 19 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	 	9.2	Regulatory Actions 

  

					
		 	9.2.1	  	INTERMUNE will notify CATALENT of any regulatory actions on the PRODUCT that may impact CATALENT. INTERMUNE will promptly forward any regulatory correspondence on the PRODUCT to CATALENT.

			
		 	9.2.2	  	CATALENT agrees to supply INTERMUNE with any manufacturing, testing, or storage data within [ * ], if requested, as the result of a regulatory inspection, or a potential regulatory
exposure such as a recall, field alert, or significant PRODUCT complaint.

  

	 	9.3	Regulatory Affairs 

  

					
		 	9.3.1	  	INTERMUNE is responsible for [ * ].
			
		 	9.3.2	  	CATALENT will support the preparation of the regulatory submission section of the NDA (for example, review. the Quality sections of the NDA).
			
		 	9.3.3	  	CATALENT will support the review of all documentation provided to INTERMUNE to support regulatory submission.
			
		 	9.3.4	  	INTERMUNE will be responsible for making final decisions regarding CMC regulatory strategy.
			
		 	9.3.5	  	INTERMUNE will provide a copy of final regulatory submissions to CATALENT Quality Assurance for reference during inspections.
			
		 	9.3.6	  	CATALENT will provide support for INTERMUNE with respect to proposing appropriate CMC regulatory strategies and identifying potential regulatory consequences for issues involving PRODUCT.

			
		 	9.3.7	  	INTERMUNE is responsible for preparing any Annual Report as required by applicable regulations. At least [ * ] ([ * ]) calendar days before the Annual Report due date, INTERMUNE
shall request in writing from CATALENT the chemistry, manufacturing, and controls data required for submission of the Annual Report. CATALENT will provide the requested information to INTERMUNE within [ * ] ([ * ]) calendar days of the
request.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 20 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	 	9.4	Right to Audit 

  

					
		 	9.4.1	  	Upon reasonable notice to CATALENT, CATALENT shall permit INTERMUNE or its mutually agreed upon appointed representatives (hereinafter “Auditors”) to conduct audits of all
documents, procedures and facilities of CATALENT applicable to PRODUCT for the purposes described herein (hereinafter an “Audit”).
			
		 	9.4.2	  	INTERMUNE or its Auditors may have access to CATALENT for routine audit purposes [ * ] a year for [ * ] ([ * ]) to [ * ] ([ * ]) days with up to [ * ]
([ * ]) Auditors for [ * ] PRODUCT.
			
		 	9.4.3	  	Any Auditor conducting an audit shall be advised of confidentiality obligations, shall be instructed on relevant CATALENT security policies and shall follow such security and FACILITY access
procedures as are reasonably designated by CATALENT.
			
		 	9.4.4	  	Further audits or additional Auditors may be accommodated by mutual agreement. Such audits shall be conducted during regular business hours.
			
		 	9.4.5	  	INTERMUNE and its Auditors shall be entitled to (a) conduct “for cause” investigative audits to address significant PRODUCT quality or safety problems, and (b) perform
on-site reviews of completed PRODUCT BATCH RECORDS.
			
		 	9.4.6	  	For Cause audits shall relate to significant operational concerns at CATALENT, and may include, but are not limited to, lot rejection by INTERMUNE, unresolved OOS investigations, an FDA
Warning Letter or any deficiency letter issued by a Health Authority, as they pertain to systems or observations associated with the testing of PRODUCT. Such inspections or audits, to the extent reasonably practical, shall be conducted in a manner
that shall not materially interrupt or impair any significant operations at CATALENT.

  

	 	9.5	Audit Closeout 

  

					
		 	9.5.1	  	An exit meeting shall be held between representatives from CATALENT and INTERMUNE and/or its Auditors to discuss significant audit observations.
			
		 	9.5.2	  	INTERMUNE shall provide a written notification of all Audit observations within [ * ] ([ * ]) business days to CATALENT.

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 21 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

					
		 	9.5.3	  	CATALENT shall provide INTERMUNE with a written response within [ * ] ([ * ]) business days of receiving the written notification of audit observations from INTERMUNE. CATALENT
shall use its best efforts to correct all noted deficiencies as soon as practicable.

  

	10.	ANNUAL PRODUCT REVIEW, ANNUAL REVIEW 

  

	 	10.1	Annual Product Review –Commercial Product 

 CATALENT will supply INTERMUNE with the information necessary for INTERMUNE to perform an Annual Product Review for the PRODUCT. All information should be reported whether or not it affects the safety, identity, strength, purity or quality
(SISPQ) of the Product. Such information represents activities that occurred at CATALENT in the manufacturing, testing, storage or validation of the Product in the previous year, and a summary of lots made, released, and rejected, analytical test
results (finished product and in-process) and trends, trends of critical process parameters, summaries of investigations, deviations, change controls, corrective actions, etc. 
 CATALENT will send INTERMUNE a copy of [ * ] executed batch record on an annual basis after the Initial Period. 
  

	 	10.2	Annual Review - Clinical Trial Material 

 CATALENT will perform an Annual Review for the product and will issue a report to INTERMUNE. This report will cover all manufacturing and testing performed by CATALENT. Changes to the manufacturing process, testing or validation of the
Product will be reviewed on an annual basis and a summary of lots produced, released and rejected will be provided. 
  

	11.	DISPUTE RESOLUTION 

  

	 	11.1	Non-Conformity Dispute 

 In the event that a
dispute arises between CATALENT and INTERMUNE regarding the nonconformity of a lot of the PRODUCT, or regarding other matters, then both companies shall in good faith promptly attempt to resolve disputed issues. INTERMUNE may only dispute a lot of
PRODUCT which has been Dispositioned for Release by CATALENT. Financial liability shall be determined according to the SUPPLY Agreement. INTERMUNE Quality Representatives will resolve any disputes or conflicts relating to this QUALITY AGREEMENT in a
timely

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 22 of 23

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 
and equitable manner, in compliance with all applicable regulatory requirements, and in accordance with CCGMPs. Such resolutions shall be in writing and will be signed by CATALENT and INTERMUNE.
If any issue remains unresolved for more than [ * ] ([ * ]) business days, senior corporate representatives from each party will meet to resolve the issue. 
  

	 	11.2	Test Result Dispute 

 In the event that a
dispute arises between CATALENT and INTERMUNE in the testing performed by CATALENT for the PRODUCT, the resolution will proceed in stages. The first stage requires direct communication between Quality representatives from both Parties to determine
that the methods of analysis are the same and are being executed in the same manner at both sites. Second, carefully controlled and split samples according to a mutually agreed upon plan should be sent from one site to another in an attempt to reach
agreement. Should there be a failure to achieve resolution, analysts from both parties will be required to meet to work through the analysis of a mutually agreeable sample. If these actions fail to achieve resolution, and only after these avenues
have been exhausted, a qualified referee laboratory will be used to achieve resolution. This laboratory must be agreeable to both parties prior to use. The results from this referee laboratory will be used as final authority to determine
responsibilities, but whatever the outcome, INTERMUNE retains the right to determine Product release status. 
  

	12.	MISCELLANEOUS 

  

	 	12.1	Amendments / Review 

 This QUALITY AGREEMENT
may only be amended or modified by written agreement of both PARTIES. This QUALITY AGREEMENT or any current amended version will stand until otherwise amended. This QUALITY AGREEMENT will be periodically reviewed. 
  

	13.	COUNTERPARTS 

  

	 	13.1	This QUALITY AGREEMENT may be executed in one or more counterparts, each of which will be deemed an original, and all of which together shall constitute one and the same
instrument. 

  

			
	 InterMune/Catalent - KY Quality Agreement
	  	Confidential
		  	Page 23 of 23EXHIBIT 4.1

 Exhibit 4.1 
 Indenture, dated December 16, 2009, by and among DuPont Fabros Technology, L.P., DuPont Fabros 
 Technology, Inc., certain of its subsidiaries and U.S. Bank National Association 
  
  
 DuPont Fabros
Technology, L.P. 
 as Issuer 
 the Guarantors party hereto 
 and 
 U.S. Bank National Association 
 as Trustee 
  
  
 Indenture 

 Dated as of December 16, 2009 
  
  
 8 1/2% 
 Senior Notes 

 Due 2017 
  
  

 CROSS-REFERENCE TABLE 
  

						
	 TIA Sections
	  	 Indenture Sections

	§	310	 	 (a)
	  	7.10
			 	 (b)
	  	7.08
	§	311	 		  	7.03
	§	312	 		  	11.02
	§	313	 		  	7.06
	§	314	 	 (a)
	  	4, 4.02
			 	 (c)
	  	11.04
			 	 (e)
	  	11.05
	§	315	 	 (a)
	  	7.01, 7.02
			 	 (b)
	  	7.02, 7.05
			 	 (c)
	  	7.01
			 	 (d)
	  	7.02
			 	 (e)
	  	6.12, 7.02
	§	316	 	 (a)
	  	2.05, 6.02, 6.04, 6.05
			 	 (b)
	  	6.06, 6.07
			 	 (c)
	  	11.02
	§	317	 	 (a) (1)
	  	6.08
			 	 (a) (2)
	  	6.09
			 	 (b)
	  	2.03
	§	318	 		  	11.01

  

 i 

 RECITALS 
  

					
	ARTICLE 1
	DEFINITIONS AND INCORPORATION BY REFERENCE
			
	Section 1.01.	 	 Definitions.
	  	2
	
	ARTICLE 2
	THE NOTES
			
	Section 2.01.	 	 Form, Dating and Denominations; Legends
	  	30
	Section 2.02.	 	 Execution and Authentication; Exchange Notes; Additional Notes
	  	32
	Section 2.03.	 	 Registrar, Paying Agent and Authenticating Agent; Paying Agent to Hold Money in Trust
	  	33
	Section 2.04.	 	 Replacement Notes
	  	33
	Section 2.05.	 	 Outstanding Notes
	  	34
	Section 2.06.	 	 Temporary Notes
	  	34
	Section 2.07.	 	 Cancellation
	  	35
	Section 2.08.	 	 CUSIP and CINS Numbers
	  	35
	Section 2.09.	 	 Registration, Transfer and Exchange
	  	35
	Section 2.10.	 	 Restrictions on Transfer and Exchange
	  	39
	Section 2.11.	 	 Temporary Offshore Global Notes
	  	41
	
	ARTICLE 3
	REDEMPTION; OFFER TO PURCHASE
			
	Section 3.01.	 	 Optional Redemption
	  	42
	Section 3.02.	 	 Optional Redemption upon Equity Offerings
	  	42
	Section 3.03.	 	 Method and Effect of Redemption
	  	43
	Section 3.04.	 	 Offer to Purchase
	  	44
	
	ARTICLE 4
	COVENANTS
			
	Section 4.01.	 	 Payment Of Notes
	  	46
	Section 4.02.	 	 Maintenance of Office or Agency
	  	46
	Section 4.03.	 	 Existence
	  	47
	Section 4.04.	 	 Payment of Taxes and other Claims
	  	47
	Section 4.05.	 	 Maintenance of Properties and Insurance
	  	47
	Section 4.06.	 	 Limitation on Indebtedness.
	  	48
	Section 4.07.	 	 Maintenance of Total Unencumbered Assets
	  	51
	Section 4.08.	 	 Limitation on Sale and Leaseback Transactions
	  	51
	Section 4.09.	 	 Limitation on Restricted Payments
	  	52

  

 ii 

					
	Section 4.10.	 	 Limitation on Dividend and Other Payment Restrictions Affecting Restricted Subsidiaries
	  	57
	Section 4.11.	 	 Limitation on Issuance and Sale of Capital Stock of Restricted Subsidiaries
	  	59
	Section 4.12.	 	 Limitation on Guarantees by Restricted Subsidiaries
	  	59
	Section 4.13.	 	 Limitation on Transactions with Affiliates
	  	60
	Section 4.14.	 	 Limitation on Asset Sales
	  	62
	Section 4.15.	 	 Repurchase of Notes Upon a Change of Control
	  	64
	Section 4.16.	 	 SEC Reports and Reports to Holders
	  	65
	Section 4.17.	 	 Reports to Trustee
	  	66
	Section 4.18.	 	 Suspension of Covenants
	  	66
	Section 4.19.	 	 Sale of Restricted Securities
	  	68
	
	ARTICLE 5
	CONSOLIDATION, MERGER AND SALE OF ASSETS
			
	Section 5.01.	 	 Consolidation, Merger and Sale of Assets by the Company
	  	68
	Section 5.02.	 	 Consolidation, Merger and Sale of Assets by a Guarantor
	  	69
	
	ARTICLE 6
	DEFAULT AND REMEDIES
			
	Section 6.01.	 	 Events of Default
	  	70
	Section 6.02.	 	 Acceleration
	  	72
	Section 6.03.	 	 Other Remedies
	  	73
	Section 6.04.	 	 Waiver of Past Defaults
	  	73
	Section 6.05.	 	 Control by Majority
	  	73
	Section 6.06.	 	 Limitation on Suits
	  	73
	Section 6.07.	 	 Rights of Holders to Receive Payment
	  	74
	Section 6.08.	 	 Collection Suit by Trustee
	  	74
	Section 6.09.	 	 Trustee May File Proofs of Claim
	  	74
	Section 6.10.	 	 Priorities
	  	75
	Section 6.11.	 	 Restoration of Rights and Remedies
	  	75
	Section 6.12.	 	 Undertaking for Costs
	  	75
	Section 6.13.	 	 Rights and Remedies Cumulative
	  	75
	Section 6.14.	 	 Delay or Omission Not Waiver
	  	76
	Section 6.15.	 	 Waiver of Stay, Extension or Usury Laws
	  	76
	
	ARTICLE 7
	THE TRUSTEE
			
	Section 7.01.	 	 General
	  	76
	Section 7.02.	 	 Certain Rights of Trustee
	  	77
	Section 7.03.	 	 Individual Rights of Trustee
	  	79

  

 iii 

					
	Section 7.04.	 	 Trustee’s Disclaimer
	  	79
	Section 7.05.	 	 Notice of Default
	  	79
	Section 7.06.	 	 Reports by Trustee to Holders
	  	80
	Section 7.07.	 	 Compensation And Indemnity
	  	80
	Section 7.08.	 	 Replacement of Trustee
	  	80
	Section 7.09.	 	 Successor Trustee by Merger
	  	82
	Section 7.10.	 	 Eligibility
	  	82
	Section 7.11.	 	 Money Held in Trust
	  	82
	
	ARTICLE 8
	DEFEASANCE AND DISCHARGE
			
	Section 8.01.	 	 Discharge of Company’s Obligations
	  	82
	Section 8.02.	 	 Legal Defeasance
	  	83
	Section 8.03.	 	 Covenant Defeasance
	  	85
	Section 8.04.	 	 Application of Trust Money
	  	85
	Section 8.05.	 	 Repayment to Company
	  	85
	Section 8.06.	 	 Reinstatement
	  	86
	
	ARTICLE 9
	AMENDMENTS, SUPPLEMENTS AND WAIVERS
			
	Section 9.01.	 	 Amendments Without Consent of Holders
	  	86
	Section 9.02.	 	 Amendments With Consent of Holders
	  	87
	Section 9.03.	 	 Effect of Consent
	  	88
	Section 9.04.	 	 Trustee’s Rights and Obligations
	  	88
	Section 9.05.	 	 Conformity With Trust Indenture Act
	  	89
	Section 9.06.	 	 Payments for Consents
	  	89
	
	ARTICLE 10
	GUARANTEES
			
	Section 10.01.	 	 The Guarantees
	  	89
	Section 10.02.	 	 Guarantee Unconditional
	  	89
	Section 10.03.	 	 Discharge; Reinstatement
	  	90
	Section 10.04.	 	 Waiver by the Guarantors
	  	90
	Section 10.05.	 	 Subrogation and Contribution
	  	91
	Section 10.06.	 	 Stay of Acceleration
	  	91
	Section 10.07.	 	 Limitation on Amount of Guarantee
	  	91
	Section 10.08.	 	 Execution and Delivery of Guarantee
	  	91
	Section 10.09.	 	 Release of Guarantee
	  	91

  

 iv 

					
	ARTICLE 11
	MISCELLANEOUS
			
	Section 11.01.	 	 Trust Indenture Act of 1939
	  	92
	Section 11.02.	 	 Noteholder Communications; Noteholder Actions
	  	92
	Section 11.03.	 	 Notices
	  	94
	Section 11.04.	 	 Certificate and Opinion as to Conditions Precedent
	  	94
	Section 11.05.	 	 Statements Required in Certificate or Opinion
	  	95
	Section 11.06.	 	 Payment Date Other Than a Business Day
	  	95
	Section 11.07.	 	 Governing Law
	  	95
	Section 11.08.	 	 No Adverse Interpretation of Other Agreements
	  	95
	Section 11.09.	 	 Successors
	  	95
	Section 11.10.	 	 Duplicate Originals
	  	95
	Section 11.11.	 	 Separability
	  	96
	Section 11.12.	 	 Table of Contents and Headings
	  	96
	Section 11.13.	 	 No Liability of Directors, Officers, Employees, Incorporators, Members and Stockholders
	  	96

  

 v 

			
	EXHIBITS	  	
	EXHIBIT A	  	Form of Note
	EXHIBIT B	  	Form of Supplemental Indenture
	EXHIBIT C	  	Restricted Legend
	EXHIBIT D	  	DTC Legend
	EXHIBIT E	  	Regulation S Certificate
	EXHIBIT F	  	Rule 144A Certificate
	EXHIBIT G	  	Accredited Investor Certificate
	EXHIBIT H	  	Certificate of Beneficial Ownership
	EXHIBIT I	  	Temporary Offshore Global Note Legend

  

 vi 

 INDENTURE, dated as of December 16, 2009, between DuPont Fabros Technology, L.P., a
Maryland limited partnership, as the Company, the Guarantors party hereto, and U.S. Bank National Association, a national banking association, as Trustee. 
 RECITALS 
 The Company has duly authorized the
execution and delivery of the Indenture to provide for the issuance of up to $550,000,000 aggregate principal amount of the Company’s 8 1/2% Senior Notes Due 2017, and, if and when issued, any Additional Notes, together with any Exchange Notes issued therefor as provided herein (the
“Notes”). All things necessary to make the Indenture a valid agreement of the Company, in accordance with its terms, have been done, and the Company has done all things necessary to make the Notes (in the case of the Additional
Notes, when duly authorized), when executed by the Company and authenticated and delivered by the Trustee and duly issued by the Company, the valid obligations of the Company as hereinafter provided. 
 In addition, the Guarantors party hereto have duly authorized the execution and delivery of the Indenture as guarantors of the Notes. All
things necessary to make the Indenture a valid agreement of each Guarantor, in accordance with its terms, have been done, and each Guarantor has done all things necessary to make the Note Guarantees, when the Notes are executed by the Company and
authenticated and delivered by the Trustee and duly issued by the Company, the valid obligations of such Guarantor as hereinafter provided. 
 The Indenture is subject to, and will be governed by, the provisions of the Trust Indenture Act that are required to be a part of and govern indentures qualified under the Trust Indenture Act. 

 THIS INDENTURE WITNESSETH 
 For and in consideration of the premises and the purchase of the Notes by the Holders thereof, the parties hereto covenant and agree, for
the equal and proportionate benefit of all Holders, as follows: 
 ARTICLE 1 
 DEFINITIONS AND INCORPORATION BY REFERENCE 
 Section 1.01. Definitions.  
 “Accredited Investor” shall have the meaning set forth in Rule 501(a) of the Securities Act. 
 “Accredited Investor Certificate” means a certificate substantially in the form of Exhibit G hereto. 
 “Acquired Indebtedness” means Indebtedness of a Person existing at the time such Person becomes a Restricted Subsidiary or assumed in connection with an Asset Acquisition from such Person
by a Restricted Subsidiary whether or not Incurred by such Person in connection with, or in anticipation of, such Person becoming a Restricted Subsidiary or such Asset Acquisition; provided that Indebtedness of such Person that is redeemed,
defeased, retired or otherwise repaid at the time of or immediately upon consummation of the transactions by which such Person becomes a Restricted Subsidiary or such Asset Acquisition shall not be Acquired Indebtedness. 
 “act” of a Holder has the meaning set forth in Section 11.02(b)(1). 
 “Additional Interest” means additional interest owed to the Holders pursuant to a Registration Rights Agreement.

 “Additional Notes” means any Notes issued under the Indenture in addition to the Original Notes, including
any Exchange Notes issued in exchange for such Additional Notes, having the same terms in all respects as the Original Notes except that interest will accrue on the Additional Notes from their date of issuance. 
 “Adjusted Consolidated Net Income” means, for any period, the aggregate net income (or loss) of the Company and its
Restricted Subsidiaries for such period determined on a consolidated basis in conformity with GAAP (without taking into account Unrestricted Subsidiaries); provided that the following items shall be excluded in computing Adjusted Consolidated
Net Income, without duplication: 
 (1) the net income (or loss) of any Person, other than the Company or a
Restricted Subsidiary, except to the extent of the amount of dividends or other distributions actually paid to the Company or any of its Restricted Subsidiaries by such Person during such period; 
  

 2 

 (2) the net income (or loss) of any Restricted Subsidiary to the extent that
the declaration or payment of dividends or similar distributions by such Restricted Subsidiary of such net income is not at the time permitted by the operation of the terms of its charter or any agreement, instrument, judgment, decree, order,
statute, rule or governmental regulation applicable to such Restricted Subsidiary; 
 (3) any after-tax gains or
losses attributable to Asset Sales; 
 (4) any after-tax gains or losses from the extinguishment of debt
including gains and losses from the termination of Interest Rate Agreements; 
 (5) all extraordinary gains and
extraordinary losses; 
 (6) any gain or loss realized as a result of the cumulative effect of a change in
accounting principles; 
 (7) any non-cash goodwill or intangible asset impairment charges or tangible asset
impairment charges resulting from the application of Statement of Financial Accounting Standards Nos. 141, 141R, 142, or 144, as applicable; and 
 (8) all non-cash expenses related to stock-based compensation plans or other non-cash compensation, including stock option non-cash expenses. 
 “Adjusted EBITDASC” means EBITDASC, which shall be further adjusted, for the purposes of the Interest Coverage Ratio and
the Leverage Ratio, for Pro Forma Lease Revenues until the Four Quarter Period ended September 30, 2010. 
 “Adjusted Total Assets” means, for any Person, the sum of: 
 (1) Total Assets for such
Person as of the end of the calendar quarter preceding the Transaction Date as set forth on the most recent quarterly or annual consolidated balance sheet of the Company and its Restricted Subsidiaries, prepared in conformity with GAAP; and

 (2) any increase in Total Assets following the end of such quarter including, without limitation, any increase
in Total Assets resulting from the application of the proceeds of any additional Indebtedness. 
 “Affiliate”
means, as applied to any Person, any other Person directly or indirectly controlling, controlled by, or under direct or indirect common control

  

 3 

 
with, such Person. For purposes of this definition, “control” (including, with correlative meanings, the terms “controlling,” “controlled by” and “under common
control with”), as applied to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract
or otherwise. 
 “Agent” means any Registrar, Paying Agent or Authenticating Agent. 
 “Agent Member” means a member of, or a participant in, the Depositary. 
 “AI Global Note” means a Global Note representing Notes subsequently resold to Accredited Investors. 
 “Applicable Premium” means, with respect to any Note on any redemption date the greater of (i) 1.0% of the principal
amount of such Note and (ii) the excess (if any) of (a) the present value at such redemption date of (1) the redemption price of such Note at December 15, 2013, as set forth in Section 3.01 plus (2) all required
interest payments due on such Note through December 15, 2013 (excluding accrued but unpaid interest), computed using a discount rate equal to the Treasury Rate on such redemption date plus 50 basis points over (b) the principal
amount of such Note. 
 “Asset Acquisition” means: 
 (1) an investment by the Company or its Restricted Subsidiaries in any other Person pursuant to which such Person shall
become a Restricted Subsidiary or shall be merged into or consolidated with the Company or any of its Restricted Subsidiaries; or 
 (2) an acquisition by the Company or any of its Restricted Subsidiaries from any other Person that constitutes substantially all of a division or line of business of such Person. 
 “Asset Disposition” means the sale or other disposition by the Company or any of its Restricted Subsidiaries, other than to
the Company or another Restricted Subsidiary, of: 
 (1) all or substantially all of the Capital Stock of any
Restricted Subsidiary, or 
 (2) all or substantially all of the assets that constitute a division or line of
business of the Company or any of its Restricted Subsidiaries. 
 “Asset Period” has the meaning assigned to
such term in Section 4.14. 
  

 4 

 “Asset Sale” means any sale, transfer or other disposition, including by
way of merger, consolidation or Sale and Leaseback Transaction, in one transaction or a series of related transactions by the Company or any of its Restricted Subsidiaries to any Person other than the Company or any of its Restricted Subsidiaries of
any assets or properties consisting of: 
 (1) all or any of the Capital Stock of any Restricted Subsidiary;

 (2) all or substantially all of the property and assets of an operating unit or business of the Company or any
of its Restricted Subsidiaries; or 
 (3) any other property and assets of the Company or any of its Restricted
Subsidiaries (other than Capital Stock of a Person that is not a Restricted Subsidiary) and, in each case, that is not governed by Section 5.01; 
 provided that “Asset Sale” shall not include: 
  

	 	(a)	sales or other dispositions of property or assets (including leases of real estate assets) in the ordinary course of business of the Company or such Restricted
Subsidiary; 

  

	 	(b)	sales or other dispositions of inventory, receivables and other current assets; 

  

	 	(c)	sales, transfers or other dispositions of assets with a Fair Market Value, or involving net proceeds to the Company or a Restricted Subsidiary, not in excess of $10
million in any transaction or series of related transactions; 

  

	 	(d)	sales or other dispositions of assets for consideration at least equal to the Fair Market Value of the assets sold or disposed of, to the extent that the consideration
received would satisfy the requirements for reinvestment set forth in Section 4.14; 

  

	 	(e)	the sale or other disposition of cash or Temporary Cash Investments; 

  

	 	(f)	dispositions of accounts receivable in connection with the compromise, settlement or collection thereof in the ordinary course of business; 

  

	 	(g)	a Restricted Payment or Permitted Investment that is permitted by Section 4.09; 

  

 5 

	 	(h)	the exchange of assets, provided that (x) the Board of Directors has determined in good faith that the Fair Market Values of the exchanged assets are approximately
equal and (y) at least 75% of the consideration for such exchange constitutes assets or other property of a kind useful to or usable by the Company or any of its Restricted Subsidiaries in its business as conducted prior to the date of such
exchange; provided, however, that any cash consideration shall constitute Net Cash Proceeds subject to Section 4.14; 

  

	 	(i)	the creation and existence of a Lien not prohibited by the Indenture and the sale or transfer of assets pursuant to, or as a result of, foreclosure of any such Lien;

  

	 	(j)	the sale or other disposition of damaged, worn out or other obsolete property in the ordinary course of business. 

 “Attributable Debt” means, in respect of a Sale and Leaseback Transaction, the present value, discounted at the interest
rate implicit in the Sale and Leaseback Transaction, of the total obligations of the lessee for rental payments during the remaining term of the lease in the Sale and Leaseback Transaction. 
 “Authenticating Agent” refers to a Person engaged to authenticate the Notes in the stead of the Trustee. 
 “Average Life” means at any date of determination with respect to any debt security, the quotient obtained by dividing:

  

	 	(1)	the sum of the products obtained by multiplying: 

  

	 	(A)	the number of years from such date of determination to the dates of each successive scheduled principal payment of such debt security, and 

  

	 	(B)	the amount of such principal payment; by 

  

	 	(2)	the sum of all such principal payments. 

 “bankruptcy default” has the meaning assigned to such term in Section 6.01. 
  

 6 

 “Board of Directors” means: 
 (1) with respect to the Company, its board of directors or, if the Company does not have a board of directors, the board of
directors of its general partner; 
 (2) with respect to Holdings, its board of directors; and 
 (3) with respect to any other Person, (i) if the Person is a corporation, the board of directors of the corporation,
(ii) if the Person is a partnership, the board of directors of the general partner of the partnership, (iii) if the Person is a member managed limited liability company, the Board of Directors of its managing member, and (iv) with
respect to any other Person, the board or committee of such Person serving a similar function. 
 “Board
Resolution” means a copy of a resolution certified by the Secretary or an Assistant Secretary of a company to have been duly adopted by the Board of Directors of such company and to be in full force and effect on the date of such
certificate, and delivered to the Trustee. 
 “Business Day” means any day except a Saturday, Sunday or other
day on which commercial banks in Washington, D.C., New York City or in the city where the Corporate Trust Office of the Trustee is located are authorized by law to close. 
 “Capital Stock” means, with respect to any Person, any and all shares, interests, participation or other equivalents (however designated, whether voting or non-voting), including
partnership interests, whether general or limited, in the equity of such Person, whether outstanding on the Issue Date or issued thereafter. 
 “Capitalized Lease” means, as applied to any Person, any lease of any property, whether real, personal or mixed, of which the discounted present value of the rental obligations of such
Person as lessee, in conformity with GAAP, is required to be capitalized on the balance sheet of such Person. 
 “Capitalized Lease Obligations” means the discounted present value of the rental obligations under a Capitalized Lease as reflected on the balance sheet of such Person in accordance with GAAP. 
 “Certificate of Beneficial Ownership” means a certificate substantially in the form of Exhibit H. 
 “Certificated Note” means a Note in registered individual form without interest coupons. 
  

 7 

 “Change of Control” means such time as: 
 (1) a “person” or “group” (as such terms are defined in Sections 13(d) and 14(d)(2) of the Exchange Act),
other than Lammot J. du Pont, Hossein Fateh or any entities at least 75% of the Voting Stock of which is owned by Lammot J. du Pont and/or Hossein Fateh, becomes the ultimate “beneficial owner” (as defined in Rule 13d-3 under the Exchange
Act) of more than 50% of the total voting power of the Voting Stock of Holdings or, other than by Holdings, of the Company; 
 (2) during any period of two consecutive years after the Issue Date, individuals who at the beginning of such period constitute the Board of Directors of Holdings or the Company (together with any new or
replacement directors whose election by the Board of Directors or whose nomination by the Board of Directors for election by Holding’s shareholders was approved by a vote of at least a majority of the members of the Board of Directors then
still in office who either were members of the Board of Directors on the Issue Date or whose election or nomination for election was so approved) cease for any reason to constitute a majority of the members of the Board of Directors then in office;
or 
 (3) Holdings ceases to be the general partner of the Company. 
 “Code” means the Internal Revenue Code of 1986. 
 “Commission” means the Securities and Exchange Commission. 
 “Common Stock” means, with respect to any Person, any and all shares, interests, participations or other equivalents
(however designated, whether voting or non-voting) that have no preference on liquidation or with respect to distributions over any other class of Capital Stock, including partnership interests, whether general or limited, of such Person’s
equity, whether outstanding on the Issue Date or issued thereafter, including, without limitation, all series and classes of common stock. 
 “Company” means the party named as such in the first paragraph of the Indenture or any successor obligor under the Indenture and the Notes pursuant to Section 5.01. 
 “Consolidated Interest Expense” means, for any period, without duplication, the aggregate amount of interest expense, in
respect of Indebtedness during such period, all as determined on a consolidated basis (without taking into account Unrestricted Subsidiaries) in conformity with GAAP including, without limitation: 
 (1) capitalized interest; 
  

 8 

 (2) (i) amortization of original issue discount with respect to
(x) the Notes and (y) any other Indebtedness and (ii) the interest portion of any deferred payment obligation, calculated in accordance with GAAP; 
 (3) all commissions, discounts and other fees and expenses owed with respect to letters of credit and bankers’
acceptance financing; 
 (4) the net costs associated with Interest Rate Agreements and Indebtedness that is
Guaranteed or secured by assets of the Company or any of its Restricted Subsidiaries; and 
 (5) all but the
principal component of rentals in respect of Capitalized Lease Obligations paid, accrued or scheduled to be paid or to be accrued by the Company and its Restricted Subsidiaries; 
 excluding (A) the amount of such interest expense of any Restricted Subsidiary if the net income of such Restricted Subsidiary is excluded in the calculation of Adjusted Consolidated Net
Income pursuant to clause (2) of the definition thereof (but only in the same proportion as the net income of such Restricted Subsidiary is excluded from the calculation of Adjusted Consolidated Net Income pursuant to clause (2) of the
definition thereof), (B) any premiums, fees and expenses (and any amortization thereof) paid in connection with the incurrence of any Indebtedness, all as determined on a consolidated basis (without taking into account Unrestricted
Subsidiaries) in conformity with GAAP, (C) any non-cash interest expense arising from the application of Statement of Financial Accounting Standards No. 133 or the adoption of FASB Staff Position No. APB 14-1, including unrealized gains or
losses from Interest Rate Agreements and (D) any after-tax gains or losses from the termination of Interest Rate Agreements. 
 “Corporate Trust Office” means the office of the Trustee at which the corporate trust business of the Trustee is principally administered, which at the date of the Indenture is located at 60 Livingston Avenue, St. Paul,
Minnesota 55107-2292. 
 “Covenant Suspension Event” has the meaning assigned to such term in
Section 4.18. 
 “Currency Agreement” means any foreign exchange contract, currency swap agreement or
other similar agreement or arrangement. 
 “Default” means any event that is, or after notice or passage of
time or both would be, an Event of Default. 
 “Depositary” means the depositary of each Global Note, which
will initially be DTC. 
  

 9 

 “Disqualified Stock” means any class or series of Capital Stock of any
Person that by its terms or otherwise is: 
 (1) required to be redeemed prior to the Stated Maturity of the
Notes; 
 (2) redeemable at the option of the holder of such class or series of Capital Stock, other than Units,
at any time prior to the Stated Maturity of the Notes; or 
 (3) convertible into or exchangeable for Capital
Stock referred to in clause (1) or (2) above or Indebtedness having a scheduled maturity prior to the Stated Maturity of the Notes, 
 provided that any Capital Stock that would not constitute Disqualified Stock but for provisions thereof giving holders thereof the right to require such Person to repurchase or redeem such Capital Stock upon the occurrence of an
“asset sale” or “change of control” occurring prior to the Stated Maturity of the Notes shall not constitute Disqualified Stock if the “asset sale” or “change of control” provisions applicable to such Capital
Stock are no more favorable to the holders of such Capital Stock than the provisions contained in Section 4.14 and Section 4.15 and such Capital Stock specifically provides that such Person will not repurchase or redeem any such stock
pursuant to such provision prior to the Company’s repurchase of the Notes as are required to be repurchased pursuant to Section 4.14 and Section 4.15. 
 “DTC” means The Depository Trust Company, a New York corporation, and its successors. 
 “DTC Legend” means the legend set forth in Exhibit D. 
 “EBITDASC” means, for any period, without duplication, Adjusted Consolidated Net Income for such period plus, to the extent such amount was deducted in calculating such Adjusted Consolidated Net Income: 

(1) Consolidated Interest Expense, and to the extent not reflected in Consolidated Interest Expense but otherwise deducted
in calculating Adjusted Consolidated Net Income, (i) amortization of original issue discount with respect to (x) the Notes and (y) any other Indebtedness Incurred after the Issue Date and (ii) the interest portion of any deferred
payment obligation, calculated in accordance with GAAP; 
 (2) income taxes (other than income taxes (either
positive or negative) attributable to extraordinary gains or losses or sales of assets); 
  

 10 

 (3) depreciation expense; 
 (4) amortization expense; and 
 (5) all other non-cash items reducing Adjusted Consolidated Net Income (other than items that will require cash payments and for which an accrual or reserve is, or is required by GAAP to be, made),

 less all non-cash items increasing Adjusted Consolidated Net Income (other than straight line rent and below market lease
amortization), all as determined on a consolidated basis for the Company and its Restricted Subsidiaries in conformity with GAAP; provided that, if any Restricted Subsidiary is not a Wholly Owned Restricted Subsidiary, EBITDASC (or Adjusted
EBITDASC, as appropriate) shall be reduced (to the extent not otherwise reduced in accordance with GAAP) by an amount equal to: 
 (a) the amount of the Adjusted Consolidated Net Income attributable to such Restricted Subsidiary multiplied by 
 (b) the percentage ownership interest in the income of such Restricted Subsidiary not owned on the last day of such period by
the Company or any of its Restricted Subsidiaries. 
 “Equity Interests” means Capital Stock and all warrants,
options or other rights to acquire Capital Stock (but excluding any debt security that is convertible into, or exchangeable for, Capital Stock). 
 “Equity Offering” means a public or private offering of Capital Stock (other than Disqualified Stock) of the Company or Holdings, if such proceeds are contributed as equity to the
Company. 
 “Event of Default” has the meaning assigned to such term in Section 6.01. 
 “Excess Proceeds” has the meaning assigned to such term in Section 4.14. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 “Exchange Notes” means the Notes of the Company issued pursuant to the Indenture in exchange for, and in an aggregate
principal amount equal to, the Initial Notes or any Initial Additional Notes in compliance with the terms of a Registration Rights Agreement and containing terms substantially identical to the Initial Notes or any Initial Additional Notes (except
that (i) such Exchange Notes will be registered under the Securities Act and will not be subject to transfer restrictions or bear the Restricted Legend, and (ii) the provisions relating to Additional Interest will be eliminated).

  

 11 

 “Exchange Offer” means an offer by the Company to the Holders of the
Initial Notes or any Initial Additional Notes to exchange outstanding Notes for Exchange Notes, as provided for in a Registration Rights Agreement. 
 “Exchange Offer Registration Statement” means the Exchange Offer Registration Statement as defined in a Registration Rights Agreement. 
 “Fair Market Value” means the price that would be paid in an arm’s-length transaction under the applicable
circumstances, as determined in good faith by the Board of Directors, whose determination shall be conclusive if evidenced by a Board Resolution. 
 “Four Quarter Period” means the then most recent four fiscal quarters prior to the applicable Transaction Date for which financial information is available. 
 “Funds From Operations” for any period means the consolidated net income of the Company and its Restricted Subsidiaries for
such period in conformity with GAAP (without taking into account Unrestricted Subsidiaries) excluding gains or losses from debt restructurings and sales of depreciable operating property, plus depreciation of real property (including
furniture and equipment) and amortization related to real property and other non-cash charges related to real property, after adjustments for unconsolidated partnerships and joint ventures. 
 “GAAP” means generally accepted accounting principles in the United States of America as in effect as of the Issue Date,
including without limitation, as set forth in the Financial Accounting Standards Board’s “Accounting Standards Codification.” All ratios and computations contained or referred to in the Indenture shall be computed in conformity with
GAAP applied on a consistent basis. 
 “Global Note” means a Note in registered global form without interest
coupons. 
 “Guarantee” means any obligation, contingent or otherwise, of any Person directly or indirectly
guaranteeing any Indebtedness of any other Person and, without limiting the generality of the foregoing, any obligation, direct or indirect, contingent or otherwise, of such Person: 
 (1) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness of such other Person; or

  

 12 

 (2) entered into for purposes of assuring in any other manner the obligee of
such Indebtedness of the payment thereof or to protect such obligee against loss in respect thereof (in whole or in part); 
 provided,
that the term “Guarantee” shall not include endorsements for collection or deposit in the ordinary course of business. The term “Guarantee” used as a verb has a corresponding meaning. 
 “Guaranteed Indebtedness” has the meaning set forth in Section 4.12. 
 “Guarantor” means Holdings and the Subsidiary Guarantors, collectively. 
 “Holder” or “Noteholder” means the registered holder of any Note. 
 “Holdings” means DuPont Fabros Technology, Inc., and any permitted successor pursuant to Section 5.02. 
 “Incur” means, with respect to any Indebtedness, to incur, create, issue, assume, Guarantee or otherwise become liable for
or with respect to, or become responsible for, the payment of, contingently or otherwise, such Indebtedness, including an “Incurrence” of Acquired Indebtedness; provided that neither the accrual of interest nor the accretion of
original issue discount shall be considered an Incurrence of Indebtedness. 
 “Indebtedness” means, with
respect to any Person at any date of determination (without duplication): 
 (1) all indebtedness of such Person
for borrowed money; 
 (2) all obligations of such Person evidenced by bonds, debentures, notes or other similar
instruments; 
 (3) the face amount of letters of credit or other similar instruments (excluding obligations with
respect to letters of credit (including trade letters of credit) securing obligations (other than obligations described in (1) or (2) above or (5), (6) or (7) below) entered into in the ordinary course of business of such Person
to the extent such letters of credit are not drawn upon or, if drawn upon, to the extent such drawing is reimbursed no later than the third Business Day following receipt by such Person of a demand for reimbursement); 
 (4) all unconditional obligations of such Person to pay the deferred and unpaid purchase price of property or services, which
purchase price is due more than six months after the date of placing such property in service or taking delivery and title thereto or the completion of such services, except Trade Payables; 
  

 13 

 (5) all Capitalized Lease Obligations; 
 (6) all Indebtedness of other Persons secured by a Lien on any asset of such Person, whether or not such Indebtedness is
assumed by such Person; provided that the amount of such Indebtedness shall be the lesser of (A) the Fair Market Value of such asset at that date of determination and (B) the amount of such Indebtedness; 
 (7) all Indebtedness of other Persons Guaranteed by such Person to the extent such Indebtedness is Guaranteed by such Person;
and 
 (8) to the extent not otherwise included in this definition or the definition of Consolidated Interest
Expense, obligations under Currency Agreements and Interest Rate Agreements, 
 if, and to the extent, any of the preceding items (other than
items (3), (6), (7) or (8)) would appear as a liability upon a balance sheet of such Person prepared in accordance with GAAP. 
 The amount of Indebtedness of any Person at any date shall be the outstanding balance at such date of all unconditional obligations of the type described above and, with respect to obligations under any
Guarantee, the maximum liability upon the occurrence of the contingency giving rise to the obligation; provided that: 
 (a) the amount outstanding at any time of any Indebtedness issued with original issue discount shall be deemed to be the face amount with respect to such Indebtedness less the remaining unamortized
portion of the original issue discount of such Indebtedness at the date of determination in conformity with GAAP; and 
 (b) Indebtedness shall not include any liability for federal, state, local or other taxes. 
 “Indenture” means this indenture, as amended or supplemented from time to time. 
 “Initial
Additional Notes” means Additional Notes issued in an offering not registered under the Securities Act and any Notes issued in replacement thereof, but not including any Exchange Notes issued in exchange therefor. 
  

 14 

 “Initial Notes” means the Notes issued on the Issue Date and any Notes
issued in replacement thereof, but not including any Exchange Notes issued in exchange therefor. 
 “Initial
Purchasers” means the initial purchasers party to a purchase agreement with the Company relating to the sale of the Initial Notes or Initial Additional Notes by the Company. 
 “interest”, in respect of the Notes, unless the context otherwise requires, refers to interest and Additional Interest, if
any. 
 “Interest Coverage Ratio” means, on any Transaction Date, the ratio of: 
 (i) the aggregate amount of EBITDASC (or Adjusted EBITDASC, as appropriate) for the Four Quarter Period; to 
 (ii) the aggregate Consolidated Interest Expense during such Four Quarter Period. 
 In making the foregoing calculation, 
 (1) pro forma effect shall be given to any Indebtedness Incurred or repaid during the period (“Reference Period”) commencing on the first day of the Four Quarter Period and ending on the
Transaction Date, in each case as if such Indebtedness had been Incurred or repaid on the first day of such Reference Period; 
 (2) Consolidated Interest Expense attributable to interest on any Indebtedness (whether existing or being Incurred) computed on a pro forma basis and bearing a floating interest rate shall be computed as
if the rate in effect on the Transaction Date (taking into account any Interest Rate Agreement applicable to such Indebtedness if such Interest Rate Agreement has a remaining term in excess of 12 months or, if shorter, at least equal to the
remaining term of such Indebtedness) had been the applicable rate for the entire period; 
 (3) pro forma effect
shall be given to Asset Dispositions and Asset Acquisitions (including giving pro forma effect to the application of proceeds of any Asset Disposition) that occur during such Reference Period as if they had occurred and such proceeds had been
applied on the first day of such Reference Period; and 
 (4) pro forma effect shall be given to asset
dispositions and asset acquisitions (including giving pro forma effect to the application of proceeds of any asset disposition) that have been made by any Person that

  

 15 

 
has become a Restricted Subsidiary or has been merged with or into the Company or any of its Restricted Subsidiaries during such Reference Period and that would have constituted Asset
Dispositions or Asset Acquisitions during such Reference Period but subsequent to the end of the related Four Quarter Period had such transactions occurred when such Person was a Restricted Subsidiary as if such asset dispositions or asset
acquisitions were Asset Dispositions or Asset Acquisitions and had occurred on the first day of such Reference Period; provided that to the extent that clause (3) or (4) of this sentence requires that pro forma effect be given to an
Asset Acquisition or Asset Disposition, such pro forma calculation shall be based upon the four full fiscal quarters immediately preceding the Transaction Date of the Person, or division or line of business of the Person that is acquired or disposed
of to the extent that such financial information is available. 
 “Interest Rate Agreement” means any interest
rate protection agreement, interest rate future agreement, interest rate option agreement, interest rate swap agreement, interest rate cap agreement, interest rate collar agreement, interest rate hedge agreement, option or future contract or other
similar agreement or arrangement with respect to interest rates. 
 “Interest Payment Date” means each
June 15 and December 15 of each year, commencing June 15, 2010. 
 “Investment” in any Person
means any direct or indirect advance, loan or other extension of credit (including without limitation by way of Guarantee or similar arrangement, but excluding advances to customers in the ordinary course of business that are, in conformity with
GAAP, recorded as accounts receivable on the consolidated balance sheet of the Company and its Restricted Subsidiaries, and residual liabilities with respect to assigned leaseholds incurred in the ordinary course of business) or capital contribution
to (by means of any transfer of cash or other property (tangible or intangible) to another Person or any payment for property or services solely for the account or use of another Person, or otherwise), or any purchase or acquisition of Capital
Stock, bonds, notes, debentures or other similar instruments issued by, such Person and shall include: 
 (1) the
designation of a Restricted Subsidiary as an Unrestricted Subsidiary; and 
 (2) the Fair Market Value of the
Capital Stock (or any other Investment), held by the Company or any of its Restricted Subsidiaries of (or in) any Person that has ceased to be a Restricted Subsidiary, including without limitation, by reason of any transaction permitted by clause
(3) of Section 4.11; 
  

 16 

 provided that the Fair Market Value of the Investment remaining in any Person that has ceased to be a
Restricted Subsidiary shall be deemed not to exceed the aggregate amount of Investments previously made in such Person valued at the time such Investments were made, less the net reduction of such Investments. For purposes of the definition of
“Unrestricted Subsidiary” and Section 4.09: 
 (a) “Investment” shall include the Fair
Market Value of the assets (net of liabilities (other than liabilities to the Company or any of its Restricted Subsidiaries)) of any Restricted Subsidiary at the time such Restricted Subsidiary is designated an Unrestricted Subsidiary; 

(b) the Fair Market Value of the assets (net of liabilities (other than liabilities to the Company or any of its
Restricted Subsidiaries)) of any Unrestricted Subsidiary at the time that such Unrestricted Subsidiary is designated a Restricted Subsidiary shall be considered a reduction in outstanding Investments; and 
 (c) any property transferred to or from an Unrestricted Subsidiary shall be valued at its Fair Market Value at the time of
such transfer. 
 “Investment Grade” means a rating equal to or higher than Baa3 (or the equivalent) by
Moody’s and BBB- (or the equivalent) by S&P. 
 “Issue Date” means the date on which the Original
Notes are originally issued under the Indenture. 
 “Leverage Ratio” means, on any date, the ratio of
(i) the aggregate amount of, without duplication, Indebtedness of the Company and its Restricted Subsidiaries on a consolidated basis, to (ii) the aggregate amount of EBITDASC (or Adjusted EBITDASC, as appropriate) of the Company and its
Restricted Subsidiaries for the Four Quarter Period, calculated on a pro forma basis in the manner set forth in the definition of “Interest Coverage Ratio.” 
 “Lien” means any mortgage, deed of trust, pledge, security interest, encumbrance, lien or charge of any kind (including without limitation, any conditional sale or other title retention
agreement or lease in the nature thereof). 
 “Line of Credit” means one or more debt facilities, commercial
paper facilities or other debt instruments, indentures or agreements, providing for revolving credit loans, term loans, receivables financing (including through the sale of receivables to such lenders or to special purpose entities formed to borrow
from such lenders against such receivables), letters of credit or other debt obligations, in each case, as amended, restated, modified, renewed, refunded, restructured, supplemented, replaced or refinanced in whole or in part from time

  

 17 

 
to time, including without limitation any amendment increasing the amount of Indebtedness Incurred or available to be borrowed thereunder, extending the maturity of any Indebtedness Incurred
thereunder or contemplated thereby or deleting, adding or substituting one or more parties thereto (whether or not such added or substituted parties are banks or other institutional lenders). 
 “Moody’s” means Moody’s Investors Service, Inc. and its successors. 
 “Net Cash Proceeds”: 
 (1) with respect to any Asset Sale, the proceeds received by the Company or any Restricted Subsidiary of such Asset Sale in the form of cash or cash equivalents and including payments in respect of
deferred payment obligations (to the extent corresponding to the principal, but not interest, component thereof) when received in the form of cash or cash equivalents (except to the extent the assets sold are financed or sold with recourse to the
Company or any of its Restricted Subsidiaries) and proceeds from the conversion of other property received when converted to cash or cash equivalents, without duplication, net of: 
 (a) brokerage commissions and other fees and expenses (including fees and expenses of counsel and investment bankers) related
to such Asset Sale; 
 (b) provisions for all taxes actually paid or payable, as reasonably determined by the
Company, as a result of such Asset Sale by the Company and its Restricted Subsidiaries, taken as a whole, including (without duplication) taxes that would have been payable as a result of such Asset Sale by the Company and its Restricted
Subsidiaries if the Company and each Restricted Subsidiary in which the Company owns less than 100% of the interests were taxable as a corporation or as a real estate investment trust, as such term is defined in the Code, for federal, state and
local income tax purposes, whichever is greater, and in each case without taking into account any deductions, credits or other tax attributes that are not related to such Asset Sale, and at the highest rate that would be applicable to such entity at
such time; 
 (c) payments made to repay Indebtedness or any other obligation outstanding at the time of such
Asset Sale that either (A) is secured by a Lien on the property or assets sold or (B) is required to be paid as a result of such sale; 
 (d) amounts reserved by the Company and its Restricted Subsidiaries against any liabilities associated with such Asset Sale,

  

 18 

 
including without limitation, pension and other post-employment benefit liabilities, liabilities related to environmental matters and liabilities under any indemnification obligations associated
with such Asset Sale, all as determined on a consolidated basis in conformity with GAAP; and 
 (e) any payments
required under Tax Protection Agreements as a result of such Asset Sale; and 
 (2) with respect to any issuance
or sale of Capital Stock, for purposes of Section 4.09, the proceeds of such issuance or sale received by the Company or any Restricted Subsidiary in the form of cash or cash equivalents, and including payments in respect of deferred payment
obligations (to the extent corresponding to the principal, but not interest, component thereof) when received in the form of cash or cash equivalents and proceeds from the conversion of other property received when converted to cash or cash
equivalents, net of attorney’s fees, accountants’ fees, underwriters’ or placement agents’ fees, discounts or commissions and brokerage, consultant and other fees incurred in connection with such issuance or sale and net of tax
paid or payable as a result thereof. 
 “Non-U.S. Person” means a Person that is not a U.S. person, as defined
in Regulation S. 
 “Notes” has the meaning assigned to such term in the Recitals. 
 “Note Guarantee” means a Guarantee of the Notes. 
 “Offer to Purchase” has the meaning set forth in Section 3.04 
 “Officer” means the chairman of the Board of Directors, the president or chief executive officer, any vice president, the
chief financial officer, the treasurer or any assistant treasurer, or the secretary or any assistant secretary, of the Company. 
 “Officers’ Certificate” means a certificate signed in the name of the Company (i) by the chairman of the Board of Directors, the president or chief executive officer or a vice president of the Company or Holdings
and (ii) by the chief financial officer, the treasurer or any assistant treasurer or the secretary or any assistant secretary of the Company or Holdings. 
 “Offshore Global Note” means a Global Note representing Notes issued and sold pursuant to Regulation S. 
 “Opinion of Counsel” means a written opinion signed by legal counsel, who may be an employee of or counsel to the Company. 
  

 19 

 “Original Notes” means the Initial Notes and any Exchange Notes issued in
exchange therefor. 
 “Partnership Agreement” means that certain Amended and Restated Agreement of Limited
Partnership of the Company, dated as of October 24, 2007, by and among the partners named therein, as amended on the Issue Date. 
 “Payment Date” has the meaning set forth in Section 3.04. 
 “Paying Agent”
refers to a Person engaged to perform the obligations of the Trustee in respect of payments made or funds held hereunder in respect of the Notes. 
 “Permanent Offshore Global Note” means an Offshore Global Note that does not bear the Temporary Offshore Global Note Legend. 
 “Permitted Investments” means: 
 (1) an Investment in the Company or any of its Restricted Subsidiaries or a Person that will, upon the making of such
Investment, become a Restricted Subsidiary or be merged or consolidated with or into or transfer or convey all or substantially all its assets to, the Company or any of its Restricted Subsidiaries; provided that such person’s primary
business is related, ancillary, incidental or complementary to the businesses of the Company or any of its Restricted Subsidiaries on the date of such Investment; 
 (2) Temporary Cash Investments; 
 (3) one or more Investments in a Permitted Joint Venture in an amount not to exceed 10% of Total Assets at any one time outstanding; 
 (4) Investments in Permitted Mortgage Investments in an amount not to exceed 2% of Total Assets at any time outstanding;

 (5) payroll, travel and similar advances to cover matters that are expected at the time of such advances
ultimately to be treated as expenses in accordance with GAAP; 
 (6) any Investment made as a result of the
receipt of non-cash consideration from an Asset Sale that was made pursuant to and in compliance with Section 4.14 or any disposition of assets or rights not constituting an Asset Sale by reason of the threshold contained in the definition
thereof; 
  

 20 

 (7) stock, obligations or securities received in connection with the
bankruptcy or reorganization of, or settlement of delinquent accounts and disputes with, customers and suppliers, in each case in the ordinary course of business or received in satisfaction of judgment; 
 (8) any Investment of the Company or any of its Restricted Subsidiaries existing on the date of the Indenture, and any
extension, modification or renewal of any such Investments, but only to the extent not involving additional advances, contributions or other Investments of cash or other assets or other increases thereof (other than as a result of the accrual or
accretion of interest or original issue discount or the issuance of pay-in-kind securities), in each case, pursuant to the terms of such Investment as in effect on the Issue Date; 
 (9) Guarantees of Indebtedness permitted to be Incurred by the primary obligor pursuant to Section 4.06; 
 (10) Investments in respect of Currency Agreements and Interest Rate Agreements; and 
 (11) other Investments in any Person having an aggregate Fair Market Value (measured on the date each such Investment was
made and without giving effect to subsequent changes in value), that, when taken with all other Investments made pursuant to this clause (11), does not exceed 2% of Total Assets. 
 “Permitted Joint Venture” means a Person owned 50% or more by the Company and/or any of its Restricted Subsidiaries if
(A) such Person is engaged in business related to that of the Company, Holdings or any Restricted Subsidiary and (B) the Company or its Restricted Subsidiaries has the right to appoint at least half of the Board of Directors of such
Person. 
 “Permitted Mortgage Investment” means an investment in a secured note, mortgage, deed of trust,
collateralized mortgage obligations, commercial mortgage-backed securities, other secured debt securities, secured debt derivative or other debt instruments, so long as such investment relates directly or indirectly to real property that constitutes
or is used as a data center or other property customarily constituting an asset of a real estate investment trust specializing in the ownership, acquisition, development and operation of wholesale data centers. 
 “Permitted Tax Payments” means, with respect to any year, any distributions to holders of Equity Interests of the Company
and a Restricted Subsidiary in which the Company owns less than 100% of the Equity Interests equal to the amount of federal, state and local income taxes, as reasonably

  

 21 

 
determined by the Company, that the Company or Restricted Subsidiary would have been required to pay with respect to such year if the Company or Restricted Subsidiary were and always had been
taxable as a corporation or a real estate investment trust, as such term is defined in the Code, for federal, state and local income tax purposes, whichever is greater, and in each case calculated at the highest marginal rate that would be
applicable to such entity with respect to such year. 
 “Person” means an individual, partnership, corporation,
limited liability company, unincorporated organization, trust (including a real estate investment trust) or joint venture, or a governmental agency or political subdivision thereof or other entity. 
 “Preferred Stock” means, with respect to any Person, any and all shares, interests, participation or other equivalents
(however designated, whether voting or non-voting) that have a preference on liquidation or with respect to distributions over any other class of Capital Stock, including preferred partnership interests, whether general or limited, or such
Person’s preferred or preference stock, whether outstanding on the Issue Date or issued thereafter, including, without limitation, all series and classes of such preferred or preference stock. 
 “principal” of any Indebtedness means the principal amount of such Indebtedness, (or if such Indebtedness was issued with
original issue discount, the face amount of such Indebtedness less the remaining unamortized portion of the original issue discount of such Indebtedness), together with, unless the context otherwise indicates, any premium then payable on such
Indebtedness. 
 “Pro Forma Lease Revenues” means the following amounts in respect of certain leases entered
into by a Restricted Subsidiary which shall be deemed to be: $32.5 million for the Four Quarter Period ended September 30, 2009, $26.5 million for the Four Quarter Period ended December 31, 2009, $17.7 million for the Four Quarter Period
ended March 30, 2010 and $9.9 million for the Four Quarter Period ended June 30, 2010. 
 “Rating
Agencies” means S&P and Moody’s; provided, that if either S&P or Moody’s (or both) shall cease issuing a rating on the Notes for reasons outside the control of the Company, the Company may select a nationally
recognized statistical rating agency to substitute for S&P or Moody’s (or both). 
 “Reference Period”
has the meaning set forth in the definition of “Interest Coverage Ratio”. 
 “Register” has the
meaning assigned to such term in Section 2.09. 
  

 22 

 “Registrar” means a Person engaged to maintain the Register. 
 “Registration Rights Agreement” means (i) the Registration Rights Agreement dated on or about the Issue Date between
the Company and the Initial Purchasers party thereto with respect to the Initial Notes, and (ii) with respect to any Additional Notes, any registration rights agreements between the Company and the Initial Purchasers party thereto relating to
rights given by the Company to the purchasers of Additional Notes to register such Additional Notes or exchange them for Notes registered under the Securities Act. 
 “Regular Record Date” for the interest payable on any Interest Payment Date means the June 1 or December 1 (whether or not a Business Day) next preceding such Interest Payment
Date. 
 “Regulation S” means Regulation S under the Securities Act. 
 “Regulation S Certificate” means a certificate substantially in the form of Exhibit E hereto. 
 “Reinstatement Date” has the meaning set forth in Section 4.18. 
 “Responsible Officer” shall mean, when used with respect to the Trustee, any officer within the corporate trust department
of the Trustee, including any vice president, assistant vice president, assistant secretary, assistant treasurer, trust officer or any other officer of the Trustee who customarily performs functions similar to those performed by the Persons who at
the time shall be such officers, respectively, or to whom any corporate trust matter is referred because of such person’s knowledge of and familiarity with the particular subject and who shall have direct responsibility for the administration
of the Indenture. 
 “Restricted Legend” means the legend set forth in Exhibit C. 
 “Restricted Payment” has the meaning assigned to such term in Section 4.09. 
 “Restricted Period” means the relevant 40-day distribution compliance period as defined in Regulation S. 
 “Restricted Subsidiary” means any Subsidiary of the Company other than an Unrestricted Subsidiary. 
 “Rule 144A” means Rule 144A under the Securities Act. 
 “Rule 144A Certificate” means (i) a certificate substantially in the form of Exhibit F hereto or (ii) a
written certification addressed to the Company and the

  

 23 

 
Trustee to the effect that the Person making such certification (x) is acquiring such Note (or beneficial interest) for its own account or one or more accounts with respect to which it
exercises sole investment discretion and that it and each such account is a qualified institutional buyer within the meaning of Rule 144A, (y) is aware that the transfer to it or exchange, as applicable, is being made in reliance upon the
exemption from the provisions of Section 5 of the Securities Act provided by Rule 144A, and (z) acknowledges that it has received such information regarding the Company as it has requested pursuant to Rule 144A(d)(4) or has determined not
to request such information. 
 “Sale and Leaseback Transaction” means, with respect to any Person, an
arrangement whereby such Person enters into a lease of property previously transferred by such Person to the lessor. 
 “Securities Act” means the Securities Act of 1933, as amended. 
 “Secured
Indebtedness” means any Indebtedness secured by a Lien upon the property of the Company or any of its Restricted Subsidiaries. 
 “Shelf Registration Statement” means the Shelf Registration Statement as defined in a Registration Rights Agreement. 
 “Significant Subsidiary” means, at any determination date, any Restricted Subsidiary that, together with its Subsidiaries:

 (1) for the most recent fiscal year of the Company, accounted for more than 10% of the consolidated revenues
of the Company and its Restricted Subsidiaries; or 
 (2) as of the end of such fiscal year, was the owner of
more than 10% of the consolidated assets of the Company and its Restricted Subsidiaries, all as set forth on the most recently available consolidated financial statements thereof for such fiscal year. 
 “S&P” means Standard & Poor’s and its successors. 
 “Stated Maturity” means: 
 (1) with respect to any debt security, the date specified in such debt security as the fixed date on which the final installment of principal of such debt security is due and payable; and 
 (2) with respect to any scheduled installment of principal of or interest on any debt security, the date specified in such
debt security as the fixed date on which such installment is due and payable. 
  

 24 

 “Subsidiary” means, with respect to any Person, any corporation,
association or other business entity of which more than 50% of the voting power of the outstanding Voting Stock is owned, directly or indirectly, by such Person and/or one or more other Subsidiaries of such Person and the accounts of which would be
consolidated with those of such Person in its consolidated financial statements in accordance with GAAP, if such statements were prepared as of such date. 
 “Subsidiary Debt” means all unsecured Indebtedness of which a non-Guarantor Restricted Subsidiary is the obligor. 
 “Subsidiary Guarantee” means a Guarantee by each Subsidiary Guarantor for payment of the Notes by such Subsidiary
Guarantor. 
 “Subsidiary Guarantor” means each of the Subsidiary Guarantors identified as such on the
signature page to the Indenture and thereafter any other Restricted Subsidiary that executes a Subsidiary Guarantee in compliance with Section 4.12, but in each case excluding any Persons whose guarantees have been released pursuant to the
terms of the Indenture. 
 “Suspension Period” has the meaning set forth in Section 4.18. 
 “Tax Protection Agreement” means that certain Tax Protection Agreement, dated as of October 24, 2007, by and among
Holdings, the Company, Safari Ventures LLC, Rhino Interests LLC, Quill Ventures LLC, Lemur Ventures LLC, Meerkat Interests LLC and Grizzly Interests LLC. 
 “Temporary Cash Investment” means any of the following: 
 (1) direct obligations of the United States of America or any agency thereof or obligations fully and unconditionally guaranteed by the United States of America or any agency thereof; 
 (2) time deposits accounts, certificates of deposit and money market deposits maturing within 180 days of the date of
acquisition thereof issued by a bank or trust company which is organized under the laws of the United States of America, or any state thereof, and which bank or trust company has capital, surplus and undivided profits aggregating in excess of $50
million and has outstanding debt which is rated “A” (or such similar equivalent rating) or higher by at least one nationally recognized statistical rating organization (as defined in Rule 436 under the Securities Act) or any money-market
fund sponsored by a registered broker dealer or mutual fund distributor; 
  

 25 

 (3) repurchase obligations with a term of not more than 30 days for
underlying securities of the types described in clause (1) above entered into with a bank meeting the qualifications described in clause (2) above; 
 (4) commercial paper, maturing not more than 90 days after the date of acquisition, issued by a corporation (other than an
Affiliate of the Company) organized and in existence under the laws of the United States of America or any state of the United States of America with a rating at the time as of which any investment therein is made of “P-2” (or higher)
according to Moody’s or “A-2” (or higher) according to S&P; 
 (5) securities with maturities
of six months or less from the date of acquisition issued or fully and unconditionally guaranteed by any state, commonwealth or territory of the United States of America, or by any political subdivision or taxing authority thereof, and rated at
least “A” by S&P or Moody’s; 
 (6) money market funds at least 95% of the assets of which
constitute Temporary Cash Investments of the kinds described in clauses (1) through (5) of this definition; 
 (7) repurchase obligations of any commercial bank organized under the laws of the United States of America or any state thereof having capital and surplus aggregating at least $500.0 million, having a term of not more than 30 days, with
respect to securities referred to in clause (2) of this definition; and 
 (8) instruments equivalent to
those referred to in clauses (1) to (7) above denominated in euro or any other foreign currency comparable in credit quality and tenor to those referred to above and customarily used by corporations for cash management purposes in any
jurisdiction outside the United States to the extent reasonably required in connection with any business conducted by a Restricted Subsidiary organized in such jurisdiction. 
 “Temporary Offshore Global Note” means an Offshore Global Note that bears the Temporary Offshore Global Note Legend.

 “Temporary Offshore Global Note Legend” means the legend set forth in Exhibit I. 
 “Trustee” means the party named as such in the first paragraph of the Indenture or any successor trustee under the
Indenture pursuant to Article 7. 
  

 26 

 “Trust Indenture Act” means the Trust Indenture Act of 1939, as amended.

 “Total Assets” means the sum of: 
 (1) Undepreciated Real Estate Assets; and 
 (2) all other assets of the Company and its Restricted Subsidiaries on a consolidated basis determined in conformity with
GAAP (but excluding intangibles). 
 “Total Unencumbered Assets” as of any date means the sum of: 

(1) those Undepreciated Real Estate Assets, excluding any Undepreciated Real Estate Assets of a non-Guarantor Subsidiary,
not securing any portion of Secured Indebtedness; and 
 (2) all other assets (but excluding intangibles) of the
Company and the Subsidiary Guarantors not securing any portion of Secured Indebtedness determined on a consolidated basis in accordance with GAAP 
 but excluding any other assets (including intangibles) of a non-Guarantor Subsidiary. 
 “Trade
Payables” means, with respect to any Person, any accounts payable or any other Indebtedness or monetary obligation to trade creditors created, assumed or Guaranteed by such Person or any of its Subsidiaries arising in the ordinary course of
business in connection with the acquisition of goods or services. 
 “Transaction Date” means, with respect to
the Incurrence of any Indebtedness by the Company or any of its Restricted Subsidiaries, the date such Indebtedness is to be Incurred, with respect to any Restricted Payment, the date such Restricted Payment is to be made, and with respect to any
transaction described in Article 5, the day on which such transaction is to be consummated. 
 “Treasury Rate”
means, as of any redemption date, the yield to maturity as of such redemption date of United States Treasury securities with a constant maturity (as compiled and published in the most recent Federal Reserve Statistical Release H.15 (519) that
has become publicly available at least two Business Days prior to the redemption date (or, if such Statistical Release is no longer published, any publicly available source of similar market data)) most nearly equal to the period from the redemption
date to December 15, 2013; provided that if the period from the redemption date to such date is not equal to the constant maturity

  

 27 

 
of a United States Treasury security for which a yield is given, the Treasury yield shall be obtained by linear interpolation (calculated to the nearest one-twelfth of a year) from the yields of
the nearest United States Treasury securities for which such yields are given, except that if the period from the redemption date to such date is less than one year, the weekly average yield on actually traded United States Treasury securities
adjusted to a constant maturity of one year will be used. 
 “Undepreciated Real Estate Assets” means, as of
any date, the gross book value of real estate assets of the Company and its Restricted Subsidiaries on such date, before depreciation and amortization of such real estate assets, determined on a consolidated basis in conformity with GAAP.

 “U.S. Global Note” means a Global Note that bears the Restricted Legend representing Notes issued and sold
pursuant to Rule 144A. 
 “U.S. Government Obligations” means obligations issued or directly and fully
guaranteed or insured by the United States of America or by any agent or instrumentality thereof, provided that the full faith and credit of the United States of America is pledged in support thereof. 
 “Units” means the limited partnership units of the Company, that by their terms are redeemable at the option of the holder
thereof and that, if so redeemed, at the election of Holdings are redeemable for cash or Common Stock of Holdings. 
 “Unrestricted Subsidiary” means 
 (1) any Subsidiary of the Company that at the time
of determination shall be designated an Unrestricted Subsidiary by the Board of Directors in the manner provided below; and 
 (2) any Subsidiary of an Unrestricted Subsidiary. 
 The Board of Directors may
designate any Restricted Subsidiary (including any newly acquired or newly formed Subsidiary of the Company) to be an Unrestricted Subsidiary unless such Subsidiary owns any Capital Stock of, or owns or holds any Lien on any property of, the Company
or any of its Restricted Subsidiaries (other than Capital Stock of any Subsidiaries of such Subsidiary); provided that: 
 (a) any Guarantee by the Company or any of its Restricted Subsidiaries of any Indebtedness of the Subsidiary being so designated shall be deemed an “Incurrence” of such Indebtedness and an
“Investment” by the Company or its Restricted Subsidiary at the time of such designation; 
  

 28 

 (b) either (i) the Subsidiary to be so designated has total assets of
$1,000 or less or (ii) if such Subsidiary has assets greater than $1,000, such designation would be permitted under Section 4.09; and 
 (c) if applicable, the Incurrence of Indebtedness and the Investment referred to in (a) of this proviso would be permitted under Section 4.06 and Section 4.09. 
 The Board of Directors may designate any Unrestricted Subsidiary to be a Restricted Subsidiary; provided that: 
 (A) no Default or Event of Default shall have occurred and be continuing at the time of or after giving effect to such
designation; and 
 (B) all Liens and Indebtedness of such Unrestricted Subsidiary outstanding immediately after
such designation would, if Incurred at such time, have been permitted to be Incurred (and shall be deemed to have been Incurred) for all purposes of the Indenture. 
 Any such designation by the Board of Directors shall be evidenced to the Trustee by promptly filing with the Trustee a copy of the Board Resolution giving effect to such designation and an Officers’
Certificate certifying that such designation complied with the foregoing provisions. 
 “Unsecured
Indebtedness” means any Indebtedness of the Company or any of its Restricted Subsidiaries that is not Secured Indebtedness. 
 “Voting Stock” means with respect to any Person, Capital Stock of any class or kind ordinarily having the power to vote for the election of directors, managers or other voting members of the governing body of such Person.

 “Wholly Owned” means, with respect to any Subsidiary of any Person, the ownership of all of the outstanding
Capital Stock of such Subsidiary (other than any director’s qualifying shares or Investments by individuals mandated by applicable law) by such Person or one or more Wholly Owned Subsidiaries of such Person; provided that for purposes of
this definition Safari Ventures LLC will be deemed to be Wholly Owned by both the Company and Holdings and DF Property Management LLC will be deemed to be Wholly Owned by both Safari Ventures and the Company, in each case for so long as
Holdings’ proportionate interest in Safari Ventures LLC does not increase after the Issue Date. 
 SECTION 1.02. Rules of Construction. Unless the context otherwise requires or except as otherwise expressly provided, 
 (1) an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP; 
  

 29 

 (2) “herein,” “hereof” and other words of similar import
refer to the Indenture as a whole and not to any particular Section, Article or other subdivision; 
 (3) all
references to Sections or Articles or Exhibits refer to Sections or Articles or Exhibits of or to the Indenture unless otherwise indicated; 
 (4) references to agreements or instruments, or to statutes or regulations, are to such agreements or instruments, or statutes or regulations, as amended from time to time (or to successor statutes and
regulations); and 
 (5) in the event that a transaction meets the criteria of more than one category of
permitted transactions or listed exceptions the Company, in its sole discretion, may classify such transaction and only be required to include such transaction in one category of permitted transactions or listed exceptions. 
 ARTICLE 2 
 THE NOTES 
 Section 2.01. Form, Dating and Denominations; Legends. The Notes
and the Trustee’s certificate of authentication will be substantially in the form attached as Exhibit A. The terms and provisions contained in the form of the Notes annexed as Exhibit A constitute, and are hereby expressly made, a
part of the Indenture. The Notes may have notations, legends or endorsements required by law, rules of or agreements with national securities exchanges to which the Company is subject, or usage. Each Note will be dated the date of its
authentication. The Notes will be issuable in denominations of $2,000 in principal amount and any higher integral multiple of $1,000. 
 (b) (1) Except as otherwise provided in paragraph Section 2.01(c), Section 2.09(b)(4), or Section 2.10(b)(3), (b)(5), or (c), each Initial Note or Initial Additional Note (other than a
Permanent Offshore Note) will bear the Restricted Legend. 
 (2) Each Global Note, whether or not an Initial Note
or Additional Note, will bear the DTC Legend for so long as DTC is serving as the Depositary thereof. 
  

 30 

 (3) Each Temporary Offshore Global Note will bear the Temporary Offshore
Global Note Legend. 
 (4) Initial Notes and Initial Additional Notes offered and sold in reliance on Regulation
S will be issued as provided in Section 2.11(a). 
 (5) Initial Notes and Initial Additional Notes initially
offered and sold in reliance on any exception under the Securities Act other than Regulation S and Rule 144A will be issued, and upon the request of the Company to the Trustee, Initial Notes offered and sold in reliance on Rule 144A may be issued,
in the form of Certificated Notes. Initial Notes sold to Accredited Investors in subsequent resale may be issued in the form of an AI Global Note. 
 (6) Exchange Notes will be issued, subject to Section 2.09(b), in the form of one or more Global Notes. 
 (c) (1) If the Company determines (upon the advice of counsel and such other certifications and evidence as the Company may reasonably require) that a Note is eligible for resale pursuant to Rule 144
under the Securities Act (or a successor provision) and that the Restricted Legend is no longer necessary or appropriate in order to ensure that subsequent transfers of the Note (or a beneficial interest therein) are effected in compliance with the
Securities Act; provided, however, that in the case of this Section 2.01(c)(1) that the Company has delivered an Opinion of Counsel to the Trustee with respect to the foregoing, or 
 (2) after an Initial Note or any Initial Additional Note is 
 (x) sold pursuant to an effective registration statement under the Securities Act, pursuant to the Registration Rights
Agreement or otherwise, or (y) is validly tendered for exchange into an Exchange Note pursuant to an Exchange Offer 
 the Company may
instruct the Trustee to cancel the Note and issue to the Holder thereof (or to its transferee) a new Note of like tenor and amount, registered in the name of the Holder thereof (or its transferee), that does not bear the Restricted Legend, and the
Trustee will comply with such instruction. 
 (d) By its acceptance of any Note bearing the Restricted Legend (or any beneficial
interest in such a Note), each Holder thereof and each owner of a beneficial interest therein acknowledges the restrictions on transfer of such Note (and any such beneficial interest) set forth in the Indenture and in the Restricted

  

 31 

 
Legend and agrees that it will transfer such Note (and any such beneficial interest) only in accordance with the Indenture and such legend. 
 Section 2.02. Execution and Authentication; Exchange Notes; Additional Notes. (a) An Officer shall execute the Notes for
the Company by facsimile or manual signature in the name and on behalf of the Company. If an Officer whose signature is on a Note no longer holds that office at the time the Note is authenticated, the Note will still be valid. 
 (b) A Note will not be valid until the Trustee manually signs the certificate of authentication on the Note, with the signature conclusive
evidence that the Note has been authenticated under the Indenture. 
 (c) At any time and from time to time after the execution
and delivery of the Indenture, the Company may deliver Notes executed by the Company to the Trustee for authentication. The Trustee will authenticate and deliver 
 (i) Initial Notes for original issue in the aggregate principal amount not to exceed $550,000,000, 
 (ii) Initial Additional Notes from time to time for original issue in aggregate principal amounts specified by the Company,
and 
 (iii) Exchange Notes from time to time for issue in exchange for a like principal amount of Initial Notes
or Initial Additional Notes 
 after the following conditions have been met: 
 (1) Receipt by the Trustee of an Officers’ Certificate specifying 
 (A) the amount of Notes to be authenticated and the date on which the Notes are to be authenticated, 
 (B) whether the Notes are to be Initial Notes, Additional Notes or Exchange Notes, 
 (C) in the case of Initial Additional Notes, that the issuance of such Notes does not contravene any provision of Article 4,

 (D) whether the Notes are to be issued as one or more Global Notes or Certificated Notes, 
 (E) other information the Company may determine to include or the Trustee may reasonably request; and 
  

 32 

 (F) that all conditions precedent to the issuance under the Indenture have
been complied with. 
 (2) In the case of Exchange Notes, effectiveness of an Exchange Offer Registration
Statement and consummation of the exchange offer thereunder (and receipt by the Trustee of an Officers’ Certificate to that effect). Initial Notes or Initial Additional Notes exchanged for Exchange Notes will be cancelled by the Trustee.

 Section 2.03. Registrar, Paying Agent and Authenticating Agent; Paying Agent to Hold Money in Trust. (a) The
Company may appoint one or more Registrars and one or more Paying Agents, and the Trustee may appoint an Authenticating Agent, in which case each reference in the Indenture to the Trustee in respect of the obligations of the Trustee to be performed
by that Agent will be deemed to be references to the Agent. The Company may act as Registrar or (except for purposes of Article 8) Paying Agent. In each case the Company and the Trustee will enter into an appropriate agreement with the Agent
implementing the provisions of the Indenture relating to the obligations of the Trustee to be performed by the Agent and the related rights. The Company initially appoints the Trustee as Registrar and Paying Agent. 
 (b) The Company will require each Paying Agent other than the Trustee to agree in writing that the Paying Agent will hold in trust for the
benefit of the Holders or the Trustee all money held by the Paying Agent for the payment of principal of and interest on the Notes and will promptly notify the Trustee of any default by the Company in making any such payment. The Company at any time
may require a Paying Agent to pay all money held by it to the Trustee and account for any funds disbursed, and the Trustee may at any time during the continuance of any payment default, upon written request to a Paying Agent, require the Paying
Agent to pay all money held by it to the Trustee and to account for any funds disbursed. Upon doing so, the Paying Agent will have no further liability for the money so paid over to the Trustee. 
 Section 2.04. Replacement Notes. If a mutilated Note is surrendered to the Trustee or if a Holder claims that its Note has been
lost, destroyed or wrongfully taken, the Company will issue and the Trustee will authenticate a replacement Note of like tenor and principal amount and bearing a number not contemporaneously outstanding. Every replacement Note is an additional
obligation of the Company and entitled to the benefits of the Indenture. If required by the Trustee or the Company, an indemnity must be furnished that is sufficient in the judgment of both the Trustee and the Company to protect the Company and the
Trustee from any loss they may suffer if a Note is replaced. The Company may charge the Holder for the expenses of the Company and the Trustee in replacing a Note. In case the mutilated, lost, destroyed or wrongfully

  

 33 

 
taken Note has become or is about to become due and payable, the Company in its discretion may pay the Note instead of issuing a replacement Note. 
 Section 2.05. Outstanding Notes. (a) Notes outstanding at any time are all Notes that have been authenticated by the
Trustee except for 
 (1) Notes cancelled by the Trustee or delivered to it for cancellation; 
 (2) any Note which has been replaced pursuant to Section 2.04 unless and until the Trustee and the Company receive proof
satisfactory to them that the replaced Note is held by a bona fide purchaser; and 
 (3) on or after the
maturity date or any redemption date or date for purchase of the Notes pursuant to an Offer to Purchase, those Notes payable or to be redeemed or purchased on that date for which the Trustee (or Paying Agent, other than the Company or an Affiliate
of the Company) holds money sufficient to pay all amounts then due. 
 (b) A Note does not cease to be outstanding because the
Company or one of its Affiliates holds the Note, provided that in determining whether the Holders of the requisite principal amount of the outstanding Notes have given or taken any request, demand, authorization, direction, notice, consent,
waiver or other action hereunder, Notes owned by the Company or any Affiliate of the Company will be disregarded and deemed not to be outstanding, (it being understood that in determining whether the Trustee is protected in relying upon any such
request, demand, authorization, direction, notice, consent, waiver or other action, only Notes which the Trustee knows to be so owned will be so disregarded). Notes so owned which have been pledged in good faith may be regarded as outstanding if the
pledgee establishes to the satisfaction of the Trustee the pledgee’s right so to act with respect to such Notes and that the pledgee is not the Company or any Affiliate of the Company. 
 Section 2.06. Temporary Notes. Until definitive Notes are ready for delivery, the Company may prepare and the Trustee will
authenticate temporary Notes. Temporary Notes will be substantially in the form of definitive Notes but may have insertions, substitutions, omissions and other variations determined to be appropriate by the Officer executing the temporary Notes, as
evidenced by the execution of the temporary Notes. If temporary Notes are issued, the Company will cause definitive Notes to be prepared without unreasonable delay. After the preparation of definitive Notes, the temporary Notes will be exchangeable
for definitive Notes upon surrender of the temporary Notes at the office or agency of the Company designated for the purpose pursuant to Section 4.02, without charge to the Holder. Upon surrender for cancellation of any temporary Notes the

  

 34 

 
Company will execute and the Trustee will authenticate and deliver in exchange therefor a like principal amount of definitive Notes of authorized denominations. Until so exchanged, the temporary
Notes will be entitled to the same benefits under the Indenture as definitive Notes. 
 Section 2.07. Cancellation.
The Company at any time may deliver to the Trustee for cancellation any Notes previously authenticated and delivered hereunder which the Company may have acquired in any manner whatsoever, and may deliver to the Trustee for cancellation any
Notes previously authenticated hereunder which the Company has not issued and sold. Any Registrar or the Paying Agent will forward to the Trustee any Notes surrendered to it for transfer, exchange or payment. The Trustee will cancel all Notes
surrendered for transfer, exchange, payment or cancellation and dispose of them in accordance with its normal procedures or the written instructions of the Company. The Company may not issue new Notes to replace Notes it has paid in full or
delivered to the Trustee for cancellation. 
 Section 2.08. CUSIP and CINS Numbers. The Company in issuing the Notes
may use “CUSIP” and “CINS” numbers, and the Trustee will use CUSIP numbers or CINS numbers in notices of redemption or exchange or in Offers to Purchase as a convenience to Holders, the notice to state that no representation is
made as to the correctness of such numbers either as printed on the Notes or as contained in any notice of redemption or exchange or Offer to Purchase. The Company will promptly notify the Trustee of any change in the CUSIP or CINS numbers.

 Section 2.09. Registration, Transfer and Exchange. (a) The Notes will be issued in registered form only,
without coupons, and the Company shall cause the Trustee to maintain a register (the “Register”) of the Notes, for registering the record ownership of the Notes by the Holders and transfers and exchanges of the Notes. 
 (b) (1) Each Global Note will be registered in the name of the Depositary or its nominee and, so long as DTC is serving
as the Depositary thereof, will bear the DTC Legend. 
 (2) Each Global Note will be delivered to the Trustee as
custodian for the Depositary. Transfers of a Global Note (but not a beneficial interest therein) will be limited to transfers thereof in whole, but not in part, to the Depositary, its successors or their respective nominees, except (a) as set
forth in Section 2.09(b)(4) and (b) transfers of portions thereof in the form of Certificated Notes may be made upon request of an Agent Member (for itself or on behalf of a beneficial owner) by written notice given to the Trustee by or on
behalf of the Depositary in accordance with customary procedures of the Depositary and in compliance with this Section and Section 2.10. 
  

 35 

 (3) Agent Members will have no rights under the Indenture with respect to
any Global Note held on their behalf by the Depositary, and the Depositary may be treated by the Company, the Trustee and any agent of the Company or the Trustee as the absolute owner and Holder of such Global Note for all purposes whatsoever.
Notwithstanding the foregoing, the Depositary or its nominee may grant proxies and otherwise authorize any Person (including any Agent Member and any Person that holds a beneficial interest in a Global Note through an Agent Member) to take any
action which a Holder is entitled to take under the Indenture or the Notes, and nothing herein will impair, as between the Depositary and its Agent Members, the operation of customary practices governing the exercise of the rights of a holder of any
security. 
 (4) If (w) the Depositary notifies the Company at any time that it is unwilling or unable to
continue as Depositary for a Global Note and a successor depositary is not appointed by the Company within 90 days of the notice, (x) the Depositary ceases to be registered as a clearing agency under the Exchange Act and a successor Depositary
is not appointed within 90 days, (y) the Company, at its option, notifies the Trustee that it elects to cause the issuance of Certificated Notes or (z) an Event of Default has occurred and is continuing and the Trustee has received a
request from the Depositary, the Trustee will promptly exchange each beneficial interest in the Global Note for one or more Certificated Notes in authorized denominations having an equal aggregate principal amount registered in the name of the owner
of such beneficial interest, as identified to the Trustee by the Depositary, and thereupon the Global Note will be deemed canceled. If such Note does not bear the Restricted Legend, then the Certificated Notes issued in exchange therefor will not
bear the Restricted Legend. If such Note bears the Restricted Legend, then the Certificated Notes issued in exchange therefor will bear the Restricted Legend, provided that any Holder of any such Certificated Note issued in exchange for a
beneficial interest in a Temporary Offshore Global Note will have the right upon presentation to the Trustee of a duly completed Certificate of Beneficial Ownership after the Restricted Period to exchange such Certificated Note for a Certificated
Note of like tenor and amount that does not bear the Restricted Legend, registered in the name of such Holder. 
 (c) Each
Certificated Note will be registered in the name of the Holder thereof or its nominee. 
  

 36 

 (d) A Holder may transfer a Note (or a beneficial interest therein) to another Person or
exchange a Note (or a beneficial interest therein) for another Note or Notes of any authorized denomination by presenting to the Trustee a written request therefor stating the name of the proposed transferee or requesting such an exchange,
accompanied by any certification, opinion or other document required by Section 2.10. The Trustee will promptly register any transfer or exchange that meets the requirements of this Section by noting the same in the register maintained by the
Trustee for the purpose; provided that 
 (x) no transfer or exchange will be effective until it is
registered in such register and 
 (y) the Trustee will not be required (i) to issue, register the transfer
of or exchange any Note for a period of 15 days before a selection of Notes to be redeemed or purchased pursuant to an Offer to Purchase, (ii) to register the transfer of or exchange any Note so selected for redemption or purchase in whole or
in part, except, in the case of a partial redemption or purchase, that portion of any Note not being redeemed or purchased, or (iii) if a redemption or a purchase pursuant to an Offer to Purchase is to occur after a Regular Record Date but on
or before the corresponding Interest Payment Date, to register the transfer of or exchange any Note on or after the Regular Record Date and before the date of redemption or purchase. Prior to the registration of any transfer, the Company, the
Trustee and their agents will treat the Person in whose name the Note is registered as the owner and Holder thereof for all purposes (whether or not the Note is overdue), and will not be affected by notice to the contrary. 
 From time to time the Company will execute and the Trustee will authenticate additional Notes as necessary in order to permit the
registration of a transfer or exchange in accordance with this Section. 
 No service charge will be imposed in connection with
any registration of transfer or exchange of any Note, but the Company may require payment of a sum sufficient to cover any transfer tax or similar governmental charge payable in connection therewith (other than a transfer tax or other similar
governmental charge payable upon exchange pursuant to subsection (b)(4)). 
 (e) (1) Global Note to
Global Note. If a beneficial interest in a Global Note is transferred or exchanged for a beneficial interest in another Global Note, the Trustee will (x) record a decrease in the principal amount of the Global Note being transferred or
exchanged equal to the principal amount of such transfer or exchange and (y) record a like increase in the principal amount of the other Global Note. Any beneficial interest in one

  

 37 

 
Global Note that is transferred to a Person who takes delivery in the form of an interest in another Global Note, or exchanged for an interest in another Global Note, will, upon transfer or
exchange, cease to be an interest in such Global Note and become an interest in the other Global Note and, accordingly, will thereafter be subject to all transfer and exchange restrictions, if any, and other procedures applicable to beneficial
interests in such other Global Note for as long as it remains such an interest. 
 (2) Global Note to
Certificated Note. If a beneficial interest in a Global Note is transferred or exchanged for a Certificated Note, the Trustee will (x) record a decrease in the principal amount of such Global Note equal to the principal amount of such
transfer or exchange and (y) deliver one or more new Certificated Notes in authorized denominations having an equal aggregate principal amount to the transferee (in the case of a transfer) or the owner of such beneficial interest (in the case
of an exchange), registered in the name of such transferee or owner, as applicable. 
 (3) Certificated Note
to Global Note. If a Certificated Note is transferred or exchanged for a beneficial interest in a Global Note, the Trustee will (x) cancel such Certificated Note, (y) record an increase in the principal amount of such Global Note equal
to the principal amount of such transfer or exchange and (z) in the event that such transfer or exchange involves less than the entire principal amount of the canceled Certificated Note, deliver to the Holder thereof one or more new
Certificated Notes in authorized denominations having an aggregate principal amount equal to the untransferred or unexchanged portion of the canceled Certificated Note, registered in the name of the Holder thereof. 
 (4) Certificated Note to Certificated Note. If a Certificated Note is transferred or exchanged for another
Certificated Note, the Trustee will (x) cancel the Certificated Note being transferred or exchanged, (y) deliver one or more new Certificated Notes in authorized denominations having an aggregate principal amount equal to the principal
amount of such transfer or exchange to the transferee (in the case of a transfer) or the Holder of the canceled Certificated Note (in the case of an exchange), registered in the name of such transferee or Holder, as applicable, and (z) if such
transfer or exchange involves less than the entire principal amount of the canceled Certificated Note, deliver to the Holder thereof one or more Certificated Notes in authorized denominations having an aggregate principal amount equal to the
untransferred or unexchanged portion of the canceled Certificated Note, registered in the name of the Holder thereof. 
  

 38 

 Section 2.10. Restrictions on Transfer and Exchange. (a) The transfer or
exchange of any Note (or a beneficial interest therein) may only be made in accordance with this Section and Section 2.09 and, in the case of a Global Note (or a beneficial interest therein), the applicable rules and procedures of the
Depositary. The Trustee shall refuse to register any requested transfer or exchange that does not comply with the preceding sentence. 
 (b) Subject to Section 2.10(c), the transfer or exchange of any Note (or a beneficial interest therein) of the type set forth in column A below for a Note (or a beneficial interest therein) of the type set forth opposite in column B
below may only be made in compliance with the certification requirements (if any) described in the clause of this paragraph set forth opposite in column C below. 
  

					
	A	 	B	 	C
	 U.S. Global Note
	 	 U.S. Global Note
	 	(1)
	 U.S. Global Note
	 	 Offshore Global Note
	 	(2)
	 U.S. Global Note
	 	 Certificated Note
	 	(3)
	 U.S. Global Note
	 	 AI Global Note
	 	(3)
	 Offshore Global Note
	 	 U.S. Global Note
	 	(4)
	 Offshore Global Note
	 	 Offshore Global Note
	 	(1)
	 Offshore Global Note
	 	 Certificated Note
	 	(5)
	 Offshore Global Note
	 	 AI Global Note
	 	(3)
	 Certificated Note
	 	 U.S. Global Note
	 	(4)
	 Certificated Note
	 	 Offshore Global Note
	 	(2)
	 Certificated Note
	 	 Certificated Note
	 	(3)
	 Certificated Note
	 	 A.I. Global Note
	 	(3)
	 A.I. Global Note
	 	 U.S. Global Note
	 	(4)
	 A.I. Global Note
	 	 Offshore Global Note
	 	(2)
	 A.I. Global Note
	 	 Certificated Note
	 	(3)
	 A.I. Global Note
	 	 A.I. Global Note
	 	(1)

 (1) No
certification is required. 
 (2) The Person requesting the transfer or exchange must deliver or cause to be
delivered to the Trustee a duly completed Regulation S Certificate; provided that if the requested transfer or exchange is made by the Holder of a Certificated Note that does not bear the Restricted Legend, then no certification is required.

 (3) The Person requesting the transfer or exchange must deliver or cause to be delivered to the Trustee
(x) a duly completed Rule 144A Certificate, (y) a duly completed Regulation S Certificate or (z) a duly completed Accredited Investor Certificate, and/or an Opinion of Counsel and such other certifications and evidence as the Company
may

  

 39 

 
reasonably require in order to determine that the proposed transfer or exchange is being made in compliance with the Securities Act and any applicable securities laws of any state of the United
States; provided that if the requested transfer or exchange is made by the Holder of a Certificated Note that does not bear the Restricted Legend, then no certification is required. In the event that (i) the requested transfer or
exchange takes place after the Restricted Period and a duly completed Regulation S Certificate is delivered to the Trustee or (ii) a Certificated Note that does not bear the Restricted Legend is surrendered for transfer or exchange, upon
transfer or exchange the Trustee will deliver a Certificated Note that does not bear the Restricted Legend. 
 (4) The Person requesting the transfer or exchange must deliver or cause to be delivered to the Trustee a duly completed Rule 144A Certificate. 
 (5) Notwithstanding anything to the contrary contained herein, no such exchange is permitted if the requested exchange involves a beneficial interest in a Temporary Offshore Global Note. If the requested
transfer involves a beneficial interest in a Temporary Offshore Global Note, the Person requesting the transfer must deliver or cause to be delivered to the Trustee (x) a duly completed Rule 144A Certificate or (y) a duly completed
Accredited Investor Certificate and/or an Opinion of Counsel and such other certifications and evidence as the Company may reasonably require in order to determine that the proposed transfer is being made in compliance with the Securities Act and
any applicable securities laws of any state of the United States. If the requested transfer or exchange involves a beneficial interest in a Permanent Offshore Global Note, no certification is required and the Trustee will deliver a Certificated Note
that does not bear the Restricted Legend. 
 (c) No certification is required in connection with any transfer or exchange of any
Note (or a beneficial interest therein) 
 (1) after such Note is eligible for resale pursuant to Rule 144 under
the Securities Act (or a successor provision); provided that the Company has provided the Trustee with an Officers’ Certificate to that effect, and the Company and Trustee may require from any Person requesting a transfer or exchange in
reliance upon this clause (1) an opinion of counsel and any other reasonable certifications and evidence in order to support such certificate; or 
 (2)(x) sold pursuant to an effective registration statement, pursuant to the Registration Rights Agreement or otherwise or (y) which is validly tendered for exchange into an Exchange Note pursuant to
an Exchange Offer. 
  

 40 

 Any Certificated Note delivered in reliance upon this paragraph will not bear the Restricted
Legend. 
 (d) The Trustee will retain copies of all certificates, opinions and other documents received in connection with the
transfer or exchange of a Note (or a beneficial interest therein), and the Company will have the right to inspect and make copies thereof at any reasonable time upon written notice to the Trustee. 
 Section 2.11. Temporary Offshore Global Notes. (a) Each Note originally sold by the Initial Purchasers in reliance upon
Regulation S will be evidenced by one or more Offshore Global Notes that bear the Temporary Offshore Global Note Legend. 
 (b)
An owner of a beneficial interest in a Temporary Offshore Global Note (or a Person acting on behalf of such an owner) may provide to the Trustee (and the Trustee will accept) a duly completed Certificate of Beneficial Ownership at any time after the
Restricted Period (it being understood that the Trustee will not accept any such certificate during the Restricted Period). Promptly after acceptance of a Certificate of Beneficial Ownership with respect to such a beneficial interest, the Trustee
will cause such beneficial interest to be exchanged for an equivalent beneficial interest in a Permanent Offshore Global Note, and will (x) permanently reduce the principal amount of such Temporary Offshore Global Note by the amount of such
beneficial interest and (y) increase the principal amount of such Permanent Offshore Global Note by the amount of such beneficial interest. 
 (c) Notwithstanding paragraph (b), if after the Restricted Period any Initial Purchaser owns a beneficial interest in a Temporary Offshore Global Note, such Initial Purchaser may, upon written request to
the Trustee accompanied by a certification as to its status as an Initial Purchaser, exchange such beneficial interest for an equivalent beneficial interest in a Permanent Offshore Global Note, and the Trustee will comply with such request and will
(x) permanently reduce the principal amount of such Temporary Offshore Global Note by the amount of such beneficial interest and (y) increase the principal amount of such Permanent Offshore Global Note by the amount of such beneficial
interest. 
 (d) Notwithstanding anything to the contrary contained herein, any owner of a beneficial interest in a Temporary
Offshore Global Note shall not be entitled to receive payment of principal or interest on such beneficial interest or other amounts in respect of such beneficial interest until such beneficial interest is

  

 41 

 
exchanged for an interest in a Permanent Offshore Global Note or transferred for an interest in another Global Note or a Certificated Note. 
 ARTICLE 3 
 REDEMPTION; OFFER TO PURCHASE 
 Section 3.01.
Optional Redemption. Except as described in this Section 3.01 and Section 3.02, the Company will not have the right to redeem any Notes prior to the Stated Maturity. The Notes will be redeemable at the option of the Company, in whole
or in part, at any time, and from time to time, on and after December 15, 2013 at the following redemption prices (expressed as percentages of the principal amount thereof) if redeemed during the 12-month period commencing December 15 of
the years indicated below, in each case together with accrued and unpaid interest and Additional Interest, if any, to the date of redemption: 
  

				
	 Year
	  	Redemption Price	 
	 2013
	  	104.250	% 
	 2014
	  	102.125	% 
	 2015 and thereafter
	  	100.000	% 

 At any time
prior to December 15, 2013, the Company may redeem the Notes, in whole or in part, on not less than 30 nor more than 60 days’ prior notice, by paying a redemption price equal to 100% of the principal amount of the Notes to be redeemed
plus the Applicable Premium as of, and accrued and unpaid interest, if any, to, the applicable redemption date (subject to the right of Holders of record on the relevant record date to receive interest due on the relevant interest payment
date). The Trustee shall have no obligation to calculate either the Applicable Premium or the Treasury Rate used in the calculation of the Applicable Premium. 
 Section 3.02. Optional Redemption upon Equity Offerings. At any time, or from time to time, on or prior to December 15, 2012, the Company may, at its option, use the net cash proceeds of
one or more Equity Offerings to redeem up to 35% of the principal amount of the Notes at a redemption price of 108.500% of the principal amount thereof, together with accrued and unpaid interest and Additional Interest, if any, to the date of
redemption; provided that: 
 (1) at least 65% of the principal amount of the Notes originally issued
under the Indenture on the Issue Date remain outstanding immediately after such redemption; and 
  

 42 

 (2) the Company makes such redemption not more than 90 days after the
consummation of any such Equity Offering. 
 Section 3.03. Method and Effect of Redemption. (a) If the Company
elects to redeem Notes, it must notify the Trustee of the redemption date and the principal amount of Notes to be redeemed by delivering an Officers’ Certificate at least 30 days before the redemption date (unless a shorter period is
satisfactory to the Trustee). In the event that the Company chooses to redeem less than all of the Notes, the Officers’ Certificate must also specify a record date not less than 15 days after the date the notice of redemption is given to the
Trustee, and selection of the Notes for redemption will be made by the Trustee either: 
 (1) in compliance with
the requirements of the principal national securities exchange, if any, on which the Notes are listed; or, 
 (2)
on a pro rata basis, by lot or by such method as the Trustee shall deem fair and appropriate. 
 No Notes of a principal
amount of $2,000 or less shall be redeemed in part. The Trustee will notify the Company promptly of the Notes or portions of Notes to be called for redemption. If a partial redemption is made with the proceeds of an Equity Offering, the Trustee will
select the Notes only on a pro rata basis or on as nearly a pro rata basis as is practicable (subject to DTC procedures) unless such method is otherwise prohibited. Notice of redemption will be mailed by the Company, or at the
Company’s request, by the Trustee in the name and expense of the Company, by first-class mail at least 30 but not more than 60 days before the redemption date to each Holder of Notes to be redeemed at its registered address; provided,
however, that at least 45 days notice must be provided to the Trustee if the Company requests the Trustee to conduct such mailing (unless a shorter period is agreed to by the Trustee). Unless the Company defaults in the payment of the
redemption price, on and after the redemption date, interest will cease to accrue on Notes or portions thereof called for redemption. 
 (b) The notice of redemption will identify the Notes to be redeemed and will include or state the following: 
 (1) the redemption date; 
 (2) the redemption price, including the portion thereof representing any
accrued interest; 
 (3) the place or places where Notes are to be surrendered for redemption; 
  

 43 

 (4) Notes called for redemption must be so surrendered in order to collect
the redemption price; 
 (5) on the redemption date the redemption price will become due and payable on Notes
called for redemption, and interest on Notes called for redemption will cease to accrue on and after the redemption date; 
 (6) if any Note is redeemed in part, on and after the redemption date, upon surrender of such Note, new Notes equal in principal amount to the unredeemed portion will be issued; and 
 (7) if any Note contains a CUSIP or CINS number, no representation is being made as to the correctness of the CUSIP or CINS
number either as printed on the Notes or as contained in the notice of redemption and that the Holder should rely only on the other identification numbers printed on the Notes. 
 (c) Once notice of redemption is sent to the Holders, Notes called for redemption become due and payable at the redemption price on the
redemption date, and upon surrender of the Notes called for redemption, the Company shall redeem such Notes at the redemption price. Commencing on the redemption date, Notes redeemed will cease to accrue interest. Upon surrender of any Note redeemed
in part, the Holder will receive a new Note equal in principal amount to the unredeemed portion of the surrendered Note. 
 Section 3.04. Offer to Purchase. This section sets out rules governing Offers to Purchase made pursuant to Section 4.14 and Section 4.15. “Offer to Purchase” means an offer to purchase Notes by the
Company, from the Holders commenced by mailing a notice to the Trustee and each Holder stating: 
 (1) the
covenant pursuant to which the offer is being made and that all Notes validly tendered will be accepted for payment on a pro rata basis; 
 (2) the purchase price and the date of purchase (which shall be a Business Day no earlier than 30 days nor later than 60 days from the date such notice is mailed) (“Payment Date”);

 (3) that any Note not tendered will continue to accrue interest pursuant to its terms; 
 (4) that, unless the Company defaults in the payment of the purchase price, any Note accepted for payment pursuant to the
Offer to Purchase shall cease to accrue interest on and after the Payment Date; 
  

 44 

 (5) that Holders electing to have a Note purchased pursuant to the Offer to
Purchase will be required to surrender the Note, together with the form entitled “Option of the Holder to Elect Purchase” on the reverse side of the Note completed, to the Paying Agent at the address specified in the notice prior to the
close of business on the Business Day immediately preceding the Payment Date; 
 (6) that Holders will be
entitled to withdraw their election if the Payment Agent receives, not later than the close of business on the third Business Day immediately preceding the Payment Date, a facsimile transmission or letter setting forth the name of such Holder, the
principal amount of Notes delivered for purchase and a statement that such Holder is withdrawing his election to have such Notes purchased; and 
 (7) that Holders whose Notes are being purchased only in part will be issued new Notes equal in principal amount to the unpurchased portion of the Notes surrendered; provided that each Note
purchased and each new Note issued shall be in a principal amount of $2,000 and any higher integral multiple of $1,000 thereof. 
 On the Payment Date, in connection with an Offer to Purchase, the Company shall 
  

	 	•	 	 accept for payment on a pro rata basis Notes or portions thereof tendered pursuant to an Offer to Purchase; 

  

	 	•	 	 deposit with the Paying Agent money sufficient to pay the purchase price of all Notes or portions thereof so accepted; and

  

	 	•	 	 promptly thereafter deliver, or cause to be delivered, to the Trustee all Notes or portions thereof so accepted together with an Officers’
Certificate specifying the Notes or portions thereof accepted for payment by the Company. 

 The Paying Agent
shall promptly mail to the Holders of Notes so accepted payment in an amount equal to the purchase price, and the Trustee shall promptly authenticate and mail to such Holders a new Note equal in principal amount to any unpurchased portion of any
Note surrendered; provided that each Note purchased and each new Note issued shall be in a principal amount of $2,000 and any higher integral multiple of $1,000. The Company shall publicly announce the results of an Offer to Purchase as soon
as practicable after the Payment Date. The Company shall comply with Rule 14e-1 under the Exchange Act and any other securities laws and regulations thereunder to the extent such laws and regulations are applicable, in the event that the Company is
required to repurchase Notes pursuant to an Offer to Purchase. 
  

 45 

 ARTICLE 4 
 COVENANTS 
 Section 4.01. Payment Of Notes.
(a) The Company agrees to pay the principal of and interest on the Notes on the dates and in the manner provided in the Notes and the Indenture. Not later than 9:00 A.M. (New York City time) on the due date of any principal of or interest
on any Notes, or any redemption or purchase price of the Notes, the Company will deposit with the Trustee (or Paying Agent) money in immediately available funds sufficient to pay such amounts, provided that if the Company or any Affiliate of
the Company is acting as Paying Agent, it will, on or before each due date, segregate and hold in a separate trust fund for the benefit of the Holders a sum of money sufficient to pay such amounts until paid to such Holders or otherwise disposed of
as provided in the Indenture. In each case the Company will promptly notify the Trustee of its compliance with this paragraph. 
 (b) An installment of principal or interest will be considered paid on the date due if the Trustee (or Paying Agent, other than the Company or any Affiliate of the Company) holds on that date money designated for and sufficient to pay the
installment. If the Company or any Affiliate of the Company acts as Paying Agent, an installment of principal or interest will be considered paid on the due date only if paid to the Holders. 
 (c) The Company agrees to pay interest on overdue principal, and overdue installments of interest at the rate per annum specified in the
Notes. 
 (d) Payments in respect of the Notes represented by the Global Notes are to be made by wire transfer of immediately
available funds to the accounts specified by the Holders of the Global Notes. With respect to Certificated Notes, the Company will make all payments by wire transfer of immediately available funds to the accounts specified by the Holders thereof,
or, at the option of the Company, payment of interest may be made by check mailed to the Holders at their addresses set forth in the Register. 
 Section 4.02. Maintenance of Office or Agency. The Company will maintain in the Borough of Manhattan, the City of New York, an office or agency where Notes may be surrendered for registration
of transfer or exchange or for presentation for payment and where notices and demands to or upon the Company

  

 46 

 
in respect of the Notes and the Indenture may be served. The Company hereby initially designates the office of the Trustee located at 100 Wall Street, Suite 1600, New York, NY 10005 as such
office of the Company. The Company will give prompt written notice to the Trustee of the location, and any change in the location, of such office or agency. If at any time the Company fails to maintain any such required office or agency or fails to
furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served to the Trustee. 
 The Company may also from time to time designate one or more other offices or agencies where the Notes may be surrendered or presented for any of such purposes and may from time to time rescind such
designations. The Company will give prompt written notice to the Trustee of any such designation or rescission and of any change in the location of any such other office or agency. 
 Section 4.03. Existence. The Company will do or cause to be done all things necessary to preserve and keep in full force and
effect its existence and the existence of each of its Restricted Subsidiaries in accordance with their respective organizational documents, and the material rights, licenses and franchises of the Company and each Restricted Subsidiary,
provided that the Company is not required to preserve any such right, license or franchise, or the existence of any Restricted Subsidiary, if the maintenance or preservation thereof is no longer desirable in the conduct of the business of the
Company and its Restricted Subsidiaries taken as a whole; and provided, further that this Section does not prohibit any transaction otherwise permitted by Section 4.14 or Article 5. 
 Section 4.04. Payment of Taxes and other Claims. The Company will pay or discharge, and cause each of its Restricted
Subsidiaries to pay or discharge before the same become delinquent (i) all material taxes, assessments and governmental charges levied or imposed upon the Company or any Restricted Subsidiary or its income or profits or property, and
(ii) all material lawful claims for labor, materials and supplies that, if unpaid, might by law become a Lien upon the property of the Company or any Restricted Subsidiary, other than any such tax, assessment, charge or claim the amount,
applicability or validity of which is being contested in good faith by appropriate proceedings and for which adequate reserves have been established. 
 Section 4.05. Maintenance of Properties and Insurance. The Company will cause all properties used or useful in the conduct of its business or the business of any of its Restricted Subsidiaries
to be maintained and kept in good condition, repair and working order as in the judgment of the Company may be necessary so that the business of the Company and its Restricted Subsidiaries may be properly and advantageously conducted at all times;
provided that nothing in this Section prevents the Company or any Restricted Subsidiary from

  

 47 

 
discontinuing the use, operation or maintenance of any of such properties or disposing of any of them, if such discontinuance or disposal is, in the judgment of the Company, desirable in the
conduct of the business of the Company and its Restricted Subsidiaries taken as a whole. 
 Section 4.06. Limitation on
Indebtedness. 
 (1) The Company will not, and will not permit any of its Restricted Subsidiaries to, Incur any Indebtedness
if, immediately after giving effect to the Incurrence of such additional Indebtedness, the aggregate principal amount of all outstanding Indebtedness of the Company and its Restricted Subsidiaries on a consolidated basis determined in accordance
with GAAP is greater than 60% of Adjusted Total Assets. 
 (2) The Company will not, and will not permit any of its Restricted
Subsidiaries to, Incur any Subsidiary Debt or any Secured Indebtedness if, immediately after giving effect to the Incurrence of such additional Subsidiary Debt or Secured Indebtedness, the aggregate principal amount of all outstanding Subsidiary
Debt and Secured Indebtedness of the Company and its Restricted Subsidiaries on a consolidated basis is greater than 40% of Adjusted Total Assets. 
 (3) The Company will not, and will not permit any of its Restricted Subsidiaries to, Incur any Indebtedness; provided that the Company or any Restricted Subsidiary may Incur Indebtedness if, after
giving effect to the Incurrence of such Indebtedness and the receipt and application of the proceeds therefrom, the Interest Coverage Ratio of the Company and its Restricted Subsidiaries on a consolidated basis would be greater than 2.0 to 1.

 (4) Notwithstanding paragraphs (1), (2) or (3), the Company or any of its Restricted Subsidiaries may Incur each and all
of the following: 
 (A) Indebtedness, Incurred after the Issue Date, outstanding under any Line of Credit at any
time in an aggregate principal amount not to exceed $100 million, less any amount of such Indebtedness under any Line of Credit permanently repaid as provided under Section 4.14; 
 (B) Indebtedness owed to: 
  

	 	(i)	the Company or a Guarantor evidenced by an unsubordinated promissory note; or 

  

	 	(ii)	any other Restricted Subsidiary, provided that if the Company or any Guarantor is an obligor, the Indebtedness is subordinated to the Notes,

  

 48 

 provided that any event which results in any such Restricted Subsidiary ceasing to be
a Restricted Subsidiary or any subsequent transfer of such Indebtedness (other than to the Company or any other Restricted Subsidiary) shall be deemed, in each case, to constitute an Incurrence of such Indebtedness not permitted by this clause (B);

 (C) Indebtedness outstanding as of the Issue Date not otherwise permitted to be Incurred under this clause
(4); 
 (D) Indebtedness issued in exchange for, or the net proceeds of which are used to extend, refinance,
renew, replace, defease or refund such outstanding Indebtedness (other than Indebtedness Incurred under clause (A), (B), (E), (H), and (I) of this paragraph (4)) and any refinancings thereof in an amount not to exceed the amount so
refinanced or refunded (plus premiums, accrued interest, fees and expenses); provided that Indebtedness the proceeds of which are used to refinance or refund Indebtedness that ranks subordinate in right of payment to, the Notes shall
be permitted under this clause (D) only if: 
  

	 	(i)	such new Indebtedness, by its terms or by the terms of any agreement or instrument pursuant to which such new Indebtedness is issued or remains outstanding, is
expressly made subordinate in right of payment to the Notes at least to the extent that the Indebtedness to be refinanced is subordinated to the Notes; and 

  

	 	(ii)	such new Indebtedness, determined as of the date of Incurrence of such new Indebtedness, does not mature prior to the Stated Maturity of the Indebtedness to be
refinanced or refunded, and the Average Life of such new Indebtedness is at least equal to the remaining Average Life of the Indebtedness to be refinanced or refunded; and 

 provided, further that in no event may Indebtedness of the Company or a Subsidiary Guarantor that ranks equally with or
subordinate in right of payment to the Notes be refinanced by means of any Indebtedness of any Restricted Subsidiary that is not a Subsidiary Guarantor pursuant to this clause (D); 
 (E) Indebtedness: 
  

	 	(i)	in respect of performance, surety or appeal bonds provided in the ordinary course of business, 

  

 49 

	 	(ii)	under Currency Agreements and Interest Rate Agreements; provided that such agreements (i) are designed solely to protect the Company or any of its
Restricted Subsidiaries against fluctuations in foreign currency exchange rates or interest rates and (ii) do not increase the Indebtedness of the obligor outstanding at any time other than as a result of fluctuations in foreign currency
exchange rates or interest rates or by reason of fees, indemnities and compensation payable thereunder, and 

  

	 	(iii)	arising from agreements providing for indemnification, adjustment of purchase price or similar obligations, or from Guarantees or letters of credit, surety bonds or
performance bonds securing any obligations of the Company or any of its Restricted Subsidiaries pursuant to such agreements, in any case Incurred in connection with the disposition of any business, assets or Restricted Subsidiary (other than
Guarantees of Indebtedness Incurred by any Person acquiring all or any portion of such business, assets or Restricted Subsidiary for the purpose of financing such acquisition), in a principal amount not to exceed the gross proceeds actually received
by the Company or any of its Restricted Subsidiaries on a consolidated basis in connection with such disposition; 

 (F) Indebtedness including Capital Leases, mortgage financings or purchase money obligations, Incurred after the Issue Date and no later than 180 days after the date of purchase or completion of
construction for the purpose of financing all or any part of the purchase price or cost of the design, construction, installation, repair or improvement of property, plant or equipment or other fixed or capital assets, provided that the
principal amount of any Indebtedness Incurred pursuant to this clause, including all refinancing Indebtedness Incurred to refund, refinance or replace any Indebtedness Incurred pursuant to this clause, may not exceed 7.5% of Total Assets in the
aggregate at any time outstanding; 
 (G) Indebtedness of the Company to the extent the net proceeds thereof are
promptly 
  

	 	(i)	used to purchase Notes tendered in an Offer to Purchase made as a result of a Change of Control; or 

  

 50 

	 	(ii)	deposited to defease the Notes pursuant to Section 8.01, Section 8.02 or Section 8.03; 

 (H) Guarantees of the Notes and Guarantees of Indebtedness of the Company or any Guarantor by any of its Restricted
Subsidiaries provided the guarantee of such Indebtedness is permitted by and made in accordance with Section 4.12; or 
 (I) Additional Indebtedness, Incurred after the Issue Date, of the Company and its Restricted Subsidiaries not to exceed 5% of Total Assets in the aggregate at any time outstanding. 
 (5) Notwithstanding any other provision of this Section 4.06, the maximum amount of Indebtedness that the Company or any of its
Restricted Subsidiaries may Incur pursuant to this Section 4.06 shall not be deemed to be exceeded, with respect to any outstanding Indebtedness due solely to the result of fluctuations in the exchange rates of currencies. 
 (6) For purposes of determining any particular amount of Indebtedness under this Section 4.06, Guarantees, Liens or obligations with
respect to letters of credit supporting Indebtedness otherwise included in the determination of such particular amount shall not be included. 
 For purposes of determining compliance with this Section 4.06, in the event that an item of Indebtedness meets the criteria of more than one of the types of Indebtedness described in the above
clauses, the Company, in its sole discretion, shall classify such item of Indebtedness and only be required to include the amount and type of such Indebtedness in one of such clauses; provided that the Company may divide and classify an item
of Indebtedness in one or more of the types of Indebtedness and may later reclassify all or a portion of such item of Indebtedness, in any manner that complies with this Section 4.06. 
 Section 4.07. Maintenance of Total Unencumbered Assets. The Company and the Subsidiary Guarantors will maintain Total
Unencumbered Assets of not less than 150% of the aggregate outstanding principal amount of the Unsecured Indebtedness of the Company and the Subsidiary Guarantors on a consolidated basis. 
 Section 4.08. Limitation on Sale and Leaseback Transactions. The Company will not, and will not permit any Restricted Subsidiary
to, enter into any Sale and Leaseback Transaction with respect to any property or asset unless 
 (1) the Company or the
Restricted Subsidiary would be entitled to Incur Indebtedness in an amount equal to the Attributable Debt with respect to

  

 51 

 
such Sale and Leaseback Transaction pursuant to Section 4.06, in which case, the corresponding Indebtedness will be deemed Incurred pursuant to Section 4.06, and 
 (2) the Company or any of its Restricted Subsidiaries, within 12 months after the sale or transfer of any assets or properties is completed,
applies an amount not less than the Net Cash Proceeds received from such sale in accordance with Section 4.14. 
 Section 4.09. Limitation on Restricted Payments. (a) The Company will not, and will not permit any of its Restricted Subsidiaries to, directly or indirectly: 
 (1) declare or pay any dividend or make any distribution on or with respect to its Capital Stock held by Persons other than the Company or
any of its Restricted Subsidiaries, other than: 
  

	 	(A)	dividends or distributions payable solely in shares of its Capital Stock (other than Disqualified Stock) or in options, warrants or other rights to acquire shares of
such Capital Stock; and 

  

	 	(B)	pro rata dividends or distributions on Common Stock of any Restricted Subsidiary held by minority stockholders; 

 (2) purchase, redeem, retire or otherwise acquire for value any shares of Capital Stock of Holdings, the Company or any Restricted
Subsidiary (including options, warrants or other rights to acquire such shares of Capital Stock) held by any Person other than the Company or any of its Restricted Subsidiaries; or 
 (3) make any voluntary or optional principal payment, redemption, repurchase, defeasance, or other acquisition or retirement for value, of
Indebtedness of the Company or any of its Restricted Subsidiaries that is subordinated in right of payment to the Notes; or 
 (4) make an Investment, other than a Permitted Investment, in any Person 
 (such payments or any other actions described in clauses
(1) through (4) above being collectively “Restricted Payments”) if, at the time of, and after giving effect to, the proposed Restricted Payment: 
 (A) a Default or Event of Default shall have occurred and be continuing; 
  

 52 

 (B) the Company could not Incur at least $1.00 of Indebtedness under paragraphs (1),
(2) and (3) of Section 4.06; or 
 (C) the aggregate amount of all Restricted Payments (the amount, if other than
in cash, to be determined as the Fair Market Value thereof in good faith by the Board of Directors, whose determination shall be conclusive and evidenced by a Board Resolution) made on or after the Issue Date shall exceed the sum of: 
  

	 	(1)	95% of the aggregate amount of the Funds From Operations (or, if the Funds From Operations is a loss, minus 100% of the amount of such loss) (determined by
excluding income resulting from transfers of assets by the Company or any of its Restricted Subsidiaries to an Unrestricted Subsidiary) accrued on a cumulative basis during the period (taken as one accounting period) beginning on January 1,
2010 and ending on the last day of the last fiscal quarter preceding the Transaction Date for which financial information is available, plus 

  

	 	(2)	the aggregate Net Cash Proceeds received by the Company after the Issue Date from the issuance and sale permitted by the Indenture of its Capital Stock (other than
Disqualified Stock) to a Person who is not a Subsidiary of the Company, including an issuance or sale permitted by the Indenture of Indebtedness of the Company for cash subsequent to the Issue Date upon the conversion of such Indebtedness into
Capital Stock (other than Disqualified Stock) of the Company, or from the issuance to a Person who is not a Subsidiary of the Company of any options, warrants or other rights to acquire Capital Stock of the Company (in each case, exclusive of any
Disqualified Stock or any options, warrants or other rights that are redeemable for cash at the option of the holder, or are required to be redeemed for cash, prior to the Stated Maturity of the Notes), plus 

  

	 	(3)	 an amount equal to the net reduction in Investments (other than reductions in Permitted Investments) in any Person resulting from payments of interest
on Indebtedness, dividends, repayments of loans or

  

 53 

	 	 
advances, or other transfers of assets, in each case to the Company or any of its Restricted Subsidiaries or from the Net Cash Proceeds from the sale of any such Investment (except, in each case,
to the extent any such payment or proceeds are included in the calculation of Funds From Operations) or from redesignations of Unrestricted Subsidiaries as Restricted Subsidiaries (valued in each case as provided in the definition of
“Investments”) not to exceed, in each case, the amount of Investments previously made by the Company and its Restricted Subsidiaries in such Person or Unrestricted Subsidiary, plus 

  

	 	(4)	the purchase price of noncash tangible assets acquired in exchange for an issuance of Capital Stock (other than Disqualified Stock) of the Company subsequent to the
Issue Date 

 provided, that any payments of bona fide obligations of the Company or any Restricted Subsidiary shall not be
deemed to be Restricted Payments solely by virtue of the fact of another Person’s co-obligations with respect thereto. 
 (b) Notwithstanding the foregoing, the Company and any Restricted Subsidiary may declare or pay any dividend or make any distribution to Holdings to fund a dividend or distribution by Holdings (and make any corresponding distributions to
the Company’s partners other than Holdings), so long as Holdings believes in good faith that Holdings qualifies as a real estate investment trust under the Code and the declaration or payment of any dividend or the making of any distribution is
necessary either to maintain Holdings’ status as a real estate investment trust under the Code for any calendar year or to enable Holdings to avoid payment of any tax for any calendar year that could be avoided by reason of a distribution by
Holdings to its shareholders, with such distribution to be made as and when determined by Holdings, whether during or after the end of, the relevant calendar year, if: 
 (1) the aggregate principal amount of all outstanding Indebtedness of the Company on a consolidated basis in accordance with GAAP at such time is less than 65% of Adjusted Total Assets; and 
 (2) no Default or Event of Default shall have occurred and be continuing. 
 (c) The foregoing provisions shall not be violated by reason of: 
 (1) the payment of any dividend within 60 days after the date of declaration thereof if, at said date of declaration, such payment would
comply with Section 4.09(a); 
  

 54 

 (2) the redemption, repurchase, defeasance or other acquisition or retirement for value of
Indebtedness that is subordinated in right of payment to the Notes including premium, if any, and accrued and unpaid interest, with the proceeds of, or in exchange for, Indebtedness Incurred under clause (D) of paragraph (4) of
Section 4.06; 
 (3) the repurchase, redemption or other acquisition of Capital Stock of the Company (or options, warrants
or other rights to acquire such Capital Stock) in exchange for, or out of the proceeds of a substantially concurrent issuance of, shares of Capital Stock (other than Disqualified Stock) (or options, warrants or other rights to acquire such Capital
Stock); 
 (4) the making of any principal payment on, or the repurchase, redemption, retirement, defeasance or other
acquisition for value of, Indebtedness of the Company which is subordinated in right of payment to the Notes in exchange for, or out of the proceeds of, a substantially concurrent issuance of, shares of the Capital Stock (other than Disqualified
Stock) of the Company (or options, warrants or other rights to acquire such Capital Stock); 
 (5) the retirement of Units upon
the conversion of such Units to Capital Stock of Holdings; 
 (6) payment distribution to dissenting stockholders pursuant to
applicable law pursuant to or in connection with a consolidation, merger or transfer of assets that complies with Section 5.01 or, with respect to Holdings, Section 5.02; 
 (7) the payment of cash (i) in lieu of the issuance of fractional shares of Equity Interests upon conversion, redemption or exchange of
securities convertible into or exchangeable for Equity Interests of the Company and (ii) in lieu of the issuance of whole shares of Equity Interests upon conversion, redemption or exchange of securities convertible into or exchangeable for
Equity Interests of the Company in an aggregate amount not to exceed $1 million; 
 (8) the acquisition or re-acquisition,
whether by forfeiture or in connection with satisfying applicable payroll or withholding tax obligations, of Capital Stock of the Company or Holdings in connection with the administration of their equity compensation programs in the ordinary course
of business; 
  

 55 

 (9)(i) the redemption, repurchase or other acquisition or retirement of any Capital Stock of
the Company, or any Restricted Subsidiary from any director, officer or employee of the Company, Holdings or any Restricted Subsidiary, or from such person’s estate, (a) pursuant to any agreement with such director, officer or employee or
(b) upon the death or termination of directorship or employment of such person, in an aggregate amount under this clause (9)(i) not to exceed $5.0 million in any twelve-month period; or (ii) payments of cash upon redemption of Units;
provided that (a) upon receipt of a Unit redemption notice, Holdings would otherwise be permitted not to use its shelf registration statement but for the expiration of the 90 day aggregate black out period under the terms of
Section 8.7(b)(ii) of the Partnership Agreement, or the redemption shelf is otherwise unavailable to Holdings to issue redemption shares thereunder due to laws and regulations, (b) such payment is not made in respect of any Units
beneficially owned by any of Lammot J. du Pont, Hoessein Fateh or any member of the Board of Directors of the Company and (c) the aggregate amount of cash paid upon redemption of Units pursuant to this clause (9)(ii) does not exceed $10.0
million; 
 (10) declaration or payment of any cash dividend or other cash distribution in respect of Capital Stock of the
Company or any of its Restricted Subsidiaries constituting Preferred Stock, so long as the Interest Coverage Ratio contemplated by paragraph (3) of Section 4.06 shall be greater than or equal to 2 to 1; 
 (11) Investments in any Person or Persons in an aggregate amount not to exceed $25.0 million; 
 (12) Restricted Payments in an aggregate amount not to exceed $35.0 million; 
 (13) the repayment, defeasance, redemption, repurchase or other acquisition of Subordinated Indebtedness or Disqualified Stock of the
Company (a) in exchange for, or out of the Net Cash Proceeds of the substantially concurrent sale (other than to any Subsidiary) of, the Disqualified Stock of the Company, or (b) pursuant to a required change of control offer or asset sale
offer arising from a Change of Control or Asset Sale, as the case may be, provided that such repayment, repurchase, redemption, acquisition or retirement occurs after all Notes tendered by Holders in connection with a related Offer to
Purchase have been repurchased, redeemed or acquired for value; 
 (14) Permitted Tax Payments; or 
  

 56 

 (15) the declaration and payment of a dividend or the distribution by the Company of up to
$9 million insofar as required to maintain Holdings’ status as a real estate investment trust under the Code for calendar year 2009, 
 provided that, in the case of clauses (9), (10), (11) and (12), no Default or Event of Default shall have occurred and be continuing or occur as a direct consequence of the actions or payments set forth therein. Each Restricted
Payment permitted pursuant to this paragraph (other than the Restricted Payment referred to in clause (2), (3), (4) , (5), (6), (8), (11), (12), (13) and (15) of this paragraph), and the Net Cash Proceeds from any issuance of Capital
Stock referred to in clauses (3) and (4), shall be included in calculating whether the conditions of clause (4)(C) of Section 4.09(a) have been met with respect to any subsequent Restricted Payments. 
 Section 4.10. Limitation on Dividend and Other Payment Restrictions Affecting Restricted Subsidiaries. (a) Except as
provided in paragraph (b), the Company will not, and will not permit any of its Restricted Subsidiaries to, create or otherwise cause or suffer to exist or become effective any consensual encumbrance or restriction of any kind on the ability of any
Restricted Subsidiary to: 
 (1) pay dividends or make any other distributions permitted by applicable law on any Capital Stock
of such Restricted Subsidiary owned by the Company or any of its Restricted Subsidiaries, 
 (2) pay any Indebtedness owed to
the Company or any other Restricted Subsidiary, 
 (3) make loans or advances to the Company or any other Restricted Subsidiary,
or 
 (4) transfer its property or assets to the Company or any other Restricted Subsidiary. 
 (b) The foregoing provisions shall not restrict any encumbrances or restrictions: 
 (1) existing on the Issue Date in the Indenture and any other agreement in effect on the Issue Date, and any extensions, refinancings,
renewals or replacements of such agreements; provided that the encumbrances and restrictions in any such extensions, refinancings, renewals or replacements are no less favorable in any material respect, taken as a whole, to the Holders than
those encumbrances or restrictions that are then in effect and that are being extended, refinanced, renewed or replaced; 
  

 57 

 (2) imposed under any applicable documents or instruments pertaining to any current or
future Secured Indebtedness permitted or not prohibited under the Indenture (and relating solely to assets constituting collateral thereunder or cash proceeds from or generated by such assets); 
 (3) existing under or by reason of applicable law, the Indenture, the Notes and the Guarantees; 
 (4) existing with respect to any Person or the property or assets of such Person acquired by the Company or any Restricted Subsidiary,
existing at the time of such acquisition and not incurred in contemplation thereof, which encumbrances or restrictions are not applicable to any Person or the property or assets of any Person other than such Person or the property or assets of such
Person so acquired; 
 (5) in the case of Section 4.10(a)(4): 
 (A) that restrict in a customary manner the subletting, assignment or transfer of any property or asset that is a lease, license, conveyance
or contract or similar property or asset, 
 (B) existing by virtue of any transfer of, agreement to transfer, option or right
with respect to, or Lien on, any property or assets of the Company or any Restricted Subsidiary not otherwise prohibited by the Indenture, 
 (C) existing under or by reason of purchase money obligations for property acquired in the ordinary course of business that impose restrictions on that property, or 
 (D) arising or agreed to in the ordinary course of business, not relating to any Indebtedness, and that do not, individually or in the
aggregate, detract from the value of property or assets of the Company or any Restricted Subsidiary in any manner material to the Company and its Restricted Subsidiaries taken as a whole; 
 (6) with respect to a Restricted Subsidiary and imposed pursuant to an agreement that has been entered into for the sale or disposition of
all or substantially all of the Capital Stock of, or property and assets of, such Restricted Subsidiary (including a restriction on distributions by that Restricted Subsidiary pending its sale or other disposition); 
 (7) contained in the terms of any Indebtedness or any agreement pursuant to which such Indebtedness was issued if: 
 (A) the encumbrance or restriction is not materially more disadvantageous to the Holders of the Notes than is customary in comparable
financings (as determined by the Company), and 
  

 58 

 (B) the Company determines that any such encumbrance or restriction will not materially
affect such Persons’ ability to make principal or interest payments on the Notes; 
 (8) existing under or by reason of
restrictions on cash or other deposits or net worth imposed by customers under contracts entered into in the ordinary course of business; or 
 (9) in connection with and pursuant to permitted extensions, refinancings thereof, or as renewals or replacements of restrictions imposed pursuant to clause (4) of this paragraph; provided
that the encumbrances and restrictions in any such extensions, refinancings, renewals or replacements are no less favorable in any material respect, taken as a whole, to the Holders than those encumbrances or restrictions that are then in effect and
that are being extended, refinanced, renewed or replaced. 
 Nothing contained in this Section 4.10 shall prevent the
Company or any Restricted Subsidiary from restricting the sale or other disposition of property or assets of the Company or its Restricted Subsidiaries that secure Indebtedness of the Company or any of its Restricted Subsidiaries. 
 Section 4.11. Limitation on Issuance and Sale of Capital Stock of Restricted Subsidiaries. The Company shall not, and shall not
permit any of its Restricted Subsidiaries, directly or indirectly, to issue or sell, any shares of Capital Stock of a Restricted Subsidiary (including options, warrants or other rights to purchase shares of such Capital Stock) except: 
 (1) to the Company or a Wholly Owned Restricted Subsidiary; 
 (2) issuances of director’s qualifying shares; or 
 (3) if, immediately after
giving effect to such issuance or sale, such Restricted Subsidiary would no longer constitute a Subsidiary and any Investment in such Person remaining after giving effect to such issuance or sale would have been permitted to be made under
Section 4.09 if made on the date of such issuance or sale. 
 Section 4.12. Limitation on Guarantees by Restricted
Subsidiaries. The Company will not permit any of its Restricted Subsidiaries (including a newly created or acquired one), directly or indirectly, to Guarantee any Indebtedness of the Company or any Restricted Subsidiary (“Guaranteed
Indebtedness”), unless: 
 (1) if such Restricted Subsidiary is not already a Subsidiary Guarantor, such Restricted
Subsidiary executes and delivers a supplemental indenture to the Indenture providing for a Subsidiary Guarantee by such Restricted Subsidiary within ten (10) Business Days; and 
  

 59 

 (2) such Restricted Subsidiary waives and will not in any manner whatsoever claim or take
the benefit or advantage of, any rights of reimbursement, indemnity or subrogation or any other rights against the Company or any other Restricted Subsidiary as a result of any payment by such Restricted Subsidiary under its Subsidiary Guarantee;

 provided that this paragraph shall not be applicable to any Guarantee of any Restricted Subsidiary that existed at the time such
Person became a Restricted Subsidiary and was not Incurred in connection with, or in contemplation of, such person becoming a Restricted Subsidiary. If the Guaranteed Indebtedness: 
 (a) ranks equally in right of payment with the Notes or Subsidiary Guarantee, then the Guarantee of such Guaranteed Indebtedness shall rank
equally with, or subordinate to, the Subsidiary Guarantee; or 
 (b) is subordinate in right of payment to the Notes, then the
Guarantee of such Guaranteed Indebtedness shall be subordinated in right of payment to the Subsidiary Guarantee at least to the extent that the Guaranteed Indebtedness is subordinated in right of payment to the Notes or Subsidiary Guarantee.

 Section 4.13. Limitation on Transactions with Affiliates. The Company will not, and will not permit any of its
Restricted Subsidiaries to, directly or indirectly, enter into, renew or extend any transaction (including, without limitations, the purchase, sale, lease or exchange of property or assets, or the rendering of any service) with any Affiliate of the
Company or the Restricted Subsidiaries, except upon fair and reasonable terms no less favorable to the Company or such Restricted Subsidiary than could be obtained, at the time of such transaction or, if such transaction is pursuant to a written
agreement, at the time of the execution of the agreement providing therefore, in a comparable arm’s-length transaction with a Person that is not such an Affiliate. 
 The foregoing limitation does not limit, and shall not apply to: 
 (1)
transactions (A) approved by a majority of the independent members of the Board of Directors or (B) for which the Company or any Restricted Subsidiary delivers to the Trustee a written opinion of (i) in the case of a real estate
transaction, an independent qualified real estate appraisal firm, or (ii) otherwise, a nationally recognized investment banking firm, stating that the transaction is fair to the Company or such Restricted Subsidiary from a financial point of
view; 
  

 60 

 (2) any transaction solely between the Company and any of its Wholly Owned Restricted
Subsidiaries or solely between Wholly Owned Restricted Subsidiaries; 
 (3) any payments or other transactions pursuant to any
tax-sharing agreement between the Company and Holdings or other Person with which the Company files a consolidated tax return or with which the Company is part of a consolidated group for tax purposes; 
 (4) any Restricted Payments not prohibited by Section 4.09; 
 (5) transactions pursuant to agreements or arrangements in effect on the Issue Date or any amendment, modification, or supplement thereto or
replacement thereof, as long as such agreement or arrangement, as so amended, modified, supplemented or replaced, taken as a whole, is not more disadvantageous to the Company and the Restricted Subsidiaries than the original agreement or arrangement
in existence on the Issue Date; 
 (6) director’s fees and any employment, consulting, service or termination agreement, or
reasonable and customary indemnification arrangements, entered into by the Company or any of its Restricted Subsidiaries with officers, directors and employees of the Company or its Restricted Subsidiaries that are Affiliates of the Company or its
Restricted Subsidiaries and the payment of compensation to such officers, directors and employees (including amounts paid pursuant to employee benefit plans, employee stock option or similar plans), or loans and advances to any officer, director or
employee, so long as such agreement has been approved by the Board of Directors; 
 (7) commission, payroll, travel and similar
advances or loans (including payment or cancellation thereof) to officers and employees of the Company or any of its Restricted Subsidiaries; 
 (8) sales of Capital Stock (other than Disqualified Stock) of the Company to Affiliates; 
  

 61 

 (9) any transaction with any Person who is not an Affiliate immediately before the
consummation of such transaction that becomes an Affiliate as a result of such transaction; or 
 (10) any transaction with a
joint venture, partnership, limited liability company or other entity that would constitute an Affiliate transaction solely because the Company or a Restricted Subsidiary owns an equity interest in such joint venture, partnership, limited liability
company or other entity. 
 Notwithstanding the foregoing, any transaction or series of related transactions covered by the
first paragraph of this Section 4.13 and not covered by (2) through (10) of the immediately foregoing paragraph, 
 (a) the aggregate amount of which exceeds $5 million in value must be approved or determined to be fair in the manner provided for in clause (1)(A) or (B) above, and 
 (b) the aggregate amount of which exceeds $10 million in value, must be determined to be fair in the manner provided for in clause
(1)(B) above. 
 Section 4.14. Limitation on Asset Sales. The Company shall not, and shall not permit any of
its Restricted Subsidiaries to, consummate any Asset Sale, unless: 
 (1) the consideration received by the Company or such
Restricted Subsidiary is at least equal to the Fair Market Value of the assets sold or disposed of, and 
 (2) at least 75% of
the consideration received consists of cash or Temporary Cash Investments; provided that, with respect to the sale of one or more real estate properties, up to 75% of the consideration may consist of Indebtedness of the purchaser of such real
estate properties so long as such Indebtedness is secured by a first priority Lien on the real estate property or properties sold; and provided, further that, for purposes of this clause (2) the amount of the following will be
deemed to be cash: 
 (a) any liabilities, as shown on the Company’s or such Restricted Subsidiaries’ most recent
balance sheet, of the Company or any such Restricted Subsidiaries (other than contingent liabilities and liabilities that are by their terms subordinated to the Notes or any Guarantee) that are assumed by the transferee of any such assets but,
except in the case of an Asset Sale to a Restricted Subsidiary, only to the extent of the reduction in the amount of such liabilities on the Company’s consolidated balance sheet; and 
  

 62 

 (b) any securities or other obligations received by the Company, any Subsidiary Guarantor or
any such Restricted Subsidiary from such transferee that are immediately converted by the Company, the Subsidiary Guarantor or such Restricted Subsidiary into cash (or as to which the Company, any Subsidiary Guarantor or such Restricted Subsidiary
has received at or prior to the consummation of the Asset Sale a commitment (which may be subject to customary conditions) from a nationally recognized investment, merchant or commercial bank to convert into cash within ninety (90) days of the
consummation of such Asset Sale and which are thereafter actually converted into cash within such 90-day period). 
 In the
event that the Net Cash Proceeds received by the Company or such Restricted Subsidiary from one or more Asset Sales occurring on or after the Issue Date in any period of twelve consecutive months (the “Asset Period”) exceeds 1% of
Total Assets (determined as of the date closest to the commencement of the Asset Period for which a consolidated balance sheet of the Company and its Restricted Subsidiaries is available), then within twelve (12) months after the date Net Cash
Proceeds exceed 1% of Total Assets as described above, the Company shall or shall cause the excess amount to be applied to: 
 (A) permanently reduce Secured Indebtedness of the Company or any Restricted Subsidiary or Indebtedness of any other Restricted Subsidiary that is not a Guarantor, in each case owing to a Person other than Holdings, the Company or any of
its Restricted Subsidiaries, or 
 (B) make a capital expenditure or invest in property or assets (other than current assets) of
a nature or type or that are used in a business (or in a Restricted Subsidiary, or a Person that becomes a Restricted Subsidiary upon such an Investment, having property and assets of a nature or type, or engaged in a business) similar or related to
the nature or type of the property and assets of, or the business of, the Company or any of its Restricted Subsidiaries existing on the date of such capital expenditure or investment (or enter into a definitive agreement committing to make such
capital expenditure or so invest within 12 months after the date of such agreement). 
 Pending the application of any such Net
Cash Proceeds as described above, the Company may invest such Net Cash Proceeds in any manner that is not prohibited by the Indenture. The amount of such excess Net Cash Proceeds required to be applied (or to be committed to be applied) during such
12-month

  

 63 

 
period as set forth in the preceding sentence and not applied as so required by the end of such period shall constitute “Excess Proceeds”. If, as of the first day of any calendar
month, the aggregate amount of Excess Proceeds not previously subject to an Offer to Purchase pursuant to this Section 4.14 totals at least $15 million, the Company must commence, not later than the fifteenth Business Day of such month, and
consummate an Offer to Purchase from the Holders of the Notes and all holders of other Indebtedness that is pari passu with the Notes containing provisions similar to those set forth in the Indenture with respect to offers to purchase or redeem with
the proceeds of sales of assets, on a pro rata basis, an aggregate principal amount of Notes and such other Indebtedness equal to the Excess Proceeds on such date, at a purchase price equal to 100% of the principal amount of the Notes and
such other Indebtedness plus, in each case, accrued interest and Additional Interest (if any) to the Payment Date. 
 If
the aggregate principal amount of the Notes and the other Indebtedness that is pari passu with the Notes tendered into such Offer to Purchase exceeds the amount of Excess Proceeds, then the Notes and the other Indebtedness that is pari passu with
the Notes will be purchased on a pro rata basis based on the principal amount of the Notes and the other Indebtedness that is pari passu with the Notes tendered. Upon completion of each Offer to Purchase, any remaining Excess Proceeds subject
to such Offer to Purchase will no longer be deemed to be Excess Proceeds. 
 Section 4.15. Repurchase of Notes Upon a
Change of Control. (a) The Company must commence, within 30 days of the occurrence of a Change of Control, and consummate an Offer to Purchase for all Notes then outstanding, at a purchase price equal to 101% of the principal amount of the
Notes, plus accrued interest and Additional Interest (if any) to the Payment Date. 
 (b) The Company will not be
required to make an Offer to Purchase upon a Change of Control if a third party makes the Change of Control Offer in the manner, at the times and otherwise in compliance with the requirements set forth in the Indenture applicable to an Offer to
Purchase made by the Company and purchases all Notes validly tendered and not withdrawn under such Offer to Purchaser. Notwithstanding anything to the contrary in the Indenture, an Offer to Purchaser may be made in advance of a Change of Control,
conditional upon such Change of Control, if a definitive agreement is in place for the Change of Control at the time of making the Offer to Purchase. 
 (c) The Company will comply with the requirements of Rule 14e-1 under the Exchange Act and any other securities laws and regulations thereunder to the extent such laws and regulations are applicable in
connection with the repurchase of the Notes as a result of a Change of Control. To the extent that the provisions of any securities laws or regulations conflict with the Change of

  

 64 

 
Control provisions of the Indenture, the Company will comply with the applicable securities laws or regulations and will not be deemed to have breached its obligations under the Change of Control
provisions of the Indenture by virtue of such compliance. 
 Section 4.16. SEC Reports and Reports to Holders.
(a) Whether or not the Company or Holdings is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, the Company and Holdings must provide the Trustee and Holders within fifteen (15) Business Days after
filing, or in the event no such filing is required, within fifteen (15) Business Days after the end of the time periods specified in those sections with: 
 (1) all quarterly and annual financial information that would be required to be contained in a filing with the SEC on Forms 10-Q and 10-K if the Company or Holdings were required to file such forms,
including a “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and, with respect to the annual financial statements only, a report thereon by the Company’s and Holding’s certified
independent accountants, and 
 (2) all current reports that would be required to be filed with the SEC on Form 8-K if the
Company and Holdings were required to file such reports, 
 provided that, the foregoing delivery requirements shall be deemed satisfied
if the foregoing materials are available on the SEC’s EDGAR system or any successor system or on the Company’s or Holding’s website within the applicable time period. 
 (b) In addition, whether or not required by the SEC, Holdings will, and, after the effectiveness of the Exchange Offer Registration
Statement or Shelf Registration Statement, in either case with respect to the Original Notes, the Company will, if the SEC will accept the filing, file a copy of all of the information and reports referred to in clauses (1) and (2) with
the SEC for public availability within the time periods specified in the SEC’s rules and regulations. In addition, the Company and Holdings will make the information and reports available to securities analysts and prospective investors upon
request. If the Company had any Unrestricted Subsidiaries during the relevant period, the Company will also provide to the Trustee and the Holders information sufficient to ascertain the financial condition and results of operations of the Company
and its Restricted Subsidiaries, excluding in all respects the Unrestricted Subsidiaries. 
 (c) For so long as any of the Notes
remain outstanding and constitute “restricted securities” under Rule 144, the Company and Holdings will furnish to the Holders of the Notes and prospective investors, upon their request, the information required to be delivered pursuant to
Rule 144A(d)(4) under the Securities Act. 
  

 65 

 (d) All obligors on the Notes will comply with Section 314(a) of the Trust Indenture
Act. 
 (e) Delivery of these reports and information to the Trustee is for informational purposes only and the Trustee’s
receipt of them will not constitute constructive notice of any information contained therein or determinable from information contained therein, including the Company’s compliance with any of its covenants hereunder (as to which the Trustee is
entitled to rely exclusively on Officers’ Certificates). 
 Section 4.17. Reports to Trustee. (a) The
Company and Holdings will deliver to the Trustee within 120 days after the end of each fiscal year a certificate from the principal executive, financial or accounting officer of the Company and Holdings stating that such officers have conducted or
supervised a review of the activities of the Company, Holdings and the Restricted Subsidiaries and their performance under the Indenture and that, based upon such review, the Company and Holdings have fulfilled all obligations hereunder or, if there
has been a Default in fulfillment of any such obligation, specifying each such Default and its nature and status. 
 (b) The
Company and Holdings will deliver to the Trustee, as soon as possible and in any event within 30 days after the Company or Holdings becomes aware or should reasonably become aware of the occurrence of a Default, an Officers’ Certificate setting
forth the details of the Default, and the action which the Company and Holdings proposes to take with respect thereto. 
 (c)
The Company and Holdings will notify the Trustee if and when any Notes are listed on any national securities exchange and of any delisting. 
 Section 4.18. Suspension of Covenants. (a) For so long as (i) the Notes are rated Investment Grade by each of S&P and Moody’s (or, if either (or both) of S&P and
Moody’s have been substituted in accordance with the definition of “Rating Agencies”, by each of the then applicable Rating Agencies) and (ii) no Default has occurred and is continuing under the Indenture (the occurrence of the
events described in the foregoing clauses (i) and (ii) being collectively referred to as a “Covenant Suspension Event”), and conditioned upon the Company promptly providing the Trustee an Officers’ Certificate and an
Opinion of Counsel as to the existence of a Covenant Suspension Event which identifies the date of such Covenant Suspension Event, the Company and its Restricted Subsidiaries will not be subject to (x) Section 4.08, Section 4.09,
Section 4.10, Section 4.11, Section 4.12, Section 4.13, Section 4.14 and clause (3) of Section 5.01 and (y) in clause (3) of Section 4.06 the reference to “2.0” shall be to “1.5”
(the “Suspended Covenants”). 
  

 66 

 (b) Additionally, during such time as the above referenced covenants are suspended, the
Company will not be permitted to designate any Restricted Subsidiary as an Unrestricted Subsidiary unless the Company would have been permitted to designate such Subsidiary as an Unrestricted Subsidiary if the covenants had been in effect for such
period. 
 (c) If at any time the Notes’ credit rating is downgraded from an Investment Grade rating or if a Default or
Event of Default occurs and is continuing, then the Suspended Covenants will thereafter be reinstated as if such covenants had never been suspended (the “Reinstatement Date”) and be applicable pursuant to the terms of the Indenture
(including in connection with performing any calculation or assessment to determine compliance with the terms of the Indenture), unless and until the Notes subsequently attain an Investment Grade rating and no Default or Event of Default is in
existence (in which event the Suspended Covenants shall no longer be in effect for such time that the Notes maintain an Investment Grade rating and no Default or Event of Default is in existence); provided, however, that no Default,
Event of Default or breach of any kind shall be deemed to exist under the Indenture, the Notes or the Guarantees with respect to the Suspended Covenants based on, and none of the Company or any of its Subsidiaries shall bear any liability for, any
actions taken or events occurring during the Suspension Period (as defined below), or any actions taken at any time pursuant to any contractual obligation arising prior to the Reinstatement Date, regardless of whether such actions or events would
have been permitted if the applicable Suspended Covenants remained in effect during such period. The period of time between the date of suspension of the covenants and the Reinstatement Date, if any, is referred to as the “Suspension
Period.” 
 (d) The Company shall promptly provide the Trustee an Officers’ Certificate and an Opinion of Counsel
as to the existence of a Reinstatement Date which identifies the date of such Reinstatement Date; provided, however, that in no case shall such Reinstatement Date be conditioned upon the receipt of such Officers’ Certificate or
Opinion of Counsel. 
 (e) Calculations made after the Reinstatement Date of the amount available to be made as Restricted
Payments under Section 4.09 will be made as though the covenants described under Section 4.09 had been in effect since the Issue Date and throughout the Suspension Period. Accordingly, Restricted Payments made during the Suspension Period
will reduce the amount available to be made as Restricted Payments under clause (4)(C) of Section 4.09(a), to the extent set forth in such covenant. 
  

 67 

 Section 4.19. Sale of Restricted Securities. Holdings and the Issuer will not,
and will not permit any current or future Subsidiaries, and will use reasonable best efforts not to permit, any other affiliates (as defined in Rule 144 under the Securities Act) to, resell any of the Notes which constitute “restricted
securities” under Rule 144 that have been reacquired by Holdings, the Issuer or any current or future Subsidiaries or any other “affiliates” (as defined in Rule 144 under the Securities Act), except pursuant to an effective
registration statement under the Securities Act. 
 ARTICLE 5 
 CONSOLIDATION, MERGER AND SALE OF ASSETS 
 Section 5.01. Consolidation, Merger and Sale of Assets by the Company. The Company will not merge with or into, or sell, convey,
transfer, lease or otherwise dispose of all or substantially all of its property and assets (as an entirety or substantially an entirety in one transaction or a series of related transactions) to, any Person or permit any Person to merge with or
into the Company unless: 
 (1) the Company shall be the continuing Person, or the Person (if other than the Company) formed by
such consolidation or into which the Company is merged or that acquired or leased such property and assets of the Company shall be an entity organized and validly existing under the laws of the United States of America or any state or jurisdiction
thereof and shall expressly assume, by a supplemental indenture, executed and delivered to the Trustee, all of the obligations of the Company on the Notes and under the Indenture; 
 (2) immediately after giving effect to such transaction, no Default or Event of Default shall have occurred and be continuing; 

(3) immediately after giving effect to such transaction on a pro forma basis the Company, or any Person becoming the successor obligor of
the Notes, as the case may be, (x) could Incur at least $1.00 of Indebtedness under paragraphs (1), (2) and (3) of Section 4.06 or (y) has a Leverage Ratio that is at least 0.25 better than immediately before giving effect
to the transaction and any related Incurrence of Indebtedness; provided that this clause (3) shall not apply to a consolidation or merger of one or more Wholly Owned Restricted Subsidiaries with or into the Company; provided,
further that, in connection with any such merger or consolidation, no consideration (other than Capital Stock (other than Disqualified Stock) in the surviving Person or the Company) shall be issued or distributed to the holders of Capital Stock
of the Company; and 
  

 68 

 (4) the Company delivers to the Trustee an Officers’ Certificate (attaching the
arithmetic computations to demonstrate compliance with clause (3), if applicable) and an Opinion of Counsel, in each case stating that such consolidation, merger or transfer and such supplemental indenture complies with this provision and that all
conditions precedent provided for herein relating to such transaction have been complied with; provided that clause (3) above does not apply if, in the good faith determination of the Board of Directors, whose determination shall be
evidenced by a Board Resolution, the principal purpose of such transaction is to change the state of domicile of the Company; and provided, further, that any such transaction shall not have as one of its purposes the evasion of the
foregoing limitations. 
 Upon any consolidation or merger or any transfer of all or substantially all of the Company’s
assets, in accordance with the foregoing, the successor Person formed by such consolidation or into which the Company is merged or to which such transfer is made, shall succeed to, be substituted for, and may exercise every one of the Company’s
rights and powers under the Indenture with the same effect as if such successor Person had been named therein as the Company and, except in the case of the lease or a sale or other transfer of less than all assets, the Company shall be released from
the obligations under the Notes. 
 Section 5.02. Consolidation, Merger and Sale of Assets by a Guarantor. No
Guarantor may merge with or into any Person, or sell, convey, transfer or dispose of all or substantially all of the Guarantor’s assets, in one transaction or a series of related transactions, to any Person (other than the Company or another
Guarantor), unless: 
 (A) the other Person becomes a Guarantor concurrently with the transaction; or 
 (B)(1) either (x) the Guarantor is the continuing Person or (y) the resulting, surviving or transferee Person expressly assumes by
supplemental indenture (or other joinder agreement, as applicable) all of the obligations of the Guarantor under its Note Guarantee and any Registration Rights Agreement; and 
 (2) immediately after giving effect to the transaction, no Default has occurred and is continuing; or 
 (C) except in the case of Holdings, the transaction constitutes a sale or other disposition (including by way of consolidation or merger) of
the Guarantor or the sale or disposition of all or substantially all the assets of the Guarantor (in each case other than to the Company or a Restricted Subsidiary) otherwise permitted or not prohibited by the Indenture. 
  

 69 

 Notwithstanding the foregoing, the Guarantee of the Notes by a Guarantor shall be
automatically released as set forth Section 10.03 and Section 10.09. 
 ARTICLE 6 
 DEFAULT AND REMEDIES 
 Section 6.01. Events of Default. An “Event of Default” occurs if 
 (1) there occurs a default in the payment of the principal of any Note when the same becomes due and payable at maturity, upon acceleration
or redemption, or otherwise; 
 (2) there occurs a default in the payment of interest (including any Additional Interest) on any
Note when the same becomes due and payable, and the default continues for a period of 30 days; 
 (3) there occurs a default in
the performance or breach of the provisions of Section 5.01 or the failure by the Company to make or consummate an Offer to Purchase in accordance with Section 4.14 or Section 4.15; 
 (4) the Company or Holdings defaults in the performance of or breaches any other covenant or agreement of the Company or Holdings in the
Indenture or under the Notes (other than a default specified in clause (1), (2) or (3) above) and such default or breach continues for a period of 60 consecutive days after written notice by the Trustee or the Holders of 25% or more in
aggregate principal amount of the Notes; 
 (5) there occurs with respect to any issue or issues of Indebtedness of the Company
or Holdings or any Significant Subsidiary having an outstanding principal amount of $25 million or more in the aggregate for all such issues of all such Persons, whether such Indebtedness now exists or shall hereafter be created: 
  

	 	(i)	an event of default that has caused the holder thereof to declare such Indebtedness to be due and payable prior to its Stated Maturity and such Indebtedness has not
been discharged in full or such acceleration has not been rescinded or annulled within 30 days of such acceleration; and/or 

  

	 	(ii)	the failure to make a principal payment at the final (but not any interim) fixed maturity and such defaulted payment shall not have been made, waived or extended within
30 days of such payment default; 

  

 70 

 (6) any final judgment or order (not covered by insurance) for the payment of money in
excess of $25 million in the aggregate for all such final judgments or orders against all such Persons (treating any deductibles, self-insurance or retention as not covered by insurance): 
  

	 	(i)	shall be rendered against the Company or Holdings or any Significant Subsidiary and shall not be paid or discharged; and 

  

	 	(ii)	there shall be any period of 60 consecutive days following entry of the final judgment or order that causes the aggregate amount for all such final judgments or orders
outstanding and not paid or discharged against all such Persons to exceed $25 million during which a stay of enforcement of such final judgment or order, by reason of a pending appeal or otherwise, shall not be in effect; 

(7) a court having jurisdiction in the premises enters a decree or order for: 
  

	 	(i)	relief in respect of the Company or Holdings or any Significant Subsidiary in an involuntary case under any applicable bankruptcy, insolvency or other similar law now
or hereafter in effect; 

  

	 	(ii)	appointment of a receiver, liquidator, assignee, custodian, trustee, sequestrator or similar official of the Company or Holdings or any Significant Subsidiary or for
all or substantially all of the property and assets of the Company or Holdings or any Significant Subsidiary; or 

  

	 	(iii)	the winding up or liquidation of the affairs of the Company or Holdings or any Significant Subsidiary and, in each case, such decree or order shall remain unstayed and
in effect for a period of 60 consecutive days; 

 (8) the Company or Holdings or any Significant Subsidiary

  

	 	(i)	commences a voluntary case under any applicable bankruptcy, insolvency or other similar law now or hereafter in effect, or consents to the entry of an order for relief
in an involuntary case under such law; 

  

	 	(ii)	 consents to the appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee, sequestrator or similar official of the
Company or Holdings or any Significant

  

 71 

	 	 
Subsidiary or for all or substantially all of the property and assets of the Company or Holdings or any Significant Subsidiary; or 

  

	 	(iii)	effects any general assignment for the benefit of its creditors (an event of default specified in clause (7) or (8) a “bankruptcy default”);
or 

 (9) any Note Guarantee ceases to be in full force and effect (other than in accordance with the terms of
such Note Guarantee and the Indenture) or any Guarantor notifies the Trustee in writing that it denies or disaffirms its obligations under its Note Guarantee. 
 Section 6.02. Acceleration. (a) If an Event of Default, other than a bankruptcy
default with respect to the Company or Holdings, occurs and is continuing under the Indenture, the Trustee or the Holders of at least 25% in aggregate principal amount of the Notes then outstanding, by written notice to the Company and Holdings (and
to the Trustee if the notice is given by the Holders), may, and the Trustee at the request of such Holders shall, declare the principal of and accrued interest on the Notes to be immediately due and payable. Upon a declaration of acceleration, such
principal and accrued interest will become immediately due and payable. In the event of a declaration of acceleration because an Event of Default set forth in clause (5) above has occurred and is continuing, such declaration of acceleration
shall be automatically rescinded and annulled if the Event of Default triggering such Event of Default pursuant to clause (5) shall be remedied or cured by the Company, Holdings or the relevant Significant Subsidiary or waived by the holders of
the relevant Indebtedness within 60 days after the declaration of acceleration with respect thereto. If a bankruptcy default occurs with respect to the Company or Holdings, the principal of and accrued interest on the Notes then outstanding shall
automatically become and be immediately due and payable without any declaration or other act on the part of the Trustee or any Holder. 
 (b) The Holders of at least a majority in principal amount of the outstanding Notes by written notice to the Company, Holdings and to the Trustee may waive all past Defaults and rescind and annul a
declaration of acceleration and its consequences if: 
 (1) all existing Events of Default, other than the
nonpayment of the principal of and interest on the Notes that have become due solely by the declaration of acceleration, have been cured or waived, and 
 (2) the rescission would not conflict with any judgment or decree of a court of competent jurisdiction. 
  

 72 

 Section 6.03. Other Remedies. If an Event of Default occurs and is continuing,
the Trustee may pursue, in its own name or as trustee of an express trust, any available remedy by proceeding at law or in equity to collect the payment of principal of and interest on the Notes or to enforce the performance of any provision of the
Notes or the Indenture. The Trustee may maintain a proceeding even if it does not possess any of the Notes or does not produce any of them in the proceeding. 
 Section 6.04. Waiver of Past Defaults. Except as otherwise provided in Sections 6.02, 6.07 and 9.02, the Holders of not less than a majority in principal amount of the outstanding Notes may,
by notice to the Trustee, waive an existing Default and its consequences. Upon such waiver, the Default will cease to exist, and any Event of Default arising therefrom will be deemed to have been cured, but no such waiver will extend to any
subsequent or other Default or impair any right consequent thereon. 
 Section 6.05. Control by Majority. The
Holders of at least a majority in aggregate principal amount of the outstanding Notes may direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on the
Trustee. However, the Trustee may refuse to follow any direction that conflicts with law or the Indenture, that may involve the Trustee in personal liability, or that the Trustee determines in good faith may be unduly prejudicial to the rights of
Holders of Notes not joining in the giving of such direction, and may take any other action it deems proper that is not inconsistent with any such direction received from Holders of Notes. 
 Section 6.06. Limitation on Suits. A Holder may not institute any proceeding, judicial or otherwise, with respect to the
Indenture or the Notes, or for the appointment of a receiver or trustee, or for any other remedy under the Indenture or the Notes, unless: 
 (1) the Holder has previously given to the Trustee written notice of a continuing Event of Default; 
 (2) Holders of at least 25% in aggregate principal amount of outstanding Notes have made written request to the Trustee to institute proceedings in respect of the Event of Default in its own name as
Trustee under the Indenture; 
 (3) such Holder or Holders have offered to the Trustee indemnity reasonably
satisfactory to the Trustee against any costs, liabilities or expenses to be incurred in compliance with such request; 
  

 73 

 (4) the Trustee for 60 days after its receipt of such notice, request and
offer of indemnity has failed to institute any such proceeding; and 
 (5) during such 60-day period, the Holders
of at least a majority in aggregate principal amount of the outstanding Notes have not given the Trustee a direction that is inconsistent with such written request. 
 Section 6.07. Rights of Holders to Receive Payment. Notwithstanding anything to the contrary, the right of a Holder of a Note to receive payment of principal of or interest on its Note on or
after the Stated Maturities thereof, or to bring suit for the enforcement of any such payment on or after such respective dates, may not be impaired or affected without the consent of that Holder. 
 Section 6.08. Collection Suit by Trustee. If an Event of Default in payment of principal or interest specified in clause
(1) or (2) of Section 6.01 occurs and is continuing, the Trustee may recover judgment in its own name and as trustee of an express trust for the whole amount of principal and accrued interest remaining unpaid, together with interest
on overdue principal and overdue installments of interest, in each case at the rate specified in the Notes, and such further amount as is sufficient to cover the costs and expenses of collection, including the reasonable compensation, expenses,
disbursements and advances of the Trustee, its agents and counsel and any other amounts due the Trustee hereunder. 
 Section 6.09. Trustee May File Proofs of Claim. The Trustee may file proofs of claim and other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for the
compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the Trustee hereunder) and the Holders allowed in any judicial proceedings relating to the Company or any Guarantor or their
respective creditors or property, and is entitled and empowered to collect, receive and distribute any money, securities or other property payable or deliverable upon conversion or exchange of the Notes or upon any such claims. Any custodian,
receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, if the Trustee consents to the making of such payments
directly to the Holders, to pay to the Trustee any amount due to it for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agent and counsel, and any other amounts due the Trustee hereunder. Nothing in the
Indenture will be deemed to empower the Trustee to authorize or consent to, or accept or adopt on behalf of any Holder, any plan of reorganization, arrangement, adjustment or composition affecting the Notes or the rights of any Holder thereof, or to
authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding. 
  

 74 

 Section 6.10. Priorities. If the Trustee collects any money pursuant to this
Article, it shall pay out the money in the following order: 
 First: to the Trustee for all amounts due
hereunder; 
 Second: to Holders for amounts then due and unpaid for principal of and interest on the Notes,
ratably, without preference or priority of any kind, according to the amounts due and payable on the Notes for principal and interest; and 
 Third: to the Company or as a court of competent jurisdiction may direct. 
 The
Trustee, upon written notice to the Company, may fix a record date and payment date for any payment to Holders pursuant to this Section 6.10. 
 Section 6.11. Restoration of Rights and Remedies. If the Trustee or any Holder has instituted a proceeding to enforce any right or remedy under the Indenture and the proceeding has been
discontinued or abandoned for any reason, or has been determined adversely to the Trustee or to the Holder, then, subject to any determination in the proceeding, the Company, any Guarantors, the Trustee and the Holders will be restored severally and
respectively to their former positions hereunder and thereafter all rights and remedies of the Company, any Guarantors, the Trustee and the Holders will continue as though no such proceeding had been instituted. 
 Section 6.12. Undertaking for Costs. In any suit for the enforcement of any right or remedy under the Indenture or in any suit
against the Trustee for any action taken or omitted by it as Trustee, a court may require any party litigant in such suit (other than the Trustee) to file an undertaking to pay the costs of the suit, and the court may assess reasonable costs,
including reasonable attorneys fees, against any party litigant (other than the Trustee) in the suit having due regard to the merits and good faith of the claims or defenses made by the party litigant. This Section does not apply to a suit by a
Holder to enforce payment of principal of or interest on any Note on the respective due dates, or a suit by Holders of more than 10% in principal amount of the outstanding Notes. 
 Section 6.13. Rights and Remedies Cumulative. No right or remedy conferred or reserved to the Trustee or to the Holders under
the Indenture is intended to be exclusive of any other right or remedy, and all such rights and remedies are, to the extent permitted by law, cumulative and in addition to every

  

 75 

 
other right and remedy hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or exercise of any right or remedy hereunder, or otherwise, will not prevent the
concurrent assertion or exercise of any other right or remedy. 
 Section 6.14. Delay or Omission Not Waiver. No
delay or omission of the Trustee or of any Holder to exercise any right or remedy accruing upon any Event of Default will impair any such right or remedy or constitute a waiver of any such Event of Default or an acquiescence therein. Every right and
remedy given by this Article 6 or by law to the Trustee or to the Holders may be exercised from time to time, and as often as may be deemed expedient, by the Trustee or by the Holders, as the case may be. 
 Section 6.15. Waiver of Stay, Extension or Usury Laws. The Company and each Guarantor covenants, to the extent that it may
lawfully do so, that it will not at any time insist upon, or plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay or extension law or any usury law or other law that would prohibit or forgive the Company or the
Guarantor from paying all or any portion of the principal of, or interest on the Notes as contemplated herein, wherever enacted, now or at any time hereafter in force, or that may affect the covenants or the performance of the Indenture. The Company
and each Guarantor hereby expressly waives, to the extent that it may lawfully do so, all benefit or advantage of any such law and covenants that it will not hinder, delay or impede the execution of any power herein granted to the Trustee, but will
suffer and permit the execution of every such power as though no such law had been enacted. 
 ARTICLE 7 
 THE TRUSTEE 
 Section 7.01. General. (a) The duties and responsibilities of the Trustee are as provided by the Trust Indenture Act and as set forth herein. Whether or not expressly so provided, every
provision of the Indenture relating to the conduct or affecting the liability of or affording protection to the Trustee is subject to this Article 7. 
 (b) Except during the continuance of an Event of Default, the Trustee need perform only those duties that are specifically set forth in the Indenture and no others, and no implied covenants or obligations
will be read into the Indenture against the Trustee. In case an Event of Default has occurred and is continuing, the Trustee shall exercise those rights and powers vested in it by the Indenture, and use the same degree of care and skill in their
exercise, as a prudent person would exercise or use under the circumstances in the conduct of such person’s own affairs. 
  

 76 

 (c) No provision of the Indenture shall be construed to relieve the Trustee from liability
for its own negligent action, its own negligent failure to act or its own willful misconduct. 
 Section 7.02. Certain
Rights of Trustee. Subject to Trust Indenture Act Sections 315(a) through (d): 
 (1) In the absence of bad
faith on its part, the Trustee may rely, and will be protected in acting or refraining from acting, upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other
evidence of indebtedness or other paper or document believed by it to be genuine and to have been signed or presented by the proper Person. The Trustee need not investigate any fact or matter stated in the document, but, in the case of any document
which is specifically required to be furnished to the Trustee pursuant to any provision hereof, the Trustee shall examine the document to determine whether it conforms to the requirements of the Indenture (but need not confirm or investigate the
accuracy of mathematical calculations or other facts stated therein). The Trustee, in its discretion, may make further inquiry or investigation into such facts or matters as it sees fit. 
 (2) Before the Trustee acts or refrains from acting, it may require an Officers’ Certificate or an Opinion of Counsel
conforming to Section 11.05 and the Trustee will not be liable for any action it takes or omits to take in good faith in reliance on the certificate or opinion. 
 (3) The Trustee may act through its attorneys and agents and will not be responsible for the misconduct or negligence of any
agent appointed with due care. 
 (4) The Trustee will be under no obligation to exercise any of the rights or
powers vested in it by the Indenture at the request or direction of any of the Holders, unless such Holders have offered to the Trustee security or indemnity satisfactory to the Trustee against the costs, expenses and liabilities that might be
incurred by it in compliance with such request or direction. 
 (5) The Trustee will not be liable for any action
it takes or omits to take in good faith that it believes to be authorized or within its rights or powers or for any action it takes or omits to take in accordance with the

  

 77 

 
direction of the Holders in accordance with Section 6.05 relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust
or power conferred upon the Trustee, under the Indenture. 
 (6) The Trustee may consult with counsel, and the
written advice of such counsel or any Opinion of Counsel will be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in reliance thereon. 
 (7) No provision of the Indenture will require the Trustee to expend or risk its own funds or otherwise incur any financial
liability in the performance of its duties hereunder, or in the exercise of its rights or powers, unless it receives indemnity satisfactory to it against any loss, liability or expense. 
 (8) In no event shall the Trustee be responsible or liable for special, indirect, or consequential loss or damage of any kind
whatsoever (including, but not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action. 
 (9) The Trustee shall not be deemed to have notice of any Default or Event of Default unless a Responsible Officer of the
Trustee has actual knowledge thereof or unless written notice of any event which is in fact such a default is received by the Trustee at the Corporate Trust Office of the Trustee, and such notice references the Notes and the Indenture. 

(10) The rights, privileges, protections, immunities and benefits given to the Trustee, including, without limitation, its
right to be indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, and each agent, custodian and other Person employed to act hereunder. 
 (11) In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations
hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or
acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts which are

  

 78 

 
consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances. 
 Section 7.03. Individual Rights of Trustee. The Trustee, in its individual or any other capacity, may become the owner or
pledgee of Notes and may otherwise deal with the Company or its Affiliates with the same rights it would have if it were not the Trustee. Any Agent may do the same with like rights. However, the Trustee is subject to Trust Indenture Act Sections
310(b) and 311. For purposes of Trust Indenture Act Section 311(b)(4) and (6): 
 (a) “cash
transaction” means any transaction in which full payment for goods or securities sold is made within seven days after delivery of the goods or securities in currency or in checks or other orders drawn upon banks or bankers and payable upon
demand; and 
 (b) “self-liquidating paper” means any draft, bill of exchange, acceptance or
obligation which is made, drawn, negotiated or incurred for the purpose of financing the purchase, processing, manufacturing, shipment, storage or sale of goods, wares or merchandise and which is secured by documents evidencing title to, possession
of, or a lien upon, the goods, wares or merchandise or the receivables or proceeds arising from the sale of the goods, wares or merchandise previously constituting the security, provided the security is received by the Trustee simultaneously
with the creation of the creditor relationship arising from the making, drawing, negotiating or incurring of the draft, bill of exchange, acceptance or obligation. 
 Section 7.04. Trustee’s Disclaimer. The Trustee (i) makes no representation as to the validity or adequacy of the Indenture or the Notes, (ii) is not accountable for the
Company’s use or application of the proceeds from the Notes, (iii) is not responsible for any statement in the Notes other than its certificate of authentication and (iv) shall not have any responsibility to monitor or ascertain
validity or compliance of any transfers, exchanges or other transactions contemplated by the Indenture with any provisions of any state or federal securities laws including exemptions therefrom. 
 Section 7.05. Notice of Default. If any Default occurs and is continuing and is known to the Trustee, the Trustee will send
notice of the Default to each Holder within 90 days after it occurs, unless the Default has been cured; provided that, except in the case of a default in the payment of the principal of or interest on any Note, the Trustee may withhold the
notice if and so long as the board of directors, the executive committee or a trust committee of directors of the Trustee in good faith determines that withholding the notice is in the interest of the

  

 79 

 
Holders. Notice to Holders under this Section will be given in the manner and to the extent provided in Trust Indenture Act Section 313(c). 
 Section 7.06. Reports by Trustee to Holders. Within 60 days after each May 15, beginning with May 15, 2010, the
Trustee will mail to each Holder, as provided in Trust Indenture Act Section 313(c), a brief report dated as of such May 15, if required by Trust Indenture Act Section 313(a), and file such reports with each stock exchange upon which
its Notes are listed and with the Commission as required by Trust Indenture Act Section 313(d). 
 Section 7.07.
Compensation And Indemnity. (a) The Company will pay the Trustee compensation as agreed upon in writing for its services. The compensation of the Trustee is not limited by any law on compensation of a Trustee of an express trust. The
Company will reimburse the Trustee upon request for all reasonable out-of-pocket expenses, disbursements and advances incurred or made by the Trustee, including the reasonable compensation and expenses of the Trustee’s agents and counsel.

 (b) The Company will indemnify the Trustee and its officers, directors, agents and employees for, and hold it harmless
against, any loss or liability or expense incurred by it without negligence or bad faith on its part arising out of or in connection with the acceptance or administration of the Indenture and its duties under the Indenture and the Notes, including
the costs and expenses of defending itself against any claim or liability and of complying with any process served upon it or any of its officers in connection with the exercise or performance of any of its powers or duties under the Indenture and
the Notes. This indemnity shall survive the resignation or removal of the Trustee and the termination of the Indenture. 
 (c)
To secure the Company’s payment obligations in this Section, the Trustee will have a lien prior to the Notes on all money or property held or collected by the Trustee, in its capacity as Trustee, except money or property held in trust to pay
principal of, and interest on particular Notes. 
 Section 7.08. Replacement of Trustee. (a) (1) The
Trustee may resign at any time by written notice to the Company. 
 (2) The Holders of at least a majority in
principal amount of the outstanding Notes may remove the Trustee by written notice to the Trustee. 
 (3) If the
Trustee is no longer eligible under Section 7.10 or in the circumstances described in Trust Indenture Act Section 310(b), any Holder that satisfies the requirements of Trust Indenture Act Section

  

 80 

 
310(b) may petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor Trustee. 
 (4) The Company may remove the Trustee if: (i) the Trustee is no longer eligible under Section 7.10; (ii) the
Trustee is adjudged a bankrupt or an insolvent; (iii) a receiver or other public officer takes charge of the Trustee or its property; or (iv) the Trustee becomes incapable of acting. 
 A resignation or removal of the Trustee and appointment of a successor Trustee will become effective only upon the successor Trustee’s
acceptance of appointment as provided in this Section 7.08. 
 (b) If the Trustee has been removed by the Holders, Holders
of at least a majority in principal amount of the Notes may appoint a successor Trustee with the consent of the Company. Otherwise, if the Trustee resigns or is removed, or if a vacancy exists in the office of Trustee for any reason, the Company
will promptly appoint a successor Trustee. If the successor Trustee does not deliver its written acceptance within 30 days after the retiring Trustee resigns or is removed, the retiring Trustee, the Company or the Holders of at least a majority in
principal amount of the outstanding Notes may petition any court of competent jurisdiction for the appointment of a successor Trustee. 
 (c) Upon delivery by the successor Trustee of a written acceptance of its appointment to the retiring Trustee and to the Company, (i) the retiring Trustee will transfer all property held by it as Trustee to the successor Trustee,
subject to the lien provided for in Section 7.07, (ii) the resignation or removal of the retiring Trustee will become effective, and (iii) the successor Trustee will have all the rights, powers and duties of the Trustee under the
Indenture. Upon request of any successor Trustee, the Company will execute any and all instruments for fully and vesting in and confirming to the successor Trustee all such rights, powers and trusts. The Company will give notice of any resignation
and any removal of the Trustee and each appointment of a successor Trustee to all Holders, and include in the notice the name of the successor Trustee and the address of its Corporate Trust Office. 
 (d) Notwithstanding replacement of the Trustee pursuant to this Section, the Company’s obligations under Section 7.07 will
continue for the benefit of the retiring Trustee. 
 (e) The Trustee agrees to give the notices provided for in, and otherwise
comply with, Trust Indenture Act Section 310(b). 
  

 81 

 Section 7.09. Successor Trustee by Merger. If the Trustee consolidates with,
merges or converts into, or transfers all or substantially all of its corporate trust business to, another corporation or national banking association, the resulting, surviving or transferee corporation or national banking association without any
further act will be the successor Trustee with the same effect as if the successor Trustee had been named as the Trustee in the Indenture. 
 Section 7.10. Eligibility. The Indenture must always have a Trustee that satisfies the requirements of Trust Indenture Act Section 310(a) and has a combined capital and surplus of at
least $25,000,000 as set forth in its most recent published annual report of condition. 
 Section 7.11. Money Held in
Trust. The Trustee will not be liable for interest on any money received by it except as it may agree with the Company. Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law and except
for money held in trust under Article 8. 
 ARTICLE 8 
 DEFEASANCE AND DISCHARGE 
 Section 8.01. Discharge of Company’s Obligations. (a) Subject to paragraph (b), the Company’s obligations under the Notes and the Indenture, and each Guarantor’s
obligations under its Note Guarantee, will terminate if: 
 (1) all Notes previously authenticated and delivered
(other than (i) destroyed, lost or stolen Notes that have been replaced or (ii) Notes that are paid pursuant to Section 4.01 or (iii) Notes for whose payment money or U.S. Government Obligations have been held in trust and then
repaid to the Company pursuant to Section 8.05) have been delivered to the Trustee for cancellation and the Company has paid all sums payable by it hereunder; or 
 (2) (A) the Notes mature within sixty days, or all of them are to be called for redemption within sixty days under
arrangements satisfactory to the Trustee for giving the notice of redemption, 
 (B) the Company irrevocably
deposits in trust with the Trustee, as trust funds solely for the benefit of the Holders, money or U.S. Government Obligations or a combination thereof sufficient, in the opinion of a nationally recognized firm of independent public accountants
expressed in a written certificate delivered to the Trustee, without consideration of any

  

 82 

 
reinvestment, to pay principal of and interest on the Notes to maturity or redemption, as the case may be, and to pay all other sums payable by it hereunder, 
 (C) no Default has occurred and is continuing on the date of the deposit, 
 (D) the deposit will not result in a breach or violation of, or constitute a default under, the Indenture or any other
agreement or instrument to which the Company is a party or by which it is bound, and 
 (E) the Company delivers
to the Trustee an Officers’ Certificate and an Opinion of Counsel, in each case stating that all conditions precedent provided for herein relating to the satisfaction and discharge of the Indenture have been complied with. 
 (b) After satisfying the conditions in clause (1), only the Company’s obligations under Section 7.07 will survive. After
satisfying the conditions in clause (2), only the Company’s obligations in Article 2 and Sections 4.01, 4.02, 7.07, 7.08, 8.05 and 8.06 will survive. In either case, the Trustee upon request will acknowledge in writing the discharge of the
Company’s obligations under the Notes and the Indenture (and each Guarantor’s obligations under its Note Guarantee) other than the surviving obligations. 
 Section 8.02. Legal Defeasance. After the 123rd day following the deposit referred to in clause (1), the Company will be deemed to have paid and will be discharged from its obligations in
respect of the Notes and the Indenture, other than its obligations in Article 2 and Sections 4.01, 4.02, 7.07, 7.08, 8.05 and 8.06, and each Guarantor’s obligations under its Note Guarantee will terminate, provided the following
conditions have been satisfied: 
 (1) The Company has irrevocably deposited in trust with the Trustee, as trust
funds solely for the benefit of the Holders, money or U.S. Government Obligations or a combination thereof sufficient, in the opinion of a nationally recognized firm of independent public accountants expressed in a written certificate thereof
delivered to the Trustee, without consideration of any reinvestment, to pay principal of and accrued interest on the Notes on the Stated Maturity of such payments in accordance with the terms of the Indenture and the Notes. 
 (2) Immediately after giving effect to the deposit referred to in clause (i) above on a pro forma basis, no Default or
Event of Default shall

  

 83 

 
have occurred and be continuing on the date of such deposit or occur at any time during the 123-day period following the deposit. 
 (3) The deposit will not result in a breach or violation of, or constitute a default under, any other material agreement or
instrument to which the Company or any of its Restricted Subsidiaries is a party or by which the Company or any of its Restricted Subsidiaries is bound. 
 (4) The Company has delivered to the Trustee 
 (A) an Opinion of
Counsel to the effect that Holders will not recognize income, gain or loss for federal income tax purposes as a result of the Company’s exercise of its option pursuant to this Section 8.02 and will be subject to federal income tax on the
same amount and in the same manner and at the same times as would otherwise have been the case if such deposit, defeasance and discharge had not occurred, which Opinion of Counsel must be based upon (and accompanied by a copy of) a ruling of the
Internal Revenue Service to the same effect unless there has been a change in applicable federal income tax law after the Issue Date such that a ruling is no longer required, and 
 (B) an Opinion of Counsel to the effect that (i) the creation of the defeasance trust does not violate the Investment
Company Act of 1940, (ii) the Holders have a valid first priority Note interest in the trust funds (subject to customary exceptions), and (iii) after the passage of 123 days following the deposit, the trust funds will not be subject to the
effect of Section 547 of the United States Bankruptcy Code or Section 15 of the New York Debtor and Creditor Law. 
 (5) If at such time the Notes are listed on a national securities exchange, the Company has delivered to the Trustee an Opinion of Counsel to the effect that such deposit, defeasance and discharge will
not cause the Notes to be delisted. 
 (6) The Company has delivered to the Trustee an Officers’ Certificate
and an Opinion of Counsel, in each case stating that all conditions precedent provided for herein relating to the defeasance have been complied with. 
 Prior to the end of the 123-day period, none of the Company’s obligations under the Indenture (nor any of the Guarantor’s obligations under each of its Note Guarantee) the will be discharged.
Thereafter, the Trustee upon request will

  

 84 

 
acknowledge in writing the discharge of the Company’s obligations under the Notes and the Indenture (and each Guarantor’s obligations under its Note Guarantee) except for the surviving
obligations specified above. 
 Section 8.03. Covenant Defeasance. After the 123rd day following the deposit
referred to in clause (1), the Company’s obligations set forth in Sections Section 4.06 through Section 4.16, inclusive, Section 4.18 and clauses (3) and (4) of Section 5.01 will terminate and clause (3) under
Section 6.01 with respect to clauses (3) and (4) of Section 5.01, clause (4) under Section 6.01 with respect to Section 4.06 through Section 4.16, inclusive, and Section 4.18 and clauses (5) and
(6) under Section 6.01 will no longer constitute Events of Default, provided the following conditions have been satisfied: 
 (1) The Company has complied with clauses (1), (2), (3), 4(B), (5) and (6) of Section 8.02; and 
 (2) the Company has delivered to the Trustee an Opinion of Counsel to the effect that the Holders will not recognize income, gain or loss for federal income tax purposes as a result of the defeasance and
will be subject to federal income tax on the same amount and in the same manner and at the same times as would otherwise have been the case. 
 Except as specifically stated above, none of the Company’s obligations under the Indenture will be discharged. 
 Section 8.04. Application of Trust Money. Subject to Section 8.05, the Trustee will hold in trust the money or U.S. Government Obligations deposited with it pursuant to Section 8.01,
8.02 or 8.03, and apply the deposited money and the proceeds from deposited U.S. Government Obligations to the payment of principal of and interest on the Notes in accordance with the Notes and the Indenture. Such money and U.S. Government
Obligations need not be segregated from other funds except to the extent required by law. 
 Section 8.05. Repayment to
Company. Subject to Sections 7.07, 8.01, 8.02 and 8.03, the Trustee will promptly pay to the Company upon request any excess money held by the Trustee at any time and thereupon be relieved from all liability with respect to such money. The
Trustee will pay to the Company upon request any money held for payment with respect to the Notes that remains unclaimed for two years, provided that before making such payment the Trustee may at the expense of the Company publish once in a
newspaper of general circulation in New York City, or send to each Holder entitled to such money, notice that the money remains unclaimed and that after a date specified in the notice (at least 30 days after the date of the publication or notice)
any remaining unclaimed balance of money will be repaid to the Company. After payment to the

  

 85 

 
Company, Holders entitled to such money must look solely to the Company for payment, unless applicable law designates another Person, and all liability of the Trustee with respect to such money
will cease. 
 Section 8.06. Reinstatement. If and for so long as the Trustee is unable to apply any money or U.S.
Government Obligations held in trust pursuant to Section 8.01, 8.02 or 8.03 by reason of any legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such
application, the Company’s and the Guarantor’s obligations under the Indenture and the Notes will be reinstated as though no such deposit in trust had been made. If the Company or a Guarantor makes any payment of principal of or interest
on any Notes because of the reinstatement of its obligations, it will be subrogated to the rights of the Holders of such Notes to receive such payment from the money or U.S. Government Obligations held in trust. 
 ARTICLE 9 
 AMENDMENTS, SUPPLEMENTS AND WAIVERS 
 Section 9.01. Amendments Without Consent of Holders. The Company, Holdings and the Trustee may amend or supplement the Indenture or the Notes without notice to or the consent of any Noteholder 
 (1) to cure any ambiguity, defect, omission or inconsistency in the Indenture or the Notes; 
 (2) to comply with Article 5; 
 (3) to comply with any requirements of the Commission in connection with the qualification of the Indenture under the Trust Indenture Act; 
 (4) to evidence and provide for the acceptance of an appointment hereunder by a successor Trustee; 
 (5) to provide for uncertificated Notes in addition to or in place of certificated Notes, provided that the
uncertificated Notes are issued in registered form for purposes of Section 163(f) of the Code, or in a manner such that the uncertificated Notes are described in Section 163(f)(2)(B) of the Code; 
 (6) to provide for any Guarantee of the Notes, to secure the Notes or to confirm and evidence the release, termination or
discharge of any Guarantee of or Lien securing the Notes when such release, termination or discharge is permitted by the Indenture; 
  

 86 

 (7) to provide for the issuance of Additional Notes in accordance with the
terms of the Indenture; 
 (8) to conform any provision of the Indenture to the “Description of the
Notes” section contained in the Preliminary Offering Memorandum of the Company relating to the Notes dated December 3, 2009 as superseded, to the extent inconsistent, by the Summary of Final Terms dated December 11, 2009; or

 (9) to make any other change that does not materially and adversely affect the rights of any Holder.

 Section 9.02. Amendments With Consent of Holders. (a) Except as otherwise provided in Sections 6.02, 6.04
and 6.07 or Section 9.02(b), the Company, Holdings and the Trustee may amend the Indenture and the Notes with the written consent of the Holders of at least a majority in principal amount of the outstanding Notes, and the Holders of at least a
majority in principal amount of the outstanding Notes by written notice to the Trustee may waive future compliance by the Company with any provision of the Indenture or the Notes. 
 (b) Notwithstanding the provisions of paragraph (a), without the consent of each Holder affected, an amendment or waiver may not 

(1) change the Stated Maturity of the principal of, or any installment of interest on, any Note; 
 (2) reduce the principal amount or interest on, any Note; 
 (3) change the place of payment of principal or interest on, any Note; 
 (4) impair the right to institute suit for the enforcement of any payment on or after the Stated Maturity (or, in the case of
a redemption, on or after the Redemption Date) of any Note; 
 (5) reduce the above-stated percentages of
outstanding Notes the consent of whose Holders is necessary to modify or amend the Indenture; 
 (6) waive a
default in the payment of principal of or interest on the Notes; 
  

 87 

 (7) voluntarily release a Guarantor of the Notes other than in accordance
with the Indenture; 
 (8) after the time an Offer to Purchase is required to have been made under
Section 4.14 or Section 4.15 reduce the purchase amount or price or extend the latest expiration date or purchase date thereunder; or 
 (9) reduce the percentage or aggregate principal amount of outstanding Notes the consent of whose Holders is necessary for waiver of compliance with certain provisions of the Indenture or for waiver of
certain defaults. 
 (c) It is not necessary for Noteholders to approve the particular form of any proposed amendment,
supplement or waiver, but is sufficient if their consent approves the substance thereof. 
 (d) An amendment, supplement or
waiver under this Section 9.02 will become effective on receipt by the Trustee of written consents from the Holders of the requisite percentage in principal amount of the outstanding Notes. After an amendment, supplement or waiver under this
Section 9.02 becomes effective, the Company will send to the Holders affected thereby a notice briefly describing the amendment, supplement or waiver. The Company will send supplemental indentures to Holders upon request. Any failure of the
Company to send such notice, or any defect therein, will not, however, in any way impair or affect the validity of any such supplemental indenture or waiver. 
 Section 9.03. Effect of Consent. (a) After an amendment, supplement or waiver becomes effective, it will bind every Holder unless it is of the type requiring the consent of each Holder
affected. If the amendment, supplement or waiver is of the type requiring the consent of each Holder affected, the amendment, supplement or waiver will bind each Holder that has consented to it and every subsequent Holder of a Note that evidences
the same debt as the Note of the consenting Holder. 
 (b) If an amendment, supplement or waiver changes the terms of a Note,
the Trustee may require the Holder to deliver it to the Trustee so that the Trustee may place an appropriate notation of the changed terms on the Note and return it to the Holder, or exchange it for a new Note that reflects the changed terms. The
Trustee may also place an appropriate notation on any Note thereafter authenticated. However, the effectiveness of the amendment, supplement or waiver is not affected by any failure to annotate or exchange Notes in this fashion. 
 Section 9.04. Trustee’s Rights and Obligations. The Trustee is entitled to receive, and will be fully protected in relying
upon, an Opinion of Counsel stating

  

 88 

 
that the execution of any amendment, supplement or waiver authorized pursuant to this Article 9 is authorized or permitted by the Indenture. If the Trustee has received such an Opinion of
Counsel, it shall sign the amendment, supplement or waiver so long as the same does not adversely affect the rights of the Trustee. The Trustee may, but is not obligated to, execute any amendment, supplement or waiver that affects the Trustee’s
own rights, duties or immunities under the Indenture. 
 Section 9.05. Conformity With Trust Indenture Act. Every
supplemental indenture executed pursuant to this Article shall conform to the requirements of the Trust Indenture Act. 
 Section 9.06. Payments for Consents. Neither the Company nor any of its Subsidiaries or Affiliates may, directly or indirectly, pay or cause to be paid any consideration, whether by way of interest, fee or otherwise, to any
Holder for or as an inducement to any consent, waiver or amendment of any of the terms or provisions of the Indenture or the Notes unless such consideration is offered to be paid or agreed to be paid to all Holders of the Notes that consent, waive
or agree to amend such term or provision within the time period set forth in the solicitation documents relating to the consent, waiver or amendment. 
 ARTICLE 10 
 GUARANTEES 
 Section 10.01. The Guarantees. Subject to the provisions of this Article 10, each Guarantor hereby irrevocably and
unconditionally guarantees, jointly and severally, on an unsecured basis, the full and punctual payment (whether at Stated Maturity, upon redemption, purchase pursuant to an Offer to Purchase or acceleration, or otherwise) of the principal of,
premium, if any, and interest on, and all other amounts payable under, each Note, and the full and punctual payment of all other amounts payable by the Company under the Indenture. Upon failure by the Company to pay punctually any such amount, each
Guarantor shall forthwith on demand pay the amount not so paid at the place and in the manner specified in the Indenture. 
 Section 10.02. Guarantee Unconditional. The obligations of each Guarantor hereunder are unconditional and absolute and, without limiting the generality of the foregoing, will not be released, discharged or otherwise affected by:

 (1) any extension, renewal, settlement, compromise, waiver or release in respect of any obligation of the
Company under the Indenture or any Note, by operation of law or otherwise; 
  

 89 

 (2) any modification or amendment of or supplement to the Indenture or any
Note; 
 (3) any change in the corporate existence, structure or ownership of the Company, or any insolvency,
bankruptcy, reorganization or other similar proceeding affecting the Company or its assets or any resulting release or discharge of any obligation of the Company contained in the Indenture or any Note; 
 (4) the existence of any claim, set-off or other rights which the Guarantor may have at any time against the Company, the
Trustee or any other Person, whether in connection with the Indenture or any unrelated transactions, provided that nothing herein prevents the assertion of any such claim by separate suit or compulsory counterclaim; 
 (5) any invalidity or unenforceability relating to or against the Company for any reason of the Indenture or any Note, or any
provision of applicable law or regulation purporting to prohibit the payment by the Company of the principal of or interest on any Note or any other amount payable by the Company under the Indenture; or 
 (6) any other act or omission to act or delay of any kind by the Company, the Trustee or any other Person or any other
circumstance whatsoever which might, but for the provisions of this paragraph, constitute a legal or equitable discharge of or defense to such Guarantor’s obligations hereunder. 
 Section 10.03. Discharge; Reinstatement. Each Guarantor’s obligations hereunder will remain in full force and effect until
the principal of, premium, if any, and interest on the Notes and all other amounts payable by the Company under the Indenture have been paid in full. If at any time any payment of the principal of, premium, if any, or interest on any Note or any
other amount payable by the Company under the Indenture is rescinded or must be otherwise restored or returned upon the insolvency, bankruptcy or reorganization of the Company or otherwise, each Guarantor’s obligations hereunder with respect to
such payment will be reinstated as though such payment had been due but not made at such time. 
 Section 10.04. Waiver
by the Guarantors. Each Guarantor irrevocably waives acceptance hereof, presentment, demand, protest and any notice not provided for herein, as well as any requirement that at any time any action be taken by any Person against the Company or any
other Person. 
  

 90 

 Section 10.05. Subrogation and Contribution. Upon making any payment with
respect to any obligation of the Company under this Article 10, the Guarantor making such payment will be subrogated to the rights of the payee against the Company with respect to such obligation, provided that the Guarantor may not enforce
either any right of subrogation, or any right to receive payment in the nature of contribution, or otherwise, from any other Guarantor, with respect to such payment so long as any amount payable by the Company hereunder or under the Notes remains
unpaid. 
 Section 10.06. Stay of Acceleration. If acceleration of the time for payment of any amount payable by the
Company under the Indenture or the Notes is stayed upon the insolvency, bankruptcy or reorganization of the Company, all such amounts otherwise subject to acceleration under the terms of the Indenture are nonetheless payable by the Guarantors
hereunder forthwith on demand by the Trustee or the Holders. 
 Section 10.07. Limitation on Amount of Guarantee.
Notwithstanding anything to the contrary in this Article 10, each Guarantor, and by its acceptance of Notes, each Holder, hereby confirms that it is the intention of all such parties that the Note Guarantee of such Guarantor not constitute a
fraudulent conveyance under applicable fraudulent conveyance provisions of the United States Bankruptcy Code or any comparable provision of state law. To effectuate that intention, the Trustee, the Holders and the Guarantors hereby irrevocably agree
that the obligations of each Guarantor under its Note Guarantee are limited to the maximum amount that would not render the Guarantor’s obligations subject to avoidance under applicable fraudulent conveyance provisions of the United States
Bankruptcy Code or any comparable provision of state law. 
 Section 10.08. Execution and Delivery of Guarantee. The
execution by each Guarantor of the Indenture (or a supplemental indenture substantially in the form of Exhibit B) evidences the Note Guarantee of such Guarantor, whether or not the person signing as an officer of the Guarantor still
holds that office at the time of authentication of any Note. The delivery of any Note by the Trustee after authentication constitutes due delivery of the Note Guarantee set forth in the Indenture on behalf of each Guarantor. 
 Section 10.09. Release of Guarantee. (a) The Note Guarantee of a Guarantor other than Holdings will automatically terminate
upon: 
 (1) a sale or other disposition (including by way of consolidation or merger) of the Guarantor, or the
Capital Stock of the Guarantor such that the Guarantor is no longer a Subsidiary, or the sale or disposition of all or substantially all the assets of the Guarantor (other than to the Company or a Restricted Subsidiary) otherwise permitted or not
prohibited by the Indenture, 
  

 91 

 (2) the release of the Guarantees of all other Indebtedness by such
Guarantor, unless at the time of such release a Default or Event of Default shall have occurred and be continuing under the Indenture; 
 (3) the designation in accordance with the Indenture of the Guarantor as an Unrestricted Subsidiary, or 
 (4) defeasance or discharge of the Notes, as provided in Section 8.01, Section 8.02 or Section 8.03. 
 (b) In addition, if on any date following the Issue Date, the Notes are rated Investment Grade by both Rating Agencies, and in connection therewith each Rating Agency received written information from the
Company stating that the release of all of the Guarantees (other than that by Holdings) will occur upon an Investment Grade rating, and no Default or Event of Default shall have occurred and be continuing under the Indenture on the date of such
release, then, beginning on that date, the Guarantors (other than Holdings) will be automatically released from their obligations under the Guarantees; provided, however, that as soon as possible following a Reinstatement Date, each of
the Company’s Restricted Subsidiaries who would have been required to Guarantee the Notes but for the foregoing, shall execute and deliver a supplemental indenture to the Indenture providing for a Subsidiary Guarantee by such Restricted
Subsidiary. 
 (c) Upon delivery by the Company to the Trustee of an Officers’ Certificate and an Opinion of Counsel to the
foregoing effect, the Trustee will execute any documents reasonably required in order to evidence the release of the Guarantor from its obligations under its Note Guarantee. 
 ARTICLE 11 
 MISCELLANEOUS 
 Section 11.01. Trust Indenture Act of 1939. The Indenture shall incorporate and be governed by the provisions of the Trust
Indenture Act that are required to be part of and to govern indentures qualified under the Trust Indenture Act. 
 Section 11.02. Noteholder Communications; Noteholder Actions. (a) The rights of Holders to communicate with other Holders with respect to the Indenture or the Notes are as provided by the Trust Indenture Act, and the
Company and the Trustee shall comply with the requirements of Trust Indenture Act Sections

  

 92 

 
312(a) and 312(b). Neither the Company nor the Trustee will be held accountable by reason of any disclosure of information as to names and addresses of Holders made pursuant to the Trust
Indenture Act. 
 (b) (1) Any request, demand, authorization, direction, notice, consent to amendment,
supplement or waiver or other action provided by the Indenture to be given or taken by a Holder (an “act”) may be evidenced by an instrument signed by the Holder delivered to the Trustee. The fact and date of the execution of the
instrument, or the authority of the person executing it, may be proved in any manner that the Trustee deems sufficient. 
 (2) The Trustee may make reasonable rules for action by or at a meeting of Holders, which will be binding on all the Holders. 
 (c) Any act by the Holder of any Note binds that Holder and every subsequent Holder of a Note that evidences the same debt as the Note of the acting Holder, even if no notation thereof appears on the Note. Subject to paragraph (d), a Holder
may revoke an act as to its Notes, but only if the Trustee receives the notice of revocation before the date the amendment or waiver or other consequence of the act becomes effective. 
 (d) The Company may, but is not obligated to, fix a record date (which need not be within the time limits otherwise prescribed by Trust
Indenture Act Section 316(c)) for the purpose of determining the Holders entitled to act with respect to any amendment or waiver or in any other regard, except that during the continuance of an Event of Default, only the Trustee may set a
record date as to notices of default, any declaration or acceleration or any other remedies or other consequences of the Event of Default. If a record date is fixed, those Persons that were Holders at such record date and only those Persons will be
entitled to act, or to revoke any previous act, whether or not those Persons continue to be Holders after the record date. No act will be valid or effective for more than 90 days after the record date. 
  

 93 

 Section 11.03. Notices. (a) Any notice or communication to the Company will
be deemed given if in writing and mailed, sent by facsimile or delivered by hand within the time prescribed. Notices or communications to a Guarantor will be deemed given if given to the Company. Any notice to the Trustee will be effective only upon
receipt. In each case the notice or communication should be addressed as follows: 
  

			
	if to the Company:
		
		  	 DuPont Fabros Technology, L.P.

		  	 1212 New York Avenue, NW, Suite 900
 Washington D.C. 20005

		  	 Attention:  General Counsel,

	
	if to the Trustee:
		
		  	 U.S. Bank National Association

		  	 60 Livingston Avenue
 EP-MN-WS3C
 St. Paul, MN 55107-2292

		  	 Attention: Corporate Trust Services – Re: DuPont Fabros
 Technology, L.P.

		  	 Fax (651) 495-8097

 The
Company or the Trustee by notice to the other may designate additional or different addresses for subsequent notices or communications. 
 (b) Except as otherwise expressly provided with respect to published notices, any notice or communication to a Holder will be deemed given when mailed to the Holder at its address as it appears on the
Register by first class mail or, as to any Global Note registered in the name of DTC or its nominee, as agreed by the Company, the Trustee and DTC. Copies of any notice or communication to a Holder, if given by the Company, will be mailed to the
Trustee at the same time. Defect in mailing a notice or communication to any particular Holder will not affect its sufficiency with respect to other Holders. 
 (c) Where the Indenture provides for notice, the notice may be waived in writing by the Person entitled to receive such notice, either before or after the event, and the waiver will be the equivalent of
the notice. Waivers of notice by Holders must be filed with the Trustee, but such filing is not a condition precedent to the validity of any action taken in reliance upon such waivers. 
 Section 11.04. Certificate and Opinion as to Conditions Precedent. Upon any request or application by the Company to the Trustee
to take any action under the Indenture, the Company will furnish to the Trustee: 
 (1) an Officers’
Certificate stating that, in the opinion of the signers, all conditions precedent, if any, provided for in the Indenture relating to the proposed action have been complied with; and 
 (2) an Opinion of Counsel stating that all such conditions precedent have been complied with. 
  

 94 

 Section 11.05. Statements Required in Certificate or Opinion. Each certificate
or opinion with respect to compliance with a condition or covenant provided for in the Indenture must include: 
 (1) a statement that each person signing the certificate or opinion has read the covenant or condition and the related definitions; 
 (2) a brief statement as to the nature and scope of the examination or investigation upon which the statement or opinion contained in the certificate or opinion is based; 
 (3) a statement that, in the opinion of each such person, that person has made such examination or investigation as is
necessary to enable the person to express an informed opinion as to whether or not such covenant or condition has been complied with; and 
 (4) a statement as to whether or not, in the opinion of each such person, such condition or covenant has been complied with, provided that an Opinion of Counsel may rely on an Officers’
Certificate or certificates of public officials with respect to matters of fact. 
 Section 11.06. Payment Date Other
Than a Business Day. If any payment with respect to a payment of any principal of, premium, if any, or interest on any Note (including any payment to be made on any date fixed for redemption or purchase of any Note) is due on a day which is not
a Business Day, then the payment need not be made on such date, but may be made on the next Business Day with the same force and effect as if made on such date, and no interest will accrue for the intervening period. 
 Section 11.07. Governing Law. The Indenture, including any Note Guaranties, and the Notes shall be governed by, and construed in
accordance with, the laws of the State of New York. 
 Section 11.08. No Adverse Interpretation of Other Agreements.
The Indenture may not be used to interpret another indenture or loan or debt agreement of the Company or any Subsidiary of the Company, and no such indenture or loan or debt agreement may be used to interpret the Indenture. 
 Section 11.09. Successors. All agreements of the Company or any Guarantor in the Indenture and the Notes will bind its
successors. All agreements of the Trustee in the Indenture will bind its successor. 
 Section 11.10. Duplicate
Originals. The parties may sign any number of copies of the Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. 
  

 95 

 Section 11.11. Separability. In case any provision in the Indenture or in the
Notes is invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired thereby. 
 Section 11.12. Table of Contents and Headings. The Table of Contents, Cross-Reference Table and headings of the Articles and Sections of the Indenture have been inserted for convenience of
reference only, are not to be considered a part of the Indenture and in no way modify or restrict any of the terms and provisions of the Indenture. 
 Section 11.13. No Liability of Directors, Officers, Employees, Incorporators, Members and Stockholders. No recourse for the payment of the principal of or interest on any of the Notes or for
any claim based thereon or otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Company or Holdings in the Indenture, or in any of the Notes or because of the creation of any Indebtedness
represented thereby, shall be had against any incorporator, partner, stockholder, officer, director, employee or controlling person of the Company, Holdings or the Subsidiary Guarantors or of any successor Person thereof in their capacity as such.
The waiver and release are part of the consideration for issuance of the Notes. 
  

 96 

 SIGNATURES 
 IN WITNESS WHEREOF, the parties hereto have caused the Indenture to be duly executed as of the date first written above. 
  

					
	 DUPONT FABROS TECHNOLOGY, L.P.,
 a Maryland limited partnership, as Issuer

		
	By:	 	DuPont Fabros Technology, Inc.,
		 	a Maryland corporation,
		 	its sole General Partner
			
		 	By:	 	/s/ Hossein Fateh
		 	Name:	 	Hossein Fateh
		 	Title:	 	President & Chief Executive Officer

  

			
	 DUPONT FABROS TECHNOLOGY, INC.,
 a Maryland corporation, as Guarantor

		
	By:	 	/s/ Hossein Fateh
	Name:	 	Hossein Fateh
	Title:	 	President & Chief Executive Officer

  

					
	 THE FOLLOWING PARTIES AS
 SUBSIDIARY GUARANTORS:
  
 SAFARI VENTURES LLC,
 a Delaware limited liability company

		
	By:	 	Dupont Fabros Technology, Inc.,
		 	A Maryland Corporation,
		 	its Managing Member
			
		 	By:	 	/s/ Hossein Fateh
		 	Name:	 	Hossein Fateh
		 	Title:	 	President & Chief Executive Officer

							
	 GRIZZLY EQUITY LLC,
 a Delaware limited liability company,

		
	By:	 	DuPont Fabros Technology, L.P.,
		 	A Maryland limited partnership,
		 	its Managing Member
			
		 	By:	 	Dupont Fabros Technology, Inc.,
		 		 	A Maryland corporation,
		 		 	Its General Partner
		 		 		 	
		 		 	By:	 	/s/ Hossein Fateh
		 		 	Name:	 	Hossein Fateh
		 		 	Title:	 	President & Chief Executive Officer

  

									
	 GRIZZLY VENTURES LLC,
 a Delaware limited liability company,

		
	By:	 	Grizzly Equity, LLC,
		 	A Delaware limited liability company,
		 	its Managing Member
			
		 	By:	 	Dupont Fabros Technology, L.P.,
		 		 	A Maryland limited partnership,
		 		 	its Managing Member
				
		 		 	By:	 	Dupont Fabros Technology, Inc.,
		 		 		 	A Maryland corporation,
		 		 		 	Its General Partner
					
		 		 		 	By:	 	/s/ Hossein Fateh
		 		 		 	Name:	 	Hossein Fateh
		 		 		 	Title:	 	President & Chief Executive Officer

							
	 LEMUR PROPERTIES LLC,
 a Delaware limited liability company

		
	By:	 	Safari Ventures LLC,
		 	a Delaware limited liability company
		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 	a Maryland corporation,
		 		 	its Managing Member
				
		 		 	By:	 	/s/ Hossein Fateh
		 		 	Name:	 	Hossein Fateh
		 		 	Title:	 	President & Chief Executive Officer

  

							
	 PORPOISE VENTURES LLC,
 a Delaware limited liability company

		
	By:	 	Safari Ventures LLC,
		 	a Delaware limited liability company
		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 	a Maryland corporation,
		 		 	its Managing Member
				
		 		 	By:	 	/s/ Hossein Fateh
		 		 	Name:	 	Hossein Fateh
		 		 	Title:	 	President & Chief Executive Officer

							
	 QUILL EQUITY LLC,
 a Delaware limited liability company

		
	By:	 	Safari Ventures LLC,
		 	a Delaware limited liability company
		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 	a Maryland corporation,
		 		 	its Managing Member
				
		 		 	By:	 	/s/ Hossein Fateh
		 		 	Name:	 	Hossein Fateh
		 		 	Title:	 	President & Chief Executive Officer

  

							
	 RHINO EQUITY LLC,
 a Delaware limited liability company

		
	By:	 	Safari Ventures LLC,
		 	a Delaware limited liability company
		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 	a Maryland corporation,
		 		 	its Managing Member
				
		 		 	By:	 	/s/ Hossein Fateh
		 		 	Name:	 	Hossein Fateh
		 		 	Title:	 	President & Chief Executive Officer

							
	 TARANTULA INTERESTS LLC,
 a Delaware limited liability company

		
	By:	 	Safari Ventures LLC,
		 	a Delaware limited liability company
		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 	a Maryland corporation,
		 		 	its Managing Member
				
		 		 	By:	 	/s/ Hossein Fateh
		 		 	Name:	 	Hossein Fateh
		 		 	Title:	 	President & Chief Executive Officer

  

									
	 TARANTULA VENTURES LLC,
 a Delaware limited liability company

		
	By:	 	Tarantula Interests LLC,
		 	a Delaware limited liability company
		 	its Managing Member
			
		 	By:	 	Safari Ventures LLC,
		 		 	a Delaware limited liability company
		 		 	its Managing Member
				
		 		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 		 	a Maryland corporation,
		 		 		 	its Managing Member
					
		 		 		 	By:	 	/s/ Hossein Fateh
		 		 		 	Name:	 	Hossein Fateh
		 		 		 	Title:	 	President & Chief Executive Officer

							
	 WHALE HOLDINGS LLC,
 a Delaware limited liability company,

		
	By:	 	DuPont Fabros Technology, L.P.,
		 	a Maryland limited partnership,
		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 	a Maryland corporation,
		 		 	its General Partner
				
		 		 	By:	 	/s/ Hossein Fateh
		 		 	Name:	 	Hossein Fateh
		 		 	Title:	 	President & Chief Executive Officer

  

									
	 WHALE INTERESTS LLC,
 a Delaware limited liability company,

		
	By:	 	Whale Holdings LLC,
		 	a Delaware limited liability company,
		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, L.P.,
		 		 	a Maryland limited partnership,
		 		 	its Managing Member
				
		 		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 		 	a Maryland corporation,
		 		 		 	its General Partner
					
		 		 		 	By:	 	/s/ Hossein Fateh
		 		 		 	Name:	 	Hossein Fateh
		 		 		 	Title:	 	President & Chief Executive Officer

											
	 WHALE VENTURES LLC,
 a Delaware limited liability company

		
	By:	 	Whale Interests LLC,
		 	a Delaware limited liability company,
		 	its Managing Member
			
		 	By:	 	Whale Holdings LLC,
		 		 	a Delaware limited liability company,
		 		 	its Managing Member
				
		 		 	By:	 	DuPont Fabros Technology, L.P.,
		 		 		 	a Maryland limited partnership,
		 		 		 	its Managing Member
					
		 		 		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 		 		 	a Maryland corporation,
		 		 		 		 	its General Partner
						
		 		 		 		 	By:	 	/s/ Hossein Fateh
		 		 		 		 	Name:	 	Hossein Fateh
		 		 		 		 	Title:	 	President & Chief Executive Officer

  

							
	 YAK MANAGEMENT LLC,
 a Delaware limited liability company,

		
	By:	 	DuPont Fabros Technology, L.P.,
		 	a Maryland limited partnership,
		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 	a Maryland corporation,
		 		 	its General Partner
				
		 		 	By:	 	/s/ Hossein Fateh
		 		 	Name:	 	Hossein Fateh
		 		 	Title:	 	President & Chief Executive Officer

							
	 YAK INTERESTS LLC,
 a Delaware limited liability company,

		
	By:	 	Yak Management LLC,
		 	a Delaware limited liability company,
		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, L.P.,
		 		 	a Maryland limited partnership,
		 		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 	a Maryland corporation,
		 		 	its General Partner
				
		 		 	By:	 	/s/ Hossein Fateh
		 		 	Name:	 	Hossein Fateh
		 		 	Title:	 	President & Chief Executive Officer

  

							
	 XERES MANAGEMENT LLC,
 a Delaware limited liability company,

		
	By:	 	DuPont Fabros Technology, L.P.,
		 	a Maryland limited partnership,
		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 	a Maryland corporation,
		 		 	its General Partner
				
		 		 	By:	 	/s/ Hossein Fateh
		 		 	Name:	 	Hossein Fateh
		 		 	Title:	 	President & Chief Executive Officer

									
	 XERES INTERESTS LLC,
 a Delaware limited liability company,

		
	By:	 	Xeres Management LLC,
		 	a Delaware limited liability company,
		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, L.P.,
		 		 	a Maryland limited partnership,
		 		 	its Managing Member
				
		 		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 		 	a Maryland corporation,
		 		 		 	its General Partner
					
		 		 		 	By:	 	/s/ Hossein Fateh
		 		 		 	Name:	 	Hossein Fateh
		 		 		 	Title:	 	President & Chief Executive Officer

  

									
	 FOX PROPERTIES LLC,
 a Delaware limited liability company

		
	By:	 	Safari Ventures LLC,
		 	a Delaware limited liability company
		 	its Managing Member
			
		 	By:	 	DuPont Fabros Technology, Inc.,
		 		 	its Managing Member
					
		 		 	By:	 		 	/s/ Hossein Fateh
		 		 	Name:	 		 	Hossein Fateh
		 		 	Title:	 		 	President & Chief Executive Officer

					
	 U.S. BANK NATIONAL ASSOCIATION
 as Trustee

		
	By:	 	   /s/ Raymond S. Haverstock

		 	Name:	 	Raymond S. Haverstock
		 	Title:	 	Vice President

 EXHIBIT A 
 [FACE OF NOTE] 
 DUPONT FABROS TECHNOLOGY, L.P. 
 8 1/2% Senior Note Due 2017 
  

			
	No.	 	 CUSIP                 
  
 $                

 DuPont Fabros Technology, L.P., a Maryland limited partnership (the “Company”, which term includes any
successor under the Indenture hereinafter referred to), for value received, promises to pay to                     , or its registered assigns, the
principal sum of              DOLLARS ($            ) [or such other amount as indicated on the Schedule of Exchange of
Notes attached hereto]1. The Company will repay a
principal amount of Notes equal to $125,000,000 of the Original Notes and, if Additional Notes are ever issued,  125/550% of the original principal amount thereof, on each of December 15, 2015 and December 15, 2016, with the remaining principal amount to be paid on December 15, 2017.

 Initial Interest Rate: 8 1/2% per annum. 
 Interest Payment Dates: June 15 and December 15, commencing June 15, 2010. 
 Regular Record Dates: June 1 and December 1. 
 Reference is hereby made to the further provisions of this Note set forth on the reverse hereof, which will for all purposes have the same effect as if set forth at this place. 
  

	1	 For Global Notes. 

  

 A-1 

 IN WITNESS WHEREOF, the Company has caused this Note to be signed manually or by facsimile
by its duly authorized officers. 
 Date: 
  

					
	DUPONT FABROS TECHNOLOGY, L.P.
		
	By:	 	DuPont Fabros Technology, Inc.,
		 	a Maryland corporation,
		 	its sole General Partner
			
		 	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

  

 A-2 

 (Form of Trustee’s Certificate of Authentication) 
 This is one of the 8 1
/2% Senior Notes Due 2017 described in the Indenture referred to in this Note. 
  

			
	 U.S. BANK NATIONAL
       ASSOCIATION, as Trustee

		
	By:	 	  

		 	Authorized Signatory

  

 A-3 

 [REVERSE SIDE OF NOTE] 
 DUPONT FABROS TECHNOLOGY, L.P. 
 8 1/2% Senior Note Due 2017 
  

	1.	Principal and Interest. 

 The Company promises to repay a principal amount of Notes equal to $125,000,000 of the Original Notes and, if Additional Notes are ever issued,  125/550% of the original principal amount thereof, on each of
December 15, 2015 and December 15, 2016, with the remaining principal amount to be paid on December 15, 2017. 
 The Company promises to pay interest on the principal amount of this Note on each interest payment date, as set forth on the face of this Note, at the rate of 8 1/2% per annum [(subject to adjustment as provided
below)].1 
 Interest will be payable semiannually (to the Holders of record of the Notes at the close of business on the June 1 or December 1
immediately preceding the interest payment date) on each interest payment date, commencing June 15, 2010. 
 [The Holder of this Note is entitled to the benefits of the Registration Rights Agreement, dated [            ], between the Company and the Initial Purchasers named therein (the
“Registration Rights Agreement”). The Company will pay Additional Interest as and when provided for in the Registration Rights Agreement]2 
 Interest on this Note will accrue from the most recent date to which interest has been paid on this Note [or the Note surrendered in exchange for this Note]3 (or, if there is no existing default in the payment of interest and if this Note is authenticated between
a regular record date and the next interest payment date, from such interest payment date) or, if no interest has been paid, from [the Issue Date].4 Interest will be computed in the basis of a 360-day year of twelve 30-day months. 
  

	1	Include only for Initial Note or Initial Additional Note. 

	2	Include only for Initial Note or Initial Additional Note. 

	3	Include only for Exchange Note. 

	4	For Additional Notes, should be the date of their original issue. 

  

 A-4 

 The Company will pay interest on overdue principal, premium, if any, and
interest at a rate per annum of 8 1/2%. Interest not
paid when due and any interest on principal, premium or interest not paid when due will be paid to the Persons that are Holders on a special record date, which will be the 15th day preceding the date fixed by the Company for the payment of such
interest, whether or not such day is a Business Day. At least 15 days before a special record date, the Company will send to each Holder and to the Trustee a notice that sets forth the special record date, the payment date and the amount of interest
to be paid. 
  

	2.	Indentures; Note Guarantee. 

 This is one of the Notes issued under an Indenture dated as of December 16, 2009 (as amended from time to time, the “Indenture”), among the Company, the Guarantors party thereto and U.S. Bank National Association, as
Trustee. Capitalized terms used herein are used as defined in the Indenture unless otherwise indicated. The terms of the Notes include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act. The
Notes are subject to all such terms, and Holders are referred to the Indenture and the Trust Indenture Act for a statement of all such terms. To the extent permitted by applicable law, in the event of any inconsistency between the terms of this Note
and the terms of the Indenture, the terms of the Indenture will control. 
 The Notes are general unsecured obligations of the
Company. The original principal amount of the Notes is $550,000,000, but Additional Notes may be issued pursuant to the Indenture, and the originally issued Notes and all such Additional Notes vote together for all purposes as a single class. This
Note is guaranteed as set forth in the Indenture. 
  

	3.	Redemption and Repurchase; Discharge Prior to Redemption or Maturity. 

 This Note is subject to optional redemption, and may be the subject of an Offer to Purchase, as further described in the Indenture. There is no sinking fund applicable to this Note, except with respect to
any mandatory redemption. 
 If the Company deposits with the Trustee money or U.S. Government Obligations sufficient to pay the
then outstanding principal of, premium, if any, and accrued interest on the Notes to redemption or maturity, the Company may in certain circumstances be discharged from the Indenture and the Notes or may be discharged from certain of its obligations
under certain provisions of the Indenture. 
  

 A-5 

	4.	Registered Form; Denominations; Transfer; Exchange. 

 The Notes are in registered form without coupons in denominations of $2,000 in principal amount and any higher integral multiple of $1,000. A Holder may register the transfer or exchange of Notes in
accordance with the Indenture. The Trustee may require a Holder to furnish appropriate endorsements and transfer documents and to pay any taxes and fees required by law or permitted by the Indenture. Pursuant to the Indenture, there are certain
periods during which the Trustee will not be required to issue, register the transfer of or exchange any Note or certain portions of a Note. 
  

	5.	Defaults and Remedies. 

 If an Event of Default, as defined in the Indenture, occurs and is continuing, the Trustee or the Holders of at least 25% in principal amount of the Notes may declare all the Notes to be due and payable. If a bankruptcy default with respect
to the Company or Holdings occurs and is continuing, the Notes automatically become due and payable. Holders may not enforce the Indenture or the Notes except as provided in the Indenture. The Trustee may require indemnity satisfactory to it before
it enforces the Indenture or the Notes. Subject to certain limitations, Holders of at least a majority in principal amount of the Notes then outstanding may direct the Trustee in its exercise of remedies. 
  

	6.	Amendment and Waiver. 

 Subject to certain exceptions, the Indenture and the Notes may be amended, or default may be waived, with the consent of the Holders of at least a majority in principal amount of the outstanding Notes. Without notice to or the consent of
any Holder, the Company, Holdings and the Trustee may amend or supplement the Indenture or the Notes to, among other things, cure any ambiguity, defect, omission or inconsistency. 
  

	7.	Authentication. 

 This
Note is not valid until the Trustee (or Authenticating Agent) signs the certificate of authentication on the other side of this Note. 
  

	8.	Governing Law. 

 This Note
shall be governed by, and construed in accordance with, the laws of the State of New York. 
  

	9.	Abbreviations. 

 Customary
abbreviations may be used in the name of a Holder or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the

  

 A-6 

 
entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian) and U/G/M/A/ (= Uniform Gifts to Minors Act). 
 The Company will furnish a copy of the Indenture to any Holder upon written request and without charge. 
  

 A-7 

 [FORM OF TRANSFER NOTICE] 
 FOR VALUE RECEIVED the undersigned registered Holder hereby sell(s), assign(s) and transfer(s) unto 
  

	
	Insert Taxpayer Identification No.
	  

	  

	Please print or typewrite name and address including zip code of assignee
	
	  

	the within Note and all rights thereunder, hereby irrevocably constituting and appointing
	  

 attorney to transfer said Note on the books of the Company with full power of substitution in the premises. 
  

 A-8 

 [THE FOLLOWING PROVISION TO BE INCLUDED ON ALL CERTIFICATES BEARING A RESTRICTED LEGEND] 
 In connection with any transfer of this Note occurring prior to the date which is one year after December 16, 2009 and the last date, if
any, that this Note (or any predecessor Note) was owned by the Company or an affiliate, the undersigned confirms that such transfer is made without utilizing any general solicitation or general advertising and further as follows: 
 Check One 
  ̈    (1) This Note is being transferred to a “qualified institutional buyer” in compliance with Rule 144A under the Securities Act of 1933, as amended and certification
substantially in the form of Exhibit F to the Indenture is being furnished herewith. 
  ̈    (2) This Note is being transferred to a Non-U.S. Person in compliance with the exemption from registration under the Securities Act of 1933, as amended, provided by Regulation S
thereunder, and certification substantially in the form of Exhibit E to the Indenture is being furnished herewith. 
 or 
  ̈    (3) This Note is being transferred other than in
accordance with (1) or (2) above and documents are being furnished which comply with the conditions of transfer set forth in this Note and the Indenture. 
 If none of the foregoing boxes is checked, the Trustee is not obligated to register this Note in the name of any Person other than the Holder hereof unless and until the conditions to any such transfer of
registration set forth herein and in the Indenture have been satisfied. 
  

									
	Date:                     	 		 		 	  

		 		 		 	Seller
					
		 		 		 	By	 	  

			
		 		 	NOTICE: The signature to this assignment must correspond with the name as written upon the face of the within-mentioned instrument in every particular, without
alteration or any change whatsoever.

  

 A-9 

 Signature Guarantee:5
                     
  

			
	By	 	  

	To be executed by an executive officer

  

	5	 Signatures must be guaranteed by an “eligible guarantor institution” meeting the requirements of the Trustee, which requirements
include membership or participation in the Securities Transfer Association Medallion Program (“STAMP”) or such other “signature guarantee program” as may be determined by the Trustee in addition to, or in
substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as amended. 

  

 A-10 

 OPTION OF HOLDER TO ELECT PURCHASE 
 If you wish to have all of this Note purchased by the Company pursuant to Section 4.14 or Section 4.15 of the Indenture, check
the box: 9 
 If you wish to have a portion of this Note purchased by the Company pursuant to Section 4.14 or Section
4.15 of the Indenture, state the amount (in original principal amount) below: 
 $            . 
 Date:                     
 Your Signature:                     
 (Sign exactly as your name appears on the other side of this Note) 
 Signature
Guarantee:6
                     
  

	6	 Signatures must be guaranteed by an “eligible guarantor institution” meeting the requirements of the Trustee, which requirements
include membership or participation in the Securities Transfer Association Medallion Program (“STAMP”) or such other “signature guarantee program” as may be determined by the Trustee in addition to, or in
substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as amended. 

  

 A-11 

 SCHEDULE OF EXCHANGES OF NOTES1 
 The following exchanges of a part of this Global Note for Physical Notes or a part of another Global Note have been made: 
  

									
	 Date of Exchange
	 	 Amount of decrease
in principal amount
of this Global
Note
	 	 Amount of increase
in principal amount
of this Global
Note
	  	Principal amount of
this Global Note
following such
decrease (or
increase)
	  	Signature of
authorized officer of
Trustee
		 		 		  		  	
		 		 		  		  	

  

	1	 For Global Notes 

  

 A-12 

 EXHIBIT B 
 SUPPLEMENTAL INDENTURE 
 dated as of
            ,          
 among 
 DuPont Fabros Technology, L.P., 
 as Issuer 
 the
Guarantor[s] Party Hereto 
 and 
 DuPont Fabros Technology, Inc., 
 as Trustee 
  
  
 8 1/
2% 
 Senior Notes due 2017 
  

 B-1 

 THIS SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), entered into
as of                 ,         , among DuPont Fabros Technology, L.P., a Maryland limited partnership (the
“Company”), [insert each Guarantor executing this Supplemental Indenture and its jurisdiction of incorporation] (each an “Undersigned”) and U.S. Bank National Association, as trustee (the
“Trustee”). 
 RECITALS 
 WHEREAS, the Company, the Guarantors party thereto and the Trustee entered into the Indenture, dated as of
December 16, 2009 (the “Indenture”), relating to the Company’s 8 1/2% Senior Notes due 2017 (the “Notes”); 
 WHEREAS, as a
condition to the Trustee entering into the Indenture and the purchase of the Notes by the Holders, the Company agreed pursuant to the Indenture not to permit any of its Restricted Subsidiaries (including a newly created or acquired one), directly or
indirectly, to Guarantee any Indebtedness of the Company or any Restricted Subsidiary, unless such Restricted Subsidiary provided a Guarantee of the Notes (subject to limited exceptions). 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the
premises and mutual covenants herein contained and intending to be legally bound, the parties to this Supplemental Indenture hereby agree as follows: 
 Section 1. Capitalized terms used herein and not otherwise defined herein are used as defined in the Indenture. 
 Section 2. Each Undersigned, by its execution of this Supplemental Indenture, agrees to be a Guarantor under the Indenture and to be bound by the terms of the Indenture applicable to Guarantors,
including, but not limited to, Article 10 thereof. 
 Section 3. This Supplemental Indenture shall be governed by
and construed in accordance with the laws of the State of New York. 
 Section 4. This Supplemental Indenture may be signed
in various counterparts which together will constitute one and the same instrument. 
 Section 5. This Supplemental
Indenture is an amendment supplemental to the Indenture and the Indenture and this Supplemental Indenture will henceforth be read together. 
  

 B-1 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the date first above written. 
  
  
  

					
	 DUPONT FABROS TECHNOLOGY, L.P.,
 a Maryland limited partnership, as Issuer

		
	By:	 	 DuPont Fabros Technology, Inc.,
 a Maryland corporation,
 its sole General Partner

			
		 	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

	
	[GUARANTOR[S]]
		
	 By:
	 	  

		 	Name:	 	
		 	Title:	 	
	
	 U.S. BANK NATIONAL
ASSOCIATION, as Trustee

		
	 By:
	 	  

		 	Name:	 	
		 	Title:	 	

  

 B-2 

 EXHIBIT C 
 RESTRICTED LEGEND FOR U.S. GLOBAL NOTES OR ACCREDITED 
 INVESTOR NOTES

 THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES
LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS SUCH
TRANSACTION IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION. THE HOLDER OF THIS SECURITY, BY ITS ACCEPTANCE HEREOF, AGREES ON ITS OWN BEHALF AND ON BEHALF OF ANY INVESTOR ACCOUNT FOR WHICH IT HAS PURCHASED SECURITIES, TO OFFER, SELL OR
OTHERWISE TRANSFER SUCH SECURITY, PRIOR TO THE DATE (THE “RESALE RESTRICTION TERMINATION DATE”) THAT IS ONE YEAR AFTER THE LATER OF THE ORIGINAL ISSUE DATE HEREOF AND THE LAST DATE ON WHICH THE COMPANY OR ANY AFFILIATE OF THE COMPANY WAS
THE OWNER OF THIS SECURITY (OR ANY PREDECESSOR OF SUCH SECURITY), ONLY (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, (B) PURSUANT TO A REGISTRATION STATEMENT THAT HAS BEEN DECLARED EFFECTIVE UNDER THE SECURITIES ACT, (C) FOR SO LONG
AS THE SECURITIES ARE ELIGIBLE FOR RESALE PURSUANT TO RULE 144A UNDER THE SECURITIES ACT (“RULE 144A”), TO A PERSON IT REASONABLY BELIEVES IS A “QUALIFIED INSTITUTIONAL BUYER” AS DEFINED IN RULE 144A THAT PURCHASES FOR ITS OWN
ACCOUNT OR FOR THE ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER TO WHOM NOTICE IS GIVEN THAT THE TRANSFER IS BEING MADE IN RELIANCE ON RULE 144A, (D) PURSUANT TO OFFERS AND SALES TO NON-U.S. PERSONS THAT OCCUR OUTSIDE THE UNITED STATES WITHIN THE
MEANING OF REGULATION S UNDER THE SECURITIES ACT, (E) TO AN “ACCREDITED INVESTOR” WITHIN THE MEANING OF RULE 501(a) UNDER THE SECURITIES ACT THAT IS NOT A QUALIFIED INSTITUTIONAL BUYER AND THAT IS PURCHASING FOR ITS OWN ACCOUNT OR FOR
THE ACCOUNT OF ANOTHER ACCREDITED INVESTOR, IN EACH CASE IN A MINIMUM PRINCIPAL AMOUNT OF $250,000 OF SECURITIES OR (F) PURSUANT TO ANOTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT, SUBJECT TO THE
COMPANY’S AND THE TRUSTEE’S RIGHT PRIOR TO ANY SUCH OFFER, SALE OR TRANSFER PURSUANT TO CLAUSES (D), (E) OR (F) TO REQUIRE THE DELIVERY OF AN

  

 C-1 

 
OPINION OF COUNSEL, CERTIFICATION AND/ OR OTHER INFORMATION SATISFACTORY TO EACH OF THEM. THIS LEGEND WILL BE REMOVED UPON THE REQUEST OF THE HOLDER AFTER THE RESALE RESTRICTION TERMINATION DATE.

 BY ITS ACQUISITION OF THIS SECURITY THE HOLDER THEREOF WILL BE DEEMED TO HAVE REPRESENTED AND WARRANTED THAT EITHER (I) NO PORTION OF
THE ASSETS USED BY SUCH HOLDER TO ACQUIRE OR HOLD THIS SECURITY CONSTITUTES THE ASSETS OF AN EMPLOYEE BENEFIT PLAN THAT IS SUBJECT TO TITLE I OF THE U.S. EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AS AMENDED (“ERISA”), OF A PLAN,
INDIVIDUAL RETIREMENT ACCOUNT OR OTHER ARRANGEMENT THAT IS SUBJECT TO SECTION 4975 OF THE U.S. INTERNAL REVENUE CODE OF 1986, AS AMENDED (THE “CODE”) OR PROVISIONS UNDER ANY OTHER FEDERAL, STATE, LOCAL, NON-U.S. OR OTHER LAWS OR
REGULATIONS THAT ARE SIMILAR TO SUCH PROVISIONS OF ERISA OR THE CODE (“SIMILAR LAWS”), OR OF AN ENTITY WHOSE UNDERLYING ASSETS ARE CONSIDERED TO INCLUDE “PLAN ASSETS” OF ANY SUCH PLAN, ACCOUNT OR ARRANGEMENT, OR (II) THE
ACQUISITION AND HOLDING OF THIS SECURITY WILL NOT CONSTITUTE OR GIVE RISE TO A NON-EXEMPT PROHIBITED TRANSACTION UNDER SECTION 406 OF ERISA OR SECTION 4975 OF THE CODE OR A SIMILAR VIOLATION UNDER ANY APPLICABLE SIMILAR LAWS. 
 RESTRICTED LEGEND FOR REGULATION S NOTES 
 THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THIS SECURITY NOR
ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS SUCH TRANSACTION IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION. THE
HOLDER OF THIS SECURITY, BY ITS ACCEPTANCE HEREOF, AGREES ON ITS OWN BEHALF AND ON BEHALF OF ANY INVESTOR ACCOUNT FOR WHICH IT HAS PURCHASED SECURITIES, TO OFFER, SELL OR OTHERWISE TRANSFER SUCH SECURITY, PRIOR TO THE DATE (THE “RESALE
RESTRICTION TERMINATION DATE”) THAT IS 40 DAYS AFTER THE LATER OF THE ORIGINAL ISSUE DATE HEREOF AND THE LAST DATE ON WHICH THE COMPANY OR ANY AFFILIATE OF THE COMPANY WAS THE OWNER OF THIS SECURITY (OR ANY

  

 C-2 

 
PREDECESSOR OF SUCH SECURITY), ONLY (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, (B) PURSUANT TO A REGISTRATION STATEMENT THAT HAS BEEN DECLARED EFFECTIVE UNDER THE SECURITIES ACT,
(C) FOR SO LONG AS THE SECURITIES ARE ELIGIBLE FOR RESALE PURSUANT TO RULE 144A UNDER THE SECURITIES ACT (“RULE 144A”), TO A PERSON IT REASONABLY BELIEVES IS A “QUALIFIED INSTITUTIONAL BUYER” AS DEFINED IN RULE 144A THAT
PURCHASES FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER TO WHOM NOTICE IS GIVEN THAT THE TRANSFER IS BEING MADE IN RELIANCE ON RULE 144A, (D) PURSUANT TO OFFERS AND SALES TO NON-U.S. PERSONS THAT OCCUR OUTSIDE THE
UNITED STATES WITHIN THE MEANING OF REGULATION S UNDER THE SECURITIES ACT, (E) TO AN “ACCREDITED INVESTOR” WITHIN THE MEANING OF RULE 501(a) UNDER THE SECURITIES ACT THAT IS NOT A QUALIFIED INSTITUTIONAL BUYER AND THAT IS PURCHASING
FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ANOTHER ACCREDITED INVESTOR, IN EACH CASE IN A MINIMUM PRINCIPAL AMOUNT OF $250,000 OF SECURITIES OR (F) PURSUANT TO ANOTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT,
SUBJECT TO THE COMPANY’S AND THE TRUSTEE’S RIGHT PRIOR TO ANY SUCH OFFER, SALE OR TRANSFER PURSUANT TO CLAUSES (D), (E) OR (F) TO REQUIRE THE DELIVERY OF AN OPINION OF COUNSEL, CERTIFICATION AND/ OR OTHER INFORMATION SATISFACTORY
TO EACH OF THEM. THIS LEGEND WILL BE REMOVED UPON THE REQUEST OF THE HOLDER AFTER THE RESALE RESTRICTION TERMINATION DATE. BY ITS ACQUISITION HEREOF, THE HOLDER HEREOF REPRESENTS THAT IT IS NOT A U.S. PERSON NOR IS IT PURCHASING FOR THE ACCOUNT OF A
U.S. PERSON AND IS ACQUIRING THIS SECURITY IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT. 
 BY ITS
ACQUISITION OF THIS SECURITY THE HOLDER THEREOF WILL BE DEEMED TO HAVE REPRESENTED AND WARRANTED THAT EITHER (I) NO PORTION OF THE ASSETS USED BY SUCH HOLDER TO ACQUIRE OR HOLD THIS SECURITY CONSTITUTES THE ASSETS OF AN EMPLOYEE BENEFIT PLAN
THAT IS SUBJECT TO TITLE I OF THE U.S. EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AS AMENDED (“ERISA”), OF A PLAN, INDIVIDUAL RETIREMENT ACCOUNT OR OTHER ARRANGEMENT THAT IS SUBJECT TO SECTION 4975 OF THE U.S. INTERNAL REVENUE CODE
OF 1986, AS AMENDED (THE “CODE”) OR PROVISIONS UNDER ANY OTHER FEDERAL, STATE, LOCAL, NON-U.S. OR OTHER LAWS OR REGULATIONS THAT ARE

  

 C-3 

 
SIMILAR TO SUCH PROVISIONS OF ERISA OR THE CODE (“SIMILAR LAWS”), OR OF AN ENTITY WHOSE UNDERLYING ASSETS ARE CONSIDERED TO INCLUDE “PLAN ASSETS” OF ANY SUCH PLAN, ACCOUNT OR
ARRANGEMENT, OR (II) THE ACQUISITION AND HOLDING OF THIS SECURITY WILL NOT CONSTITUTE OR GIVE RISE TO A NON-EXEMPT PROHIBITED TRANSACTION UNDER SECTION 406 OF ERISA OR SECTION 4975 OF THE CODE OR A SIMILAR VIOLATION UNDER ANY APPLICABLE SIMILAR
LAWS. 
  

 C-4 

 EXHIBIT D 
 DTC LEGEND 
 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE
DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER
NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR
OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS A BENEFICIAL INTEREST HEREIN. 
 TRANSFERS OF THIS GLOBAL NOTE ARE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF CEDE & CO. OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE AND TRANSFERS OF PORTIONS OF THIS GLOBAL NOTE ARE LIMITED TO
TRANSFERS MADE IN ACCORDANCE WITH THE TRANSFER PROVISIONS OF THE INDENTURE. 
  

 D-1 

 EXHIBIT E 
 Regulation S Certificate 
             ,          
 U.S. Bank National Association 
 60 Livingston Avenue 
 St. Paul, Minnesota 55107-2292 
 Attention: Corporate Trust Administration 
  

					
	Re:	  	 DuPont Fabros Technology, L.P.
 8 1/2%
Senior Notes due 2017 (the “Notes”)
 Issued under the Indenture (the “Indenture”) dated as

of December 16, 2009 relating to the Notes
	  	

 Ladies and Gentlemen: 
 Terms are used in this Certificate as used in Regulation S (“Regulation S”) under the Securities Act of 1933, as amended (the “Securities Act”), except as otherwise
stated herein. 
 [CHECK A OR B AS APPLICABLE.] 
  

					
	 ̈	 	A.	  	This Certificate relates to our proposed transfer of $             principal amount of Notes issued under the
Indenture. We hereby certify as follows:

  

	 	1.	The offer and sale of the Notes was not and will not be made to a person in the United States (unless such person is excluded from the definition of “U.S.
person” pursuant to Rule 902(k)(2)(vi) or the account held by it for which it is acting is excluded from the definition of “U.S. person” pursuant to Rule 902(k)(2)(i) under the circumstances described in Rule 902(h)(3)) and such offer
and sale was not and will not be specifically targeted at an identifiable group of U.S. citizens abroad. 

  

	 	2.	 Unless the circumstances described in the parenthetical in paragraph 1 above are applicable, either (a) at the time the buy order was originated,
the buyer was outside the United States or we and any person acting on our behalf reasonably believed that the buyer was outside the United States or (b)

  

 E-1 

	 	 
the transaction was executed in, on or through the facilities of a designated offshore securities market, and neither we nor any person acting on our behalf knows that the transaction was
pre-arranged with a buyer in the United States. 

  

	 	3.	Neither we, any of our affiliates, nor any person acting on our or their behalf has made any directed selling efforts in the United States with respect to the Notes.

  

	 	4.	The proposed transfer of Notes is not part of a plan or scheme to evade the registration requirements of the Securities Act. 

  

	 	5.	If we are a dealer or a person receiving a selling concession, fee or other remuneration in respect of the Notes, and the proposed transfer takes place during the
Restricted Period (as defined in the Indenture), or we are an officer or director of the Company or an Initial Purchaser (as defined in the Indenture), we certify that the proposed transfer is being made in accordance with the provisions of Rule
904(b) of Regulation S. 

  

					
	 ̈	 	B.	  	This Certificate relates to our proposed exchange of $            principal amount of Notes issued under the Indenture
for an equal principal amount of Notes to be held by us. We hereby certify as follows:

  

	 	1.	At the time the offer and sale of the Notes was made to us, either (i) we were not in the United States or (ii) we were excluded from the definition of
“U.S. person” pursuant to Rule 902(k)(2)(vi) or the account held by us for which we were acting was excluded from the definition of “U.S. person” pursuant to Rule 902(k)(2)(i) under the circumstances described in Rule 902(h)(3);
and we were not a member of an identifiable group of U.S. citizens abroad. 

  

	 	2.	Unless the circumstances described in paragraph 1(ii) above are applicable, either (a) at the time our buy order was originated, we were outside the United States
or (b) the transaction was executed in, on or through the facilities of a designated offshore securities market and we did not pre-arrange the transaction in the United States. 

  

 E-2 

	 	3.	The proposed exchange of Notes is not part of a plan or scheme to evade the registration requirements of the Securities Act. 

  

 E-3 

 You and the Company are entitled to rely upon this Certificate and are irrevocably
authorized to produce this Certificate or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby. 
  

					
	Very truly yours,
	
	 [NAME OF SELLER (FOR TRANSFERS) OR OWNER (FOR EXCHANGES)]

		
	By:	 	  

		 	Name:	 	
		 	Title:	 	
		 	Address:	 	

 Date:
                     
  

 E-4 

 EXHIBIT F 
 Rule 144A Certificate 
             ,          
 U.S. Bank National Association 
 60 Livingston Avenue 
 St. Paul, Minnesota 55107-2292 
 Attention: Corporate Trust Administration 
  

					
	Re:	  	 DuPont Fabros Technology, L.P.
 8 1/2%
Senior Notes due 2017 (the “Notes”)
 Issued under the Indenture (the “Indenture”) dated as

of December 16, 2009 relating to the Notes
	  	

 Ladies and Gentlemen: 
 TO BE COMPLETED BY PURCHASER IF (1) ABOVE IS CHECKED. 
 This Certificate
relates to: 
 [CHECK A OR B AS APPLICABLE.] 
  

					
	 ̈	 	A.	  	Our proposed purchase of $            principal amount of Notes issued under the Indenture.
			
	 ̈	 	B.	  	Our proposed exchange of $            principal amount of Notes issued under the Indenture for an equal principal
amount of Notes to be held by us.

 We and, if applicable, each account for which we are acting in the aggregate
owned and invested more than $100,000,000 in securities of issuers that are not affiliated with us (or such accounts, if applicable), as of             , 200    , which
is a date on or since close of our most recent fiscal year. We and, if applicable, each account for which we are acting, are a qualified institutional buyer within the meaning of Rule 144A (“Rule 144A”) under the Securities Act of
1933, as amended (the “Securities Act”). If we are acting on behalf of an account, we exercise sole investment discretion with respect to such account. We are aware that the transfer of Notes to us, or such exchange, as applicable,
is being made in reliance upon the exemption from the provisions of Section 5 of the Securities Act provided by Rule 144A. Prior to the date of this Certificate we

  

 F-1 

 
have received such information regarding the Company as we have requested pursuant to Rule 144A(d)(4) or have determined not to request such information. 
 You and the Company are entitled to rely upon this Certificate and are irrevocably authorized to produce this Certificate or a copy hereof
to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby. 
  

					
	Very truly yours,
	
	 [NAME OF PURCHASER (FOR TRANSFERS) OR OWNER (FOR EXCHANGES)]

		
	By:	 	  

		 	Name:	 	
		 	Title:	 	
		 	Address:	 	

 Date:
                     
  

 F-2 

 EXHIBIT G 
 Accredited Investor Certificate 
 U.S. Bank National Association 
 60 Livingston Avenue 
 St. Paul, Minnesota
55107-2292 
 Attention: Corporate Trust Administration 
  

					
	Re:	  	 DuPont Fabros Technology, L.P.
 8 1/2%
Senior Notes due 2017 (the “Notes”)
 Issued under the Indenture (the “Indenture”) dated as

of December 16, 2009 relating to the Notes
	  	

 Ladies and Gentlemen: 
 This Certificate relates to: 
 [CHECK A OR B AS APPLICABLE.] 
  

					
	 ̈	 	A.	  	Our proposed purchase of $             principal amount of Notes issued under the Indenture.
			
	 ̈	 	B.	  	Our proposed exchange of $             principal amount of Notes issued under the Indenture for an equal principal amount
of Notes to be held by us.

 We hereby confirm that: 
  

	 	1.	We are an “accredited investor” within the meaning of Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”) (an
“Accredited Investor”). 

  

	 	2.	Any acquisition of Notes by us will be for our own account or for the account of one or more other Accredited Investors as to which we exercise sole investment
discretion. 

  

	 	3.	We have such knowledge and experience in financial and business matters that we are capable of evaluating the merits and risks of an investment in the Notes and we and
any accounts for which we are acting are able to bear the economic risks of and an entire loss of our or their investment in the Notes. 

  

 G-1 

	 	4.	We are not acquiring the Notes with a view to any distribution thereof in a transaction that would violate the Securities Act or the securities laws of any State of the
United States or any other applicable jurisdiction; provided that the disposition of our property and the property of any accounts for which we are acting as fiduciary will remain at all times within our and their control.

  

	 	5.	We acknowledge that the Notes have not been registered under the Securities Act and that the Notes may not be offered or sold within the United States or to or for the
benefit of U.S. persons except as set forth below. 

  

	 	6.	The principal amount of Notes to which this Certificate relates is at least equal to $250,000. 

 We agree for the benefit of the Company, on our own behalf and on behalf of each account for which we are acting, that such Notes may be
offered, sold, pledged or otherwise transferred only in accordance with the Securities Act and any applicable securities laws of any State of the United States and only (a) to the Company, (b) pursuant to a registration statement which has
become effective under the Securities Act, (c) to a qualified institutional buyer in compliance with Rule 144A under the Securities Act, (d) in an offshore transaction in compliance with Rule 904 of Regulation S under the Securities Act,
(e) in a principal amount of not less than $250,000 to an Accredited Investor that, prior to such transfer, delivers to the Trustee a duly completed and signed certificate (the form of which may be obtained from the Trustee) relating to the
restrictions on transfer of the Notes or (f) pursuant to an exemption from registration provided by Rule 144 under the Securities Act or any other available exemption from the registration requirements of the Securities Act. 
 Prior to the registration of any transfer in accordance with (c) or (d) above, we acknowledge that a duly completed and signed
certificate (the form of which may be obtained from the Trustee) must be delivered to the Trustee. Prior to the registration of any transfer in accordance with (e) or (f) above, we acknowledge that the Company reserves the right to require
the delivery of such legal opinions, certifications or other evidence as may reasonably be required in order to determine that the proposed transfer is being made in compliance with the Securities Act and applicable state securities laws. We
acknowledge that no representation is made as to the availability of any Rule 144 exemption from the registration requirements of the Securities Act. 
 We understand that the Trustee will not be required to accept for registration of transfer any Notes acquired by us, except upon presentation of evidence satisfactory to the Company and the Trustee that
the foregoing

  

 G-2 

 
restrictions on transfer have been complied with. We further agree to provide to any person acquiring any of the Notes from us a notice advising such person that resales of the Notes are
restricted as stated herein and that certificates representing the Notes will bear a legend to that effect. 
 We agree to
notify you promptly in writing if any of our acknowledgments, representations or agreements herein ceases to be accurate and complete. 
 We represent to you that we have full power to make the foregoing acknowledgments, representations and agreements on our own behalf and on behalf of any account for which we are acting. 
 You and the Company are entitled to rely upon this Certificate and are irrevocably authorized to produce this Certificate or a copy hereof
to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby. 
  

			
	Very truly yours,
	
	 [NAME OF PURCHASER (FOR TRANSFERS) OR OWNER (FOR EXCHANGES)]

		
	By:	 	  

		 	Name:
		 	Title:
		 	Address:

 Date:
                     
  

 G-3 

 EXHIBIT H 
 [COMPLETE FORM I OR FORM II AS APPLICABLE.] 
 [FORM I] 
 Certificate of Beneficial Ownership 
  

	To:	U.S. Bank National Association 

	    	60 Livingston Avenue 

	    	St. Paul, Minnesota 55107-2292 

	    	Attention: Corporate Trust Administration OR 

  

	    	[Name of DTC Participant]] 

  

					
	Re:	  	 DuPont Fabros Technology, L.P.
 8 1/2%
Senior Notes due 2017 (the “Notes”)
 Issued under the Indenture (the “Indenture”) dated as
of
 December 16, 2009 relating to the Notes
	  	

 Ladies and Gentlemen: 
 We are the beneficial owner of $             principal amount of Notes issued under the Indenture and represented by a Temporary Offshore Global
Note (as defined in the Indenture). 
 We hereby certify as follows: 
 [CHECK A OR B AS APPLICABLE.] 
  

					
	 ̈	 	A.	  	We are a non-U.S. person (within the meaning of Regulation S under the Securities Act of 1933, as amended).
			
	 ̈	 	B.	  	We are a U.S. person (within the meaning of Regulation S under the Securities Act of 1933, as amended) that purchased the Notes in a transaction that did not require registration
under the Securities Act of 1933, as amended.

 You and the Company are entitled to rely upon this Certificate and
are irrevocably authorized to produce this Certificate or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby. 
  

 H-1 

			
	Very truly yours,
	
	[NAME OF BENEFICIAL OWNER]
		
	By:	 	  

		 	Name:
		 	Title:
		 	Address:

 Date:
                     
 [FORM II] 
 Certificate of Beneficial Ownership 
  

			
	To:	  	 U.S. Bank National Association
 60 Livingston Avenue
 St. Paul, Minnesota 55107-2292
 Attention: Corporate Trust Administration

		
	Re:	  	 DuPont Fabros Technology, L.P.
 8 1/2% Senior Notes due 2017 (the
“Notes”)
 Issued under the Indenture (the “Indenture”) dated as
 as of December 16, 2009 relating to the Notes

 Ladies and Gentlemen: 
 This is to certify that based solely on certifications we
have received in writing, by tested telex or by electronic transmission from Institutions appearing in our records as persons being entitled to a portion of the principal amount of Notes represented by a Temporary Offshore Global Note issued under
the above-referenced Indenture, that as of the date hereof, $             principal amount of Notes represented by the Temporary Offshore Global Note being submitted herewith for exchange
is beneficially owned by persons that are either (i) non-U.S. persons (within the meaning of Regulation S under the Securities Act of 1933, as amended) or (ii) U.S. persons that purchased the Notes in a transaction that did not require
registration under the Securities Act of 1933, as amended. 
 We further certify that (i) we are not submitting herewith
for exchange any portion of such Temporary Offshore Global Note excepted in such certifications and (ii) as of the date hereof we have not received any notification from any Institution to the effect that the statements made by such Institution
with respect

  

 H-2 

 
to any portion of such Temporary Offshore Global Note submitted herewith for exchange are no longer true and cannot be relied upon as of the date hereof. 
 You and the Company are entitled to rely upon this Certificate and are irrevocably authorized to produce this Certificate or a copy hereof
to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby. 
  

			
	Yours faithfully,
	
	[Name of DTC Participant]
		
	By:	 	  

		 	Name:
		 	Title:
		 	Address:

 Date:
                     
  

 H-3 

 EXHIBIT I 
 THIS NOTE IS A TEMPORARY GLOBAL NOTE. PRIOR TO THE EXPIRATION OF THE RESTRICTED PERIOD APPLICABLE HERETO, BENEFICIAL INTERESTS HEREIN MAY NOT BE HELD BY ANY PERSON OTHER THAN (1) A NON-U.S. PERSON OR
(2) A U.S. PERSON THAT PURCHASED SUCH INTEREST IN A TRANSACTION EXEMPT FROM REGISTRATION UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). BENEFICIAL INTERESTS HEREIN ARE NOT EXCHANGEABLE FOR PHYSICAL
NOTES OTHER THAN A PERMANENT GLOBAL NOTE IN ACCORDANCE WITH THE TERMS OF THE INDENTURE. TERMS IN THIS LEGEND ARE USED AS USED IN REGULATION S UNDER THE SECURITIES ACT. 
 NO BENEFICIAL OWNERS OF THIS TEMPORARY GLOBAL NOTE SHALL BE ENTITLED TO RECEIVE PAYMENT OF PRINCIPAL OR INTEREST HEREON UNTIL SUCH BENEFICIAL INTEREST IS EXCHANGED OR TRANSFERRED FOR AN INTEREST IN
ANOTHER NOTE. 
  

 I-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]